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Abstract 
Problems associated with poor pharmacokinetics and biodistribution, as well as 
toxic off-target effects, limit the curative potential of most anti-cancer drugs. This 
has prompted the development of nanoparticulate drug delivery systems to 
impart both more favourable pharmacological properties and precise tumour 
targeting. The vast number of formulations, ranging from fully synthetic delivery 
systems to ones derived from natural sources, currently undergoing clinical 
trials or preclinical testing underlines the significance of this field. This project is 
a proof-of-concept investigation into the feasibility and effectiveness of a novel 
drug delivery system, based on virus-like particles (VLPs) of the MS2 
bacteriophage.  
Doxorubicin (Dox) and an anti-BCL2 siRNA were used as model drug cargos. 
They were packaged inside MS2 VLPs either by chemical infusion, or via 
covalent attachment to an MS2 packaging signal, TR, respectively. An average 
loading of ~10 molecules of siRNA or ~110 molecules of Dox per VLP was 
achieved. Packaged cargos remained stably encapsidated; the siRNA was 
protected from nuclease degradation. VLPs were surface decorated with 
polyethylene glycol (PEG), and tumour-targeting ligands, human transferrin (Tf) 
or A9L, an RNA aptamer that targets prostate-specific membrane antigen 
(PSMA). Extensive PEGylation was achieved (~97% of coat proteins), and each 
VLP displayed on average ~7 molecules of Tf or ~16 molecules of A9L.  
PEGylation significantly reduced the non-specific cellular uptake of VLPs, and 
antibody binding. Further addition of tumour-targeting ligands facilitated the 
specific delivery of drug cargos to targeted cancer cells in culture, likely via 
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receptor-mediated endocytosis, and induced significant cytotoxicity with an LC50 
of ~10 nM for siRNA and ~800 nM for Dox. Importantly, negligible toxic effects 
were observed in the presence of excess free targeting ligands, or with non-
targeted control cell lines. Furthermore, the cellular uptake of VLPs did not 
appear to induce any off-target effects.  
MS2 VLPs continue to show promise as a robust, flexible and effective drug 
delivery system. This project highlights the versatility of VLPs for displaying a 
range of useful ligands on their surface, as well as packaging various 
therapeutic cargos, and demonstrated their ability to specifically deliver drugs to 
targeted cancer cells. Though further studies are required, the work presented 
here is an important step towards fully realising the potential of this drug 
delivery system.  
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1.1 A history of chemotherapy 
‘Although modern chemotherapy has now assumed its role in science and 
practical experience, it has its origin in histological staining techniques. Hence, 
it did not happen by chance that the first promising chemotherapeutical 
experiments used dyes like methylene blue and trypan red. Thus, early 
chemotherapy can be looked upon as dye therapy (Ehrlich, 1911).’ This quote 
from Paul Ehrlich’s seminal paper, ‘Aus Theorie und Praxis der Chemotherapie’, 
outlines the origins of his work in the search for ‘magic bullets’ to target disease-
causing organisms, which would establish the foundations of modern 
chemotherapy. 
The ‘magic bullet’ theory was conceived following Ehrlich’s observation that 
chemical dyes had differential affinities for specific biological structures (Ehrlich, 
1878, Ehrlich, 1911) – it postulated that such targeting mechanisms could be 
exploited to deliver toxins to microbes. Led by this speculation, Ehrlich’s team 
systematically screened hundreds of novel dyes derivatized with arsenical 
groups, and, in 1909, successfully identified a compound that had anti-syphilitic 
effects in mice and rabbits, which became known as Salvarsan (Ehrlich, 1910). 
The discovery of Salvarsan was significant not only because it validated 
Ehrlich’s hypothesis and was the first synthetic chemotherapeutic, but because 
it was the first instance of lead compound optimisation, based on principles of 
drug discovery that remain largely unchanged to this day.  
Ehrlich’s success inspired numerous groundbreaking studies that led to the 
discovery of novel treatments for other human diseases. In 1929, the physician 
Alexander Fleming published his serendipitous discovery that a fungus, 
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Penicillium notatum, grown in certain conditions, would secrete a substance 
exhibiting antibacterial properties. This substance, named penicillin, was readily 
diffusable in agar, and able to inhibit the growth of several disease-causing 
bacteria, such as diphtheria, gonococcus, pneumococcus and staphylococcus 
(Fleming, 1929). Fleming noted that penicillin was the first substance he had 
tested which was ‘more antibacterial than it was antileukocytic’, showing signs 
of a potentially powerful and selective ‘magic bullet’ therapeutic (Fleming, 
1945). 
Meanwhile, Ehrlich’s early success with dyes such as trypan red in treating 
trypanosome infections (Ehrlich and Shiga, 1904) prompted further 
developments of novel dye-based chemotherapeutics. In 1932, after five years 
of testing on thousands of azo dye derivatives, Gerhard Domagk discovered the 
sulphonamide drug, prontosil rubrum, which effectively treated haemolytic 
streptococci and staphylococci infections (Domagk, 1935). Prontosil rubrum 
became the first commercially available antibacterial drug, and its discoverer 
was awarded the 1939 Nobel Prize in Physiology or Medicine. Subsequently, 
thousands of sulphonamide-related compounds were produced, giving rise to 
improved formulations for treating a broad range of bacterial diseases.  
 
1.1.1 Cancer chemotherapy: first strides 
The success and rapid emergence of antibiotic drugs from the early 1900’s is 
reflected by the general decline in infectious disease-caused mortalities (Figure 
1.1). With this observation, Domagk stated in his Nobel lecture that the ultimate 
purpose of chemotherapy was to treat cancers (Domagk, 1947).  
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Figure 1.1. Crude mortality rates caused by infectious diseases in the USA from 1900 to 
1996. The anomalous peak from 1918 to 1920 refers to deaths caused by the Spanish flu. 
Adapted from Armstrong et al. (1999). (Armstrong et al., 1999). 
 
Development of the first cancer chemotherapeutics dates back to 1942, when 
pharmacologists Louis Goodman and Alfred Gilman investigated the therapeutic 
potential of toxins developed for chemical warfare in World War II. Following the 
observation that soldiers exposed to one agent, nitrogen mustard, displayed 
marked myeloid and lymphoid suppression, Goodman and Gilman 
hypothesised its therapeutic use against lymphoid tumours (Gilman and Philips, 
1946). This was validated in experiments in mouse models, where injected 
nitrogen mustard resulted in significant regression of transplanted lymphoid 
tumours, prompting further investigation in humans. The same anti-tumour 
effects were observed when nitrogen mustard was injected into a non-Hodgkin’s 
lymphoma patient and, although the remission was short-lived, this set the 
precedent for systemic administration of drugs to treat cancer (Gilman, 1963). In 
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1949, nitrogen mustard became the first FDA-approved cancer 
chemotherapeutic. 
 
 
 
 
 
 
 
Figure 1.2. Mechanism of action of nitrogen mustard. (A) Structures of the purines, adenine 
and guanine, highlighting their nucleophilic nitrogen atoms (N3 and N7, respectively), which are 
exposed in the grooves of the DNA double helix. (B) Nitrogen mustard forms cyclic aziridinium 
rings via displacement of a chloride ion by the amine nitrogen. These rings are readily attacked 
by guanine and adenine on DNA, producing inter- or intra-stand crosslinks.  
 
Studies on its mechanism of action revealed that nitrogen mustard forms 
covalent bonds with DNA via their alkyl groups, resulting in intra- or inter-strand 
crosslinks (Figure 1.2), inhibition of transcription and ultimately apoptosis of 
cancer cells (Goldacre et al., 1949, Masta et al., 1995, Kohn et al., 1987). This 
led to the subsequent identification of numerous other alkylating and alkylating-
like agents for treating cancer, such as chlorambucil, mitomycin C (Crooke and 
Bradner, 1976), and cisplatin (Siddik, 2003). 
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1.1.2 Anti-metabolites in cancer therapy 
Shortly after World War II, another class of cancer chemotherapeutics emerged 
following Sidney Farber’s observation that folic acid – a vitamin previously 
identified as a deficient factor in megaloblastic anaemia patients (Wills et al., 
1937) – stimulated the proliferation of cancer cells in children suffering from 
acute lymphoblastic leukaemia (ALL). This prompted Farber to synthesise 
structural analogues of folic acid, first aminopterin and methotrexate (Figure 
1.3), to inhibit its pro-tumour action. Intra-muscular injection of aminopterin 
successfully induced remissions of ALL in patients (Farber et al., 1948). 
Although these remissions were temporary, they confirmed the tumour 
suppressive capacity of anti-folates, and paved the way for the development of 
novel anti-metabolite chemotherapeutics. 
It was not until a decade after Farber’s original investigation into anti-folates that 
their mechanism of action was elucidated. In 1958, Osborn and Huennekens 
identified that aminopterin and methotrexate specifically inhibited the action of 
dihydrofolate reductase (Osborn and Huennekens, 1958, Osborn et al., 1958), 
preventing the reduction of dihydrofolic acid to tetrahydrofolic acid. This in turn 
inhibits the synthesis of thymidine monophosphate and DNA synthesis, 
ultimately resulting in apoptosis (Jolivet et al., 1983). Since then, methotrexate 
has demonstrated anti-tumour effects in a wide range of cancers, notably it 
provided a curative treatment for patients suffering from choriocarcinoma, a 
malignant trophoblastic cancer typically of the placenta, which became the first 
solid tumour to be cured by chemotherapy (Li et al., 1958). Methotrexate is 
currently used in the treatment of various cancers, as well as autoimmune 
diseases such as psoriasis and rheumatoid arthritis. 
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Figure 1.3. Structures of folic acid and folic acid analogues, aminopterin and 
methotrexate. Aminopterin differs from folic acid in the substitution of an amino group for O4; 
methotrexate contains the same amino group, and also an N-methyl group on its p-
aminobenzoate moiety.  
 
In 1942, another subclass of anti-metabolite chemotherapeutics surfaced from 
the work of George Hitchings. Equipped with the knowledge that DNA is 
composed of purines and pyrimidines, synthesised through a system of 
anabolic pathways, Hitchings hypothesised that rapidly dividing cells, such as 
bacterial or cancer cells, depended on modified anabolic pathways that promote 
DNA synthesis, and that their growth might be inhibited by the use of 
antagonists of nucleic acid synthesis (Hitchings, 1989). In collaboration with 
Gertrude Elion, Hitchings screened for purine and pyrimidine analogues using a 
Lactobacillus casei system, which can grow in the presence of adenine, 
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guanine, xanthine or hypoxanthine provided thymine is present (Elion and 
Hitchings, 1955). One compound, 2,6-diaminopurine, was able to inhibit the 
growth of L. casei, which was reversible upon the addition of adenine; strains of 
L. casei which displayed resistance to 2,6-diaminopurine grew poorly with 
adenine as the source of purine. They concluded that 2,6-diaminopurine was 
anabolised by the same enzyme as adenine, and that its product inhibited 
purine interconversion (Elion et al., 1953). 
Although 2,6-diaminopurine displayed anti-tumour effects in tumour models in 
mice and in cell culture (Biesele et al., 1951, Burchenal et al., 1949), it also 
produced off-target toxicities in the form of severe vomiting, nausea and 
myelosuppression in human patients (Burchenal et al., 1951). This prompted 
Hitchings and Elion to continue screening for purine analogues in L. casei (Balis 
et al., 1951) – one analogue, obtained by substitution of an oxygen at the 6-
position with a sulfur in hypoxanthine, was observed to inhibit purine utilisation. 
This thiopurine, known as 6-mercaptopurine, demonstrated anti-tumour effects 
in a broad range of cancers in mouse models (Elion et al., 1951, Biesele et al., 
1951) and, in subsequent clinical trials, was able to produce complete remission 
of  acute leukaemia  in children (Burchenal et al., 1953). Despite the relapse 
experienced by many of those patients after treatment, 6-mercaptopurine was 
sufficiently superior over the previous treatment of methotrexate and steroids, 
raising the median life expectancy from 4 months to 12 months, to warrant its 
FDA approval in 1953. It took many more years of research before the 
mechanism of action of 6-mercaptopurine was elucidated (Figure 1.4). 
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Figure 1.4. Mechanism of action of 6-mercaptopurine. (1) 6-mercaptopurine (6-MP) is 
converted by thiopurine S-methyltransferase (TPMT) or xanthine oxidase (XO) to inactive 
products, methyl 6-mercaptopurine (Me6-MP) or 6-thiouric acid (6-TU), respectively. (2) In a 
competing reaction, hyphoxanthine-guanine phosphoribosyltransferase (HPRT) converts 6-MP 
to thioinosine monophosphate (TIMP), (3) which can be methylated by TPMT to form methyl 
TIMP (MeTIMP). MeTIMP inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, 
the rate-limiting enzyme for de novo purine synthesis. (4) TIMP can also be converted to 
thioguanosine monophosphate (TGMP) via thioxanthosine monophosphate (TXMP). (5) The 
sequential action of kinases and reductase converts TGMP to thioguanosine triphosphate 
(TGTP) and thiodeoxyguanosine triphosphate (TdGTP), which are incorporated into RNA and 
DNA, respectively. TdGTP in DNA can trigger apoptosis via the mismatch repair pathway. 
IMPDH = inosine-5′-monophosphate dehydrogenase; GMPS = guanine monophosphate 
synthetase. 
 
1.1.3 Anti-microtubule agents in cancer therapy 
One exciting development in chemotherapy came in the late 1950s, with the 
discovery of the anti-tumour potential of Vinca alkaloids (Johnson et al., 1959, 
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Noble et al., 1958). These compounds can be extracted from leaves of the 
periwinkle plant Catharanthus roseus, which were originally tested by Robert 
Noble and Charles Beer for their purported anti-diabetic properties in rabbits 
and diabetic rats (Noble et al., 1958). The studies revealed that orally 
administered aqueous extracts of C. roseus leaves produced little effects on 
blood sugar levels and on the disease but, interestingly, reduced the white 
blood cell count in the test animals, rendering them prone to bacterial infections. 
This led to the hypothesis that these extracts contained agents that might be of 
therapeutic use against cancers of the haematopoietic system, such as 
leukemia and lymphoma. Through fractionation, Beer isolated the compounds 
vinblastine and vincristine, which dramatically decreased the white blood cell 
count in rats. In subsequent experiments, vinblastine demonstrated significant 
anti-tumour effects in rodent models of mammary tumours and leukemias (Cutts 
et al., 1960), as well as in human patients suffering from Hodgkin’s lymphoma, 
lymphosarcoma and breast cancer (Warwick et al., 1960). Numerous Vinca 
derivatives have since been developed, which are now FDA approved for 
treating a range of tumours, including acute leukemia, neuroblastoma, Wilm’s 
tumour, Hodgkin’s and other lymphomas.  
The mechanism of action of Vinca alkaloids was later identified (Jordan et al., 
1991). Vinblastine was shown to bind at the plus ends of microtubules with high 
affinity (Figure 1.5A): as little as one vinblastine per plus end could significantly 
suppress treadmilling and dynamic instability of the polymer (Jordan et al., 
1986). This stabilisation maintains microtubules in mitotic spindles in an 
attenuated or paused state, thus blocking mitosis and ultimately triggering 
apoptosis. 
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Figure 1.5. Mechanism of action of anti-microtubule chemotherapeutics. (A) Vinblastine 
suppresses microtubule dynamics via high affinity binding to the plus end of microtubules, 
inducing cell cycle arrest at M phase. (B) Paclitaxel suppresses microtubule dynamics by 
binding at the interior surface, stabilising the polymer from disassembly and ultimately inducing 
apoptosis. Adapted from Jordan and Wilson (2004). (Jordan and Wilson, 2004). 
 
Another major subtype of microtubule-targeting chemotherapeutics are the 
taxanes, most notably paclitaxel. Taxanes differ from Vinca alkaloids in their 
mechanism of action, which involves diffusing through small openings in the 
microtubule (Nogales, 2001), binding with high affinity to the β-subunit of tubulin 
along the interior surface (Nogales et al., 1995), stabilising the microtubule and 
promoting its polymerisation (Schiff et al., 1979) (Figure 1.5B). This effect is 
likely due to a binding-induced conformational change in tubulin that enhances 
their affinity for neighbouring subunits (Nogales, 2001). As for the Vinca 
alkaloids, a small number of paclitaxel molecules are sufficient to significantly 
reduce the dynamic instability of microtubules (Derry et al., 1995); suppression 
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of spindle microtubule dynamics blocks mitotic progression from metaphase to 
anaphase, ultimately leading to apoptosis (Jordan et al., 1996, Yvon et al., 
1999). Paclitaxel was approved by the FDA in 1995 and is currently used to 
treat non-small-cell lung carcinoma (NSCLC), ovarian and breast cancer and 
Kaposi’s sarcoma. 
 
1.2 Oncogene-targeted cancer therapy 
The discovery of oncogenes and tumour suppressor genes, and the subsequent 
elucidation of cellular signalling pathways, contributed greatly to our 
understanding of cancer biology on a molecular level (Hanahan and Weinberg, 
2000). The identification of the first oncogene, v-src sarcoma (Schmidt-Ruppin 
A-2) viral oncogene homolog (SRC), took decades to achieve. In 1911, Peyton 
Rous’ demonstrated that cell filtrates from chicken sarcomas could cause 
cancer in healthy chickens, suggesting the presence of cancer-inducing agents 
within the tumour, which were found to be the virus that became known as the 
Rous Sarcoma Virus (RSV) (Rous, 1911).  
Six decades later, experiments by David Baltimore and Howard Temin revealed 
that RSV had an RNA genome that could convert back to DNA and integrate 
itself within the host’s genome (Baltimore, 1970, Temin and Mizutani, 1970). 
This discovery identified that a genetic element of the viral genome was 
responsible for transforming cells, which was subsequently narrowed down to a 
single gene, the SRC oncogene (Wang et al., 1976). Homologues of SRC were 
then found in several species of bird and later across all vertebrates (Stehelin et 
al., 1976), suggesting that the viral oncogene had been acquired from host cells 
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during evolution, and that normal versions of these genes were present within 
the host genome which may cause cancer if mutated. These genes were 
termed ‘proto-oncogenes’ (Varmus, 1990). More than 50 of these have now 
been identified within the human genome (Vogelstein et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Hallmarks of cancer. A summary of characteristics exhibited by cancer cells which, 
collectively, lead to unchecked tumour growth. Adapted from Luo et al. (2009).(Luo et al., 2009). 
 
It has been reported that as many as 7-10 genetic or epigenetic alterations are 
necessary to bring about the cancer phenotypes required for tumorigenesis 
(Figure 1.6) (Renan, 1993, Hanahan and Weinberg, 2000, Brummelkamp et al., 
2002). Originally, this notion of a complex network of interacting pathways in 
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cancers led to the idea that they may be too complicated for simple effective 
treatments (Li et al., 1997, Hahn and Weinberg, 2002). However, it has since 
been shown that targeting just one specific gene or its protein product can be 
sufficient to destroy a cancer. This phenomenon was termed oncogene 
dependency by Bernard Weinstein in 2000, and has now been identified in 
numerous cancers (Weinstein, 2002, Weinstein and Joe, 2008, Shaffer et al., 
2008, Luo et al., 2009, Yan et al., 2014).  
These revolutionary insights led to the identification of many novel therapeutic 
targets, including growth factors, signalling molecules and a range of proteins 
involved in apoptosis, angiogenesis or cell cycle regulation (Hanahan and 
Weinberg, 2000), and spurred on more rational drug designs to specifically 
target them for cancer therapy. One significant landmark in targeted cancer 
therapy has been the development of the small molecule drug imatinib 
(Capdeville et al., 2002). Imatinib is a potent inhibitor of BCR-ABL, a fusion 
oncoprotein that results from a translocation between chromosomes 9 and 22, 
and is found in 95% of chronic myelogenous leukemia (CML) (Wada et al., 
1995). Wild-type ABL is a highly regulated tyrosine kinase with roles in the cell 
cycle, genotoxic stress response and integrin signalling (Deininger et al., 2000). 
The fusion of BCR-ABL results in the loss of the ABL autoinhibition domain, and 
ultimately leads to its deregulation (Pluk et al., 2002). This constitutively active 
tyrosine kinase hyper-phosphorylates a vast range of substrates involved in 
growth, cell adhesion and inhibition of apoptosis, which results in tumorigenesis. 
Imatinib inhibits BCR-ABL by binding in its active site (Figure 1.7A), locking the 
kinase in its autoinhibited conformation.  
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Figure 1.7. Structure and binding of imatinib. (A) Schematic showing the structure of imatinib 
and its interactions with amino acid residues in BCR-ABL. Imatinib binds to the kinase domain 
of ABL in its inactive conformation, via six hydrogen bonds (green) and numerous van der 
Waals interactions. Residues shown in blue form a hydrophobic face against which imatinib 
packs. Imatinib binding stabilises BCR-ABL in its inactive conformation and prevents ATP 
binding. (B) Mutations in ABL which confer resistance to imatinib. These mutations are 
highlighted as spheres, and include those that directly (1 to 3) or indirectly (4 to 13) perturb 
imatinib binding. Residues 4 to 8 are present in the P loop; residues 9 to 13 are present within 
the vicinity of the activation loop (purple) of ABL. Adapted from Shah et al. (2002). (Shah et al., 
2002).  
 
Imatinib demonstrated remarkable efficacy in clinical trials, in which 53 out of 54 
CML patients showed hematologic responses and 7 had complete cytogenetic 
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remissions; this led to the fast-tracked FDA approval of imatinib in 2001 (Druker 
et al., 2001). However, it has since emerged that drug resistance can develop in 
CML patients that renders them unresponsive to imatinib treatment, typically 
through gene amplification of BCR-ABL or mutations in its catalytic domain that 
perturb drug binding (Figure 1.7B) (Gambacorti-Passerini et al., 2003).  Such 
drug resistance is especially prevalent during the later stages of CML, including 
the accelerated phase or blast crisis (Druker, 2008), and has prompted the 
development of second generation BCR-ABL inhibitors, such as nilotinib and 
dasatinib (Weisberg et al., 2007). 
Other small molecule kinase inhibitors soon emerged from the clinical pipeline, 
for instance, gefitinib, which targets the epidermal growth factor receptor 
(EGFR). EGFR is a receptor tyrosine kinase that is involved in initiating growth 
and proliferation signalling pathways (Kolch and Pitt, 2010); its overexpression 
or mutation is a crucial event in the pathogenesis of several cancers, including 
NSCLC, breast, prostate and ovarian cancers (Ciardiello and Tortora, 2008). 
Gefitinib inhibits EGFR signalling by competing for ATP-binding sites within its 
intracellular kinase domain, and exhibited great efficacy in NSCLC patients, 
leading to its FDA approval in 2003 (Lynch et al., 2004, Pao, 2004). However, 
as for imatinib, the success of gefitinib was short-lived due to the emergence of 
drug resistance, often acquired by cancers via mutations in the drug-binding site 
of EGFR (Tartarone et al., 2013). 
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1.2.1 Exogenous antibodies for cancer therapy 
Ehrlich displayed incredible foresight with his early vision of antibodies as 
"magic bullets that identify their target themselves without harming the 
organism" (Strebhardt and Ullrich, 2008), and the hypothesis that the immune 
system can prevent cancers (Ehrlich, 1909). However, this potential was not 
realised until the identification of cancer cell surface markers, and the 
emergence of the hybridoma technology (Kohler and Milstein, 1975).  
In 1973, Schwaber reported that fusion of human peripheral blood lymphocytes 
with a mouse myeloma cell line produced hybridomas which secrete 
monospecific antibodies of both parental types (Schwaber and Cohen, 1973). 
Based on this work, Cesar Milstein and George Köhler demonstrated in 1975 
that B cells isolated from mice immunised with an antigen could be immortalised 
via fusion with immuno-deficient myeloma cells (Kohler and Milstein, 1975). The 
resulting hybridomas are diluted and segregated into individual growth 
chambers, from which clones positive for producing the desired antibodies can 
be identified by adding the antigen of interest. These can then be grown 
indefinitely, enabling the large-scale production of monoclonal antibodies. 
This revolutionary technology led to the development of the first wave of 
therapeutic antibodies for cancer, including trastuzumab and rituximab. 
Rituximab targets the B-cell transmembrane antigen, CD20, and was shown to 
specifically deplete CD20+ B-cells from circulation, the lymph nodes and bone 
marrow; it was approved by the FDA in 1997 for treating B-cell non-Hodgkin 
lymphoma (Maloney et al., 1997, McLaughlin et al., 1998). Trastuzumab targets 
ERBB2, a member of the epidermal growth factor receptor family whose 
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overexpression has a crucial role in tumorigenesis in breast and ovarian 
cancers (Slamon et al., 1989), and received FDA approval in 1998 for the 
treatment of ERBB2+ breast cancers (Hudziak et al., 1989).   
 
 
Antibody 
 
 
Target 
 
Format 
 
Indication 
 
Trastuzumab  
 
ERBB2 
 
Humanised IgG1 
 
Breast cancer 
 
Bevacizumab  
 
VEGF 
 
Humanised IgG1 
 
Colon and kidney cancer,  
NSCLC, glioblastoma  
 
Cetuximab  
 
EGFR 
 
Chimeric IgG1 
 
Colorectal cancer,  
squamous cell carcinoma 
 
Panitumumab  
 
EGFR 
 
Humanised IgG2 
 
Colorectal cancer 
 
Ipilimumab  
 
CTLA4 
 
Humanised IgG1 
 
Melanoma 
 
Rituximab  
 
CD20 
 
Chimeric IgG1 
 
Non-Hodgkin lymphoma,  
chronic lymphoid leukaemia 
 
Alemtuzumab  
 
CD52 
 
Humanised IgG1 
 
Chronic lymphoid leukaemia 
 
Ofatumumab  
 
CD20 
 
Humanised IgG1 
 
Chronic lymphoid leukaemia 
 
§
*Gemtuzumab  
ozogamicin  
 
CD33 
 
Humanised IgG4 
 
Acute myeloid leukaemia 
 
*Brentuximab  
 
CD30 
 
Humanised IgG1 
 
Hodgkin's lymphoma,  
systemic anaplastic lymphoma 
 
*Ibritumomab tiuxetan 
 
CD20 
 
Murine IgG1 
 
Non-Hodgkin lymphoma 
 
*Tositumomab  
 
 
CD20 
 
Murine IgG2 
 
Non-Hodgkin lymphoma 
 
Table 1.1. List of FDA approved monoclonal antibodies in cancer therapy and their 
mechanism of action. Many other antibody-based therapies have been approved by the FDA 
for treating other diseases, but are not included here. §Gemtuzumab ozogamicin was withdrawn 
from the market in 2010. *Antibody-drug conjugates. 
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These antibodies demonstrated anti-tumour efficacy through various 
mechanisms, including the modulation of signalling pathways, antibody-
dependent cellular toxicity, and complement-dependent cytotoxicity (Carter, 
2001, Schrama et al., 2006). Their huge clinical success prompted the 
development of many new therapeutic antibodies targeting a range of cancer-
related markers, such as EGFR, vascular endothelial growth factor (VEGF) and 
epithelial cell adhesion molecule (van Mierlo et al., 2002, Galizia et al., 2007, 
Chaudry et al., 2007, Hudziak et al., 1989), as well as antibody-toxin conjugates 
to promote tumour-specific drug delivery (Chari et al., 2014). Many of these 
have now received FDA approval (Table 1.1).  
Despite the significant impact therapeutic antibodies have made on the 
treatment of cancer, some problems have emerged, mostly related to 
mechanism-dependent toxicities. For instance, Trastuzumab has been 
associated with cardiotoxicity due to its binding to receptors in the heart 
(Seidman et al., 2002); binding of rituximab to healthy CD20+ B-cells has also 
been reported to induce toxicities (Byrd et al., 1999). Another drug, 
gemtuzumab ozogamicin, was withdrawn from the market a decade after its 
FDA approval in 2010, following observations of significantly higher mortality 
rates in patients compared to standard-of-care chemotherapies (Rowe and 
Lowenberg, 2013).  
 
1.2.2 RNA interference and its therapeutic applications 
Since its discovery in the mid-1990s (Fire et al., 1998, Baulcombe, 1996), RNA 
interference (RNAi) has rapidly transformed from a curious phenomenon in 
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worms to an invaluable tool in the study of functional genomics. The 
significance of RNAi technology was underlined by the award of the 2006 Nobel 
Prize in Physiology or Medicine to Fire and Mello (Bernards, 2006).  
RNAi describes the cellular process that occurs in various organisms, including 
mammals, plants and nematodes, whereby double-stranded (ds) RNAs mediate 
specific and potent gene silencing (Wilson and Doudna, 2013). RNAi is believed 
to have evolved from an early immune mechanism against viruses and 
transposable elements (Obbard et al., 2009). Foreign dsRNAs are recognised 
and processed by Dicer RNases into 21-24 nt fragments, known as small 
interfering RNA (siRNA), then loaded onto an Argonaute-containing RNA-
induced silencing complex (RISC). One strand of the siRNA (passenger strand) 
is degraded, whilst the other (guide strand) in complex with RISC searches 
cytoplasmic RNA for complementary sequences. Once located, Argonaute 
triggers cleavage of the targeted RNA, thereby silencing expression of the 
foreign gene. This RNAi pathway forms an important component of innate 
antiviral immunity in plants, nematodes, fungi and arthropods (Obbard et al., 
2009).  
Another RNAi pathway, the endogenous microRNA (miRNA) pathway, enables 
post-transcriptional regulation of gene expression in animals and plants (Figure 
1.8) (Carthew, 2006). This pathway commences with the transcription of 
primary miRNAs (pri-miRNA) from the host genome. These transcripts are 
typically excised by a microprocessor complex, Drosha, into 65-70 nt precursor 
miRNAs (pre-miRNA), which are then exported to the cytoplasm by exportin-5 
and Ran GTP (Lund and Dahlberg, 2006). Similar to the siRNA pathway, pre-
miRNAs are processed by Dicer to form 21-26 nt mature miRNAs, which can be 
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loaded onto RISC, forming a miRISC complex. Compared to siRNAs, miRNAs 
only partially base pair with their target sequences in the 3’-untranslated regions 
(3’-UTRs) of mRNA, mainly via 7-8 consecutive base pairs of the so-called seed 
region. Binding of miRISCs to 3’-UTRs inhibits 5’-cap dependent translational 
initiation and can trigger mRNA degradation. Individual miRNAs usually have 
several different mRNAs as targets. To date, 1,881 miRNA sequences have 
been identified within the human genome 
(http://microrna.sanger.ac.uk; accessed March, 2015) which regulate almost a 
third of protein-encoding genes (Macfarlane and Murphy, 2010). Unsurprisingly, 
endogenous RNAi plays a critical role in regulating numerous vital processes, 
including cell growth, cell proliferation, apoptosis and tissue differentiation 
(Esquela-Kerscher and Slack, 2006). 
Cellular RNAi can be exploited to silence a gene of interest by introducing 
exogenous sxRNA analogues, either siRNA or shRNA, that target its mRNA 
(Figure 1.8). SiRNAs are competent for RISC loading, and may directly enter 
the RNAi pathway once delivered to the cytoplasm. For shRNAs, viral vectors 
are typically used to deliver shRNA-encoding genes into cells for expression. 
Expressed shRNA undergoes processing to form siRNA, which can then be 
loaded onto RISC complexes. Many different sxRNA libraries now exist that 
cover the entire genomes of both mice and humans, enabling high-throughput 
loss of function analyses and the identification of essential genes for virtually 
any cellular process (Latterich, 2008).  
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Figure 1.8. The RNAi pathway. Endogenous primary miRNAs (pri-miRNA), which are ~80 nt 
dsRNAs with a hairpin turn, polyA tail and 5´ cap, are transcribed in the nucleus by RNA 
polymerase II (RNAP II). Pri-miRNA is processed by Drosha and exported out of the nucleus by 
exportin-5 as 65-70 nt precursor-miRNA (pre-miRNA). In the cytoplasm, pre-miRNA is 
processed by Dicer to form a 21-26 nt mature miRNA, consisting of a guide strand (red) and a 
passenger strand (black). The passenger strand is degraded, whilst the guide strand is loaded 
onto RISC, forming a miRISC complex. The miRNA in miRISC targets mRNA with a near 
complementary sequence in their in their 3´-UTR for binding, which leads to translational 
inhibition and degradation of the mRNA by processing bodies (P-bodies). RNAi can also be 
induced by introducing exogenous small interfering RNA (siRNA) or short hairpin RNA (shRNA). 
ShRNA requires processing by Dicer to form siRNA. The guide strand of siRNA can be loaded 
onto RISC to target complementary regions on mRNA for binding, which results in its cleavage 
by Ago2 within the RISC complex.  
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RNAi technology has played a key role in the identification of many oncogene-
dependent cancers, and the oncogenes on which they rely. One example of this 
is the identification of the oncogene, I Kappa B Kinase ε (IKBKE), in breast 
cancers. A large shRNA library targeting 1,200 genes was used to screen the 
breast cancer cell line, MCF-7, in which three shRNAs targeting IKBKE were 
able to reduce proliferation and viability of MCF-7 cells, indicating their 
dependence on IKBKE for maintenance and survival (Boehm et al., 2007). 
These findings not only added to the accumulating body of evidence for 
oncogene dependence in cancers, but also highlighted the therapeutic potential 
of sxRNA-mediated RNAi against them.  
SxRNAs have several advantages as novel therapeutic agents. They are 
synthetic and relatively easy to produce compared to protein-based 
therapeutics, can be rationally designed to target any oncogene, and can 
achieve a level of specificity far higher than that of traditional cancer 
therapeutics. Furthermore, as sxRNAs target oncogenes at the mRNA level, 
they may exhibit synergistic effects when used with drugs that target at the 
protein level. For instance, siRNA-mediated silencing of BCR-ABL and the gene 
encoding multidrug resistance protein 1 has been shown to sensitise CML cells 
to imatinib treatment (Wohlbold et al., 2003, Vasconcelos et al., 2007), 
highlighting the potential of such combinatorial therapies.  
Several barriers have severely hindered the progress of RNAi therapeutics 
towards clinical approval, including the short plasma half-lives of RNAs, their 
poor cellular uptake, and the lack of tumour-specific targeting. These issues led 
to the withdrawal of interest from big Pharma, such as Novartis, Roche and 
Merck, which in 2010 shut down their billion dollar RNAi programs (Bouchie, 
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2012). However, there has been a recent resurgence in the development of 
RNAi therapeutics, fuelled in part by advances in polymeric drug delivery 
systems which have shown it is possible to overcome or mitigate 
aforementioned problems (Yan et al., 2014). Numerous promising RNAi-based 
therapeutics are now under clinical investigation (Table 1.2). 
 
Product Description Indication Status 
 
SNS01-T 
 
 
siRNA targeting eIF-05A1 and a plasmid of 5A1; 
systemic delivery via PEI 
 
Multiple  
myeloma 
 
Phase 1b/2a 
 
CALAA-01 
 
 
siRNA targeting RRM2; 
systemic delivery by RONDEL 
 
Solid  
tumours 
 
Phase 1b 
 
Atu027 
 
 
Modified siRNA targeting PKN3;  
systemic delivery by cationic liposome 
 
Solid  
tumours 
 
Phase 1  
 
ALN-VSP02 
 
 
Modified siRNA targeting VEGF and KSP;  
systemic delivery by SNALP 
 
Liver  
cancer 
 
Phase 1  
 
TKM-PLK1 
 
 
siRNA targeting PLK1;  
systemic delivery by SNALP 
 
Solid  
tumours 
 
Phase 1  
 
siG12D 
LODER 
 
 
siRNA targeting KRAS;  
systemic delivery by LODER 
 
Pancreatic  
Cancer 
 
Phase 2 
 
  
Table 1.2. Selected examples of siRNA products in clinical trials for treating cancer. Many 
other candidates exist, which treat a wide range of diseases, such as Ebola and age-related 
macular degeneration. eIF = eukaryotic initiation factor; PEI = polyethyleneimine; RRM2 = 
ribonucleoside-diphosphate reductase subunit M2; RONDEL = RNAi/Oligonucleotide 
Nanoparticle Delivery; PKN3 = protein kinase N3; VEGF = vascular endothelial growth factor; 
KSP = kinesin spindle protein; SNALP = stable nucleic acid lipid particles; LODER = local drug 
eluter. Adapted from Bouchie (2012). (Bouchie, 2012).  
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Problem 
 
Implication 
 
Effect of Drug Delivery 
 
 
Poor 
biodistribution 
 
Drugs with widespread biodistribution can 
affect normal tissues, causing dose-limiting 
side effects, such as the cardiotoxicity of 
doxorubicin. 
 
 
Drug delivery systems can improve 
passive targeting of tumour tissues 
via the enhanced permeability and 
retention (EPR) effect. 
 
Poor selectivity 
 
Low drug concentrations in tumour tissues 
lead to suboptimal therapeutic effects. Also 
see ‘Poor distribution’. 
 
Delivery systems can utilise EPR to 
accumulate in tumour tissues, and 
targeting ligands to preferentially 
enter tumour cells. 
 
Poor solubility Hydrophobic drugs may precipitate in 
aqueous media, preventing a convenient 
pharmaceutical format. Excipients such as 
Cremophor may be used but can be toxic. 
 
Delivery systems such as micelles 
offer both hydrophilic and 
hydrophobic environments, to 
improve drug solubility. 
Poor stability in 
vivo 
Rapid breakdown of the drug under 
physiological conditions results in loss of 
activity, for instance, nuclease degradation of 
siRNA therapeutics. 
 
Delivery systems can enhance the 
stability of the drug; lowering the 
effective dosage. 
 
Tissue damage 
on extravasation 
 
Inadvertent extravasation of drugs can lead to 
tissue damage, for instance, doxorubicin-
induced tissue necrosis. 
 
Regulated drug release from the 
delivery system can mitigate tissue 
damage on extravasation. 
 
 
Unfavourable 
pharmacokinetics 
Drug is cleared quickly, for example, by rapid 
renal clearance, requiring high dosages. 
Delivery systems can dramatically 
alter the pharmacokinetics of the 
drug, and prevent its rapid renal 
clearance. 
 
 
Table 1.3. Undesirable properties of drugs and the effect of drug delivery systems. 
Adapted from Allen and Cullis (2004). (Allen and Cullis, 2004). 
 
1.3 Drug Delivery Systems 
Problems associated with poor pharmacokinetics and biodistribution have 
affected many cancer drug candidates, which is reflected in their ~95% failure 
rate (Arrondeau et al., 2010, Kola and Landis, 2004). Many of these problems, 
however, are not exclusive to novel drugs, but are also common among 
established and approved formulations. This has prompted the development of 
drug delivery systems to impart more favourable pharmacological properties to 
                                                                                                    ___   _ _                      Page 44 
 
drugs, such as increased tumour selectivity and prolonged plasma half-lives, to 
ultimately improve their efficacy whilst mitigating adverse toxicities (Table 1.3).  
A large number of systems, based on materials ranging from human viruses to 
synthetic polymers, have been explored for anti-cancer drug delivery (Figure 
1.9). These are highlighted below, attention is paid to the strengths and 
weaknesses of each delivery system as well as promising examples that are 
either approved or undergoing pre-clinical or clinical testing. 
 
 
 
 
 
 
 
Figure 1.9. Major classes of polymer-based drug delivery systems. Schematic presentation 
of delivery systems which have shown promise in preclinical or clinical testing. 
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1.3.1 Viral Drug Delivery Systems 
Eons of evolutionary fine-tuning has given viruses the ability to infiltrate specific 
cells and deliver genetic material for expression, making them an attractive 
option for delivering nucleic acid therapeutics, such as RNAi drugs. Viral 
delivery systems have largely been explored for delivering shRNA expression 
cassettes (Castanotto and Rossi, 2009). Non-essential regions within the virus 
genome can be modified to incorporate a promoter and shRNA of interest, to 
achieve long-term shRNA expression and hence repression of targeted genes 
in transfected cells. Adenoviruses, adeno-associated viruses, herpesviruses 
and lentiviruses are among those that have been tested as shRNA delivery 
vectors (Heilbronn and Weger, 2010).  
Adenoviruses are widely used in gene therapy studies due to their ability to 
incorporate large genes and deliver them to the nucleus (Campos and Barry, 
2007). Adenoviral delivery of shRNAs has been demonstrated in several human 
cancer cell lines, in which delivered shRNAs targeting the mRNA of the tumour 
suppressor protein, p53, successfully triggered gene silencing (Shen et al., 
2003). Despite these encouraging results from in vitro studies, the inherent, 
high immunogenicity of adenoviruses has severely limited their use for shRNA 
delivery in vivo (Liu and Muruve, 2003, Hartman et al., 2008).  
Systemic administration of adenoviral vectors to human patients leads to high 
liver uptake and activation of innate immunity, causing severe acute 
inflammatory responses and even fatalities (Marshall, 1999). Moreover, the 
development of neutralising anti-adenoviral antibodies prohibits repeated drug 
dosing (Yang et al., 1996). These findings seriously questioned the suitability of 
                                                                                                    ___   _ _                      Page 46 
 
adenoviral vectors for in vivo applications. However, work is under way to 
address some of these issues, in particular the immunogenicity and poor 
targeting of adenoviruses. Various approaches, including addition of 
polyethylene glycol (PEG) to the virus surface (Wonganan and Croyle, 2010) or 
liposomal modification (Wan et al., 2013) to mask viral epitopes, and genetic 
incorporation of tumour-targeting ligands (Campos and Barry, 2007), have 
shown promising results.  
Lentiviruses, of the Retroviridae family, have also been explored for therapeutic 
shRNA delivery. Lentiviruses are single stranded RNA viruses with the ability to 
reverse transcribe their RNA genome into DNA, before inserting the viral DNA 
into the host genome for expression (Sakuma et al., 2012). Brummelkamp and 
coworkers successfully used lentiviruses to deliver shRNA vectors that targeted 
an activated K-RAS oncogene to pancreatic cancer cells. Effective knockdown 
of the oncogene was achieved, resulting in the elimination of the tumorigenic 
capacity of transfected cancer cells in mice (Brummelkamp et al., 2002). 
Another lentiviral shRNA delivery system is currently under clinical evaluation 
for autologous cell therapy against AIDS-related non-Hodgkin’s lymphoma 
(Burnett et al., 2011). This involves ex vivo shRNA delivery. Haematopoietic 
progenitor cells are removed from patients via apheresis, transfected with 
lentiviral shRNA vectors and then reinfused into the patient. Early results 
revealed no short-term toxicity associated with the transfected haematopoietic 
progenitor cells, and two of four patients exhibited persistent expression of the 
shRNA (DiGiusto et al., 2010). 
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The major drawback of retroviral shRNA delivery is that random retroviral 
genome insertion may cause major disruptions to the host genome, resulting in 
a multitude of problems, including the activation of proto-oncogenes (Yi et al., 
2005). This could be particularly dangerous if a large amount of virus is taken 
up by untargeted healthy tissues. Thus, retroviruses are not ideal candidates for 
shRNA delivery in vivo.  
Hong and coworkers demonstrated that Herpesvirus saimiri can deliver shRNA 
targeting the endothelin converting enzyme 1 (ECE-1) into prostate cancer cells 
(Hong et al., 2011). ECE-1 was selected as the target due to its involvement in 
the invasion and migration of several cancers, including prostate, lung, breast, 
colorectal and ovarian (Smollich et al., 2007). The herpesvirus vector was 
tested in vitro in several cell lines and ex vivo in primary cells from three 
different forms of prostate cancer. Significant levels of ECE-1 knockdown were 
observed in all cases, which severely limited the capacity of the cancer cells to 
migrate and invade (Hong et al., 2011). However, much in vivo testing is still 
needed to evaluate the safety of herpesviruses for therapeutic applications, 
especially considering the well reported tendency of vectors based on herpes 
simplex virus 1, another member of the herpesviridae family, to trigger severe 
inflammatory responses in the central nervous system (Wood et al., 1994, 
McMenamin et al., 1998).  
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1.3.2 Non-viral Drug Delivery Systems 
Although viral drug delivery has proven effective in vitro, its clinical application 
has largely been deterred by problems associated with its oncogenic potential, 
lack of tumour-specific targeting, high immunogenicity and difficulty of large 
scale production. As a result, non-viral drug delivery systems, which can 
circumvent or minimise these problems and are able to deliver a diverse range 
of cargos not limited to nucleic acids, have attracted considerable attention in 
recent years (Cheng et al., 2012).  
Several important parameters need to be considered in the design of a non-viral 
anti-cancer drug delivery system, including: 
 Size: Particles should be 10-100 nm in diameter to avoid rapid renal 
clearance (Choi et al., 2007), and to accumulate preferentially at 
disease sites characterised by increased vascular permeability, such 
as sites of infection or tumour (Matsumura and Maeda, 1986, Tabata 
et al., 1998). 
 Zeta potential: Zeta potential is a measure of the magnitude of the 
electrostatic attraction or repulsion between particles, and is related 
to their surface charge. To minimize nonspecific electrostatic 
interactions with cells, which typically display a zeta potential within 
the range of -5 to -20 mV (Zhang et al., 2008, Bondar et al., 2012), 
and to reduce macrophage uptake, a small negative zeta potential is 
generally desirable for nanoparticles (Zahr et al., 2006). 
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 Immunomasking: A highly immunogenic delivery system can trigger 
potentially lethal inflammatory responses in patients, as seen with 
adenoviruses (Marshall, 1999), and also prohibits repeated dosing. 
This can be minimised in non-viral delivery systems via surface 
coverage with PEG molecules, which mask epitopes from the 
immune system (Knop et al., 2010). 
 Targeting: One common problem with many conventional cancer 
drugs in use today is a lack of specificity. They are readily 
internalised by healthy as well as cancer cells, thus producing side 
effects. To this end, ligands that bind cancer cell surface markers can 
be incorporated into non-viral drug delivery systems. These markers 
are typically receptors which are overexpressed on cancer cells, 
such as EGFR, and receptors for transferrin (Tf) and folate (Cheng et 
al., 2012). Targeting agents can be natural receptor ligands like Tf or 
synthetic ones like peptide or nucleic acid aptamers (Bunka and 
Stockley, 2012). Aside from preferential binding to cancer cells, 
targeting ligands also offer a mechanism of cell entry by receptor-
mediated endocytosis (Bareford and Swaan, 2007). 
 Endosomal escape: Following endocytosis, delivered drugs must 
escape the endosome into the cytosol, where many drugs mediate 
their effect. This may be achieved by incorporating endosomal 
buffering ligands, such as histidine-rich peptides and 
polyethyleneimine. These ligands can absorb protons as they are 
pumped into the endosome, acting as ‘proton sponges’, and 
promoting further proton influx. This in turn is coupled to an 
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increased influx of chloride ions and water, resulting in the osmotic 
swelling and eventual rupture of the endosome, which can then 
release its contents into the cytosol (Behr, 1997).   
A diverse range of non-viral drug delivery systems have been tested; some are 
already clinically approved or in advanced stages of clinical trials. A selection of 
some promising formulations is highlighted below; many others exist (Hamidi et 
al., 2008, Kesharwani et al., 2014, Safari and Zarnegar, 2014, Chari et al., 
2014, Alconcel et al., 2011).  
 
Liposomes 
Liposomes are self-assembling spherical vesicles with a membrane composed 
of lipid bilayers, and represent a major class of drug delivery systems. Reports 
of the first liposomes emerged as early as 1965 (Bangham et al., 1965), 
followed swiftly by speculations over their potential for drug delivery. These 
were validated three decades later with the FDA approval of Doxil – a 
PEGylated liposomal formulation of doxorubicin, which was the first FDA 
approved nanoparticulate drug delivery system, and is now used for treating 
various cancers including Kaposi's sarcoma, refractory ovarian and breast 
cancers, and multiple myeloma (Gabizon et al., 2003, James et al., 1994, Blade 
et al., 2011, Barenholz, 2012). Since then, a large number of liposomal systems 
have emerged from pre-clinical and clinical testing, that deliver a diverse range 
of drugs, from established small molecule chemotherapeutics like cisplatin to 
relatively novel drug entities such as siRNAs (Table 1.4). 
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Product 
 
Drug Indications Approval Ref 
Approved liposomal drug delivery systems 
Doxil/ 
Caelyx  
Doxorubicin Kaposi's sarcoma 1995 1-3 
 Ovarian cancer 1999 
Breast cancer 2003 
MM with bortezomib 2007, 
(Europe, Canada) 
 
Dauno-
Xome  
Daunorubicin Kaposi's sarcoma 1996 (Europe),  
1996 (USA) 
4 
Myocet  Doxorubicin Breast cancer with  
cyclophosphamide 
2000 (Europe) 5 
Lipo-Dox  Doxorubicin Kaposi's sarcoma, breast 
and ovarian cancer 
2001 (Taiwan)  
Marqibo  Vincristine ALL 2012 (USA) 6 
Liposomal drug delivery systems in clinical trials 
CPX-351  Cytarabine: 
daunorubicin 
Acute myeloid leukemia Phase II 7 
CPX-1  Irinotecan 
HCI:floxuridine 
Colorectal cancer Phase II 8 
MM-302  ErbB2/ErbB3-targeted 
doxorubicin 
ErbB2-positive breast cancer Phase I 9 
MBP-436  Tf-targeted oxaliplatin Gastric cancer Phase II 10 
Lipo-platin  cisplatin NSCLC Phase III 11 
Thermo-
Dox 
Thermosensitive 
doxorubicin 
Primary hepatocellular 
carcinoma 
Phase III 12 
Endo-Tag-
1 
Cationic liposomal 
paclitaxel 
Pancreatic cancer Phase II 13 
 Triple negative breast cancer Phase II 
TKM-
PLK1  
RNAi targeting polo-
like kinase 1  
Liver tumours Phase I  
  
Stimu-vax Anti-MUC1 cancer 
vaccine 
NSCLC Phase III 14 
 
Table 1.4. Selected examples of liposomal drug delivery systems that are clinically 
approved or undergoing clinical trials for treating cancer. References: 1=(James et al., 
1994); 2=(Blade et al., 2011); 3=(Barenholz, 2012); 4=(Petre and Dittmer, 2007); 5=(Batist et 
al., 2001); 6=(Sarris et al., 2000); 7=(Riviere et al., 2011); 8=(Dicko et al., 2010); 9=(McDonagh 
et al., 2012); 10=(Suzuki et al., 2008); 11=(Fantini et al., 2011); 12=(Poon and Borys, 2011); 
13=(Fasol et al., 2012); 14=(Bradbury and Shepherd, 2008). Adapted from Allen and Cullis 
(2013). (Allen and Cullis, 2013).  
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Liposomes can be constituted from a variety of lipid components, including 
phospholipids, cholesterols, cationic lipids and various lipid-like materials. Lipid 
composition can greatly influence the physical properties of liposomes 
(Yitbarek, 2011) and their drug delivery efficiency (Kim et al., 2010). For 
instance, cholesterols are commonly included to improve liposomal stability, 
cargo retention and uptake (Gao and Huang, 1995, Allen and Cleland, 1980, 
Cullis, 1976); some cationic derivatives of cholesterol can also facilitate 
endosomal escape (Kim et al., 2008). Synthetic phospholipids can be 
incorporated to confer useful properties to liposomes, for example, 
thermosensitivity to release their drug cargo only at elevated temperatures to 
complement hyperthermia  therapy (Poon and Borys, 2011, Needham et al., 
2000). PEGylated lipids can be incorporated to confer steric stabilisation to the 
nanoparticle, and prolong its blood circulation by evading the mononuclear 
phagocyte system (Gabizon and Papahadjopoulos, 1988, Senior et al., 1991). 
Amino-lipid derivatives containing cleavable ester bonds have recently been 
developed to improve the biodegradability of liposomes (Maier et al., 2013). A 
wide range of methods for liposome preparation are available, which can also 
influence important properties such as the size and dispersity of liposomes 
(Laouini et al., 2012, Mozafari, 2005). 
Significant progress has also been made towards cationic liposomes, in 
particular for the cellular delivery of nucleic acid therapeutics such as siRNAs. 
Cationic liposomes self-assemble with siRNA via electrostatic interactions 
between positively charged lipids and the negatively charged phosphate 
backbone of siRNA, forming lipoplexes. Lipoplexes can protect encapsulated 
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siRNA from nuclease degradation, and facilitate their transport across the cell 
membrane.   
Nucleic acid delivery by cationic liposomes is well established, as highlighted by 
the prevalence of commercially available products such as Lipofectin, 
Oligofectamine, Lipofectamine and RNAifect, which are commonly used in 
laboratories to enhance siRNA delivery in vitro (Dalby et al., 2004, Baker et al., 
2006, Bjorge et al., 2011). Furthermore, nearly half of the most promising siRNA 
drug candidates currently in clinical trials are formulated with cationic liposomes 
for delivery (Bouchie, 2012). For example, Alnylam Pharmaceuticals' ALN-
VSP02, which is a PEGylated liposome used to treat liver cancer, delivers 
siRNAs targeted against the mRNAs of vascular endothelial growth factor and 
kinesin spindle protein, both of which have important roles in tumour 
proliferation and survival. ALN-VSP02 has suitable physical properties for 
delivering siRNA in vivo, including a diameter of 80-100 nm and a small zeta 
potential of <6 mV at pH 7.4. Intravenous administration of ALN-VSP02 in 
patients with advanced cancer and liver metastases gave encouraging results, 
including siRNA-mediated cleavage of targeted mRNAs in the liver and 
pronounced tumour regression (Tabernero et al., 2013).  
One disadvantage of currently approved liposomal delivery systems, as well as 
many of the liposomal drug candidates, is the absence of a tumour targeting 
mechanism. As a result, significant levels of siRNA may be taken up by healthy 
cells alongside the cancer cells, causing dose-limiting side effects. Recent 
progress has been made to address this, with several targeted liposomes 
currently undergoing clinical or pre-clinical testing (Table 1.4). Examples include 
the Tf targeted PEG-liposome, MBP-436 (Suzuki et al., 2008), and the anti-
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HER2 antibody targeted liposome, MM-302 (McDonagh et al., 2012), which 
displayed markedly improved efficacies in vivo compared to their non-targeted 
versions. 
 
Micelles 
Polymeric micelles are spherical monolayer vesicles composed of amphiphilic 
block copolymers, which have a hydrophilic segment and a hydrophobic 
segment. These copolymers self-assemble into micelles in aqueous solution, 
with the hydrophobic segments forming a core, which functions as a 
nanoreservoir for hydrophobic drugs, surrounded by a shell formed by the 
hydrophilic segments. Polymeric micelles are typically 10-50 nm in diameter 
(Kwon and Kataoka, 1995, Allen et al., 1999), and thus can fully benefit from the 
EPR effect to passively accumulate in tumour tissues (Aliabadi and Lavasanifar, 
2006, Kwon and Forrest, 2006). Drug cargos can be packaged inside micelles 
by either physical entrapment, or chemical conjugation. Physical entrapment 
involves cargo incorporation via hydrophobic interactions between the drug and 
the micelle core, whilst chemical conjugation involves the covalent attachment 
of drugs to the hydrophobic core (Gong et al., 2012). Polymeric micelles have 
been tested for the delivery of various anti-cancer drugs, such as anthracyclines 
(Nakanishi et al., 2001, Matsumura et al., 2004) and taxanes (Kim et al., 2001, 
Kim et al., 2004, Kim et al., 2007).  
Many important properties of micelle delivery systems, including particle size, 
drug loading and release, and pharmacokinetics, can be modulated via the 
chemical composition of constituent block copolymers (Xiong et al., 2011). PEG 
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is typically used as the hydrophilic block, which sterically stabilises the resulting 
micelles and also reduces their clearance in vivo by the mononuclear phagocyte 
system (Barratt, 2003). To avoid long-term toxicities, core-forming blocks which 
can undergo hydrolysis or enzymatic degradation, such as poly(L-amino acids) 
and polyesters, can be used to confer biodegradability. Copolymers such as 
poly(N-isopropylacrylamide) and sodium 2-acrylamido-2-methyl-1-propane  can 
also be used to impart additional functions such as temperature- or pH-sensing, 
to enable degradation of the delivery system and subsequent drug release, 
upon reaching tissues or cell compartments with different environments – for 
instance, the acidic microenvironments of tumour tissues and endosomes 
(Ganta et al., 2008, Liu et al., 2011, Islam and Yasin, 2012). Tumour targeting 
ligands, such as monoclonal antibodies and nucleic acid aptamers, can be 
incorporated via attachment to the surface exposed hydrophilic termini of 
micelles (Xiong et al., 2011). 
Several micelle-based drug delivery systems have shown promise in vivo for 
the treatment of cancers. Notably, NK911, a micelle composed of PEGylated 
poly(aspartic acid) block copolymers, has been tested in phase I clinical trials 
for delivering doxorubicin to solid tumours (Nakanishi et al., 2001, Matsumura et 
al., 2004). In a study with 23 patients bearing solid tumours, some dose-limiting 
toxicity, including neutropenia, alongside mild side effects were observed at 
higher doses tested. As expected, NK911-delivered doxorubicin displayed 
longer plasma half-lives in comparison to free doxorubicin. NK911 
administration produced a partial response in one patient with metastatic 
pancreatic cancer, in which the liver metastasis had shrunk by more than 50% 
post treatment. The current clinical progress of NK911 is unclear. 
                                                                                                    ___   _ _                      Page 56 
 
Another drug, Genexol-PM, delivers the water insoluble, mitotic inhibitor 
chemotherapeutic, paclitaxel, to patients with advanced and refractory tumours. 
Genexol-PM is a micelle system composed of PEGylated poly(D,L-lactide) 
copolymers. In mouse models, significantly improved pharmacological 
properties were observed when paclitaxel was delivered by Genexol-PM, 
compared to the free drug, including a three-fold higher maximum-tolerated 
dose, 2-3 fold higher biodistribution in various tissues and tumours, as well as a 
markedly improved anti-tumour efficacy (Kim et al., 2001). These promising in 
vivo data lead to the progression of Genexol-PM to clinical trials (Kim et al., 
2004, Kim et al., 2007). A phase II trial of Genexol-PM was conducted in 69 
patients with advanced NSCLC, in which a 37.7% response rate was achieved 
and relatively low severity and frequency of toxicities were observed even at 
high paclitaxel doses. 
 
Cyclodextrin and Cyclodextrin-containing Polymers 
Cyclodextrins are cyclic oligosaccharides with a lipophilic central cavity and a 
hydrophilic outer surface (Figure 1.10). They are biocompatible, exhibit low 
toxicity and immunogenicity in humans, have strong resistance to degradation 
by human enzymes (Davis and Brewster, 2004). These properties have made 
cyclodextrin an attractive compound for the application of drug delivery.  
One important feature of cyclodextrin is the ability of its hydrophobic cavity to 
form host-guest complexes with hydrophobic molecules, which is largely driven 
by hydrogen bonding, van der Waals and charge transfer interactions and the 
release of water molecules from the cavity (Liu and Guo, 2002). The formation 
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of these inclusion complexes can greatly improve the aqueous solubility of the 
guest molecule, this has been shown for a wide range of hydrophobic drugs 
(Tiwari et al., 2010). In addition to enhanced solubility, cyclodextrin has been 
demonstrated to impart improved bioavailability (Uekama, 2004), lower toxicity 
(Nicolazzi et al., 2002), and increased stability (Ueda et al., 1998) to various 
drugs. 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. (A) Structure of β-cyclodextrin. (B) Schematic representation of the toroid structure 
of β-cyclodextrin. Adapted from Raju et al. (2010). (Raju et al., 2010). 
 
Cyclodextrins can also be incorporated into a cationic linear backbone to form 
cyclodextrin-containing polymers (CDPs, Figure 1.11A), which can package 
polyanionic cargos, such as nucleic acid therapeutics, for intracellular delivery. 
One prominent example of CDP-based drug delivery is the 
RNAi/Oligonucleotide Nanoparticle Delivery, or RONDEL platform (Heidel and 
Schluep, 2012). At the heart of RONDEL are CDPs which consist of 5-6 
                                                                                                    ___   _ _                      Page 58 
 
repeating units of β-cyclodextrin coupled to amidine charge centres and 
terminal imidazoles (Figure 1.10A). These CDPs provide several functions to 
the delivery system: (1) positively charged amidines enable electrostatic 
interactions with therapeutic siRNA cargo, (2) CDPs condense siRNAs into 
nanoparticles and protect them from nuclease degradation, and (3) imidazole 
groups utilise the proton sponge effect to promote endosomal escape.  
CDPs also serve as a structural scaffold onto which additional components can 
be incorporated, including PEG for steric stabilisation (Bellocq et al., 2003) and 
immunomasking of the delivery system (Heidel et al., 2007), and Tf for 
preferential tumour-targeting. By coupling PEG and PEG-Tf to adamantane, a 
cycloalkane which forms high affinity inclusion complexes with β-cyclodextrin 
(Pun and Davis, 2002), the CDP-siRNA core can be non-covalently surface 
decorated with these ligands (Figure 1.11B). Assembled nanoparticles are 70 
nm in diameter and thus benefit from EPR, and each contains approximately 
10,000 CDPs, 2,000 siRNAs, 4,000 PEG-adamantanes and 100 Tf-PEG-
adamatanes (Bartlett and Davis, 2007). Furthermore, the zeta potential of 
RONDEL particles can be adjusted from +15 mV to -25 mV through 
incorporation of AD-PEGs modified to contain an anionic charge (Davis, 2009).  
                                                                                                    ___   _ _                      Page 59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. The RONDEL siRNA delivery platform. (A) Chemical structure of a cyclodextrin-
containing polymer (CDP) composed of repeating units of β–cyclodextrin, positively charged 
amidine centres and terminal imidazoles. (B) Schematic illustrating RONDEL assembly. CDPs 
form high affinity inclusion complexes with adamantane (AD) coupled to PEG or PEG-Tf. 
Addition of siRNAs triggers compaction of the components via electrostatic interactions between 
amidines within CDPs and the phosphate backbone of siRNA. The resulting nanoparticle, 
approximately 70 nm in diameter, contains condensed siRNAs in its core and multiple PEG and 
PEG-Tf ligands on its exterior. Reproduced from Yan et al. (2014).  (Yan et al., 2014).    
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RONDEL demonstrated good efficacy when tested in a metastatic murine 
model of Ewing’s sarcoma, in which RONDEL was used to deliver siRNAs that 
targeted the EWS/Fli1 fusion oncogene, resulting in effective silencing of the 
oncogene and significant anti-tumour effects (Hu-Lieskovan et al., 2005). 
Further, good tolerability of the delivery system was shown in cynomolgus 
monkeys at dosages of 3 and 9 mg siRNA/kg (Heidel et al., 2007). These 
promising results led to the advancement of RONDEL into clinical trials. 
Calando Pharmaceuticals’ CALAA-01, a drug candidate currently undergoing 
phase 1b clinical evaluation (Bouchie, 2012), utilises RONDEL to deliver 
systemically siRNA targeted against the M2 subunit of ribonucleotide reductase 
(RRM2) to solid tumours. Ribonucleotide reductase is required for DNA 
synthesis and is a key component in the proliferation of cancer cells (Cerqueira 
et al., 2007). CALAA-01 has so far demonstrated promising results in human 
patients with metastatic melanoma refractory to standard therapies, in which 
delivered siRNAs localised to tumours, and levels of RRM2 mRNA decreased in 
a dose-dependent manner (Davis et al., 2010). 
 
Virus-like particles (VLPs) 
Similar to viruses, RNAi delivery by VLPs relies on capsids for the 
encapsidation, nuclease protection and intracellular delivery of RNAs. However, 
several important distinctions exist between the two types of delivery system.  
Firstly, VLP delivery utilises capsids of simple viruses, typically bacteriophages, 
to deliver siRNA, rather than complex, genetically-modified human viruses to 
deliver shRNA. Because siRNAs can directly enter the RNAi pathway and do 
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not require expression from a vector, the virus genome can be removed, 
avoiding problems associated with host genome integration, as seen in 
retroviral shRNA delivery. Secondly, the components of a VLP delivery system 
are relatively easy and cheap to prepare. Coat protein subunits that constitute 
capsids can be produced in large quantities and purified from recombinant E. 
coli expression systems (Mastico et al., 1993, Wu et al., 1995). In vitro 
assembly can then be performed to trigger capsid formation and package a 
diverse range of therapeutic cargos not limited to nucleic acids (Galaway and 
Stockley, 2013, Ashley et al., 2011, Wu et al., 1995, Wu et al., 2005, Brown et 
al., 2002, Destito et al., 2007, Stephanopoulos et al., 2010, Wu et al., 2009) 
(Figure 1.12). Thirdly, VLPs can be surface-modified to incorporate a range of 
useful ligands for immunomasking and targeting (Wu et al., 1995, Steinmetz 
and Manchester, 2009, Cheng et al., 2012, Galaway and Stockley, 2013). Thus, 
the resultant semi-synthetic particles, whilst retaining desirable viral attributes 
for drug delivery, exhibit enhanced functionalities.  
Much research on VLP-mediated drug delivery has been based on 
bacteriophage MS2 (Figure 1.12) (Ashley et al., 2011, Galaway and Stockley, 
2013). MS2 is a member of the Leviviridae family of viruses that infects E. coli.  
Its 3,569 nt ssRNA genome – one of the smallest known – was the first genome 
to be fully sequenced in 1976 (Fiers et al., 1976), and encodes only four 
proteins (Figure 1.12A), including the maturation protein (or A-protein), coat 
protein (CP), lysis protein and replicase protein. The MS2 capsid is a T=3 
icosahedral shell ~26 nm in diameter (Figure 1.12B, C), composed of 180 
copies of the CP monomer that associate as 90 non-covalent dimers (Figure 
1.12B, C) (Strauss and Sinsheimer, 1963, van Duin, 1988). Each MS2 virion 
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also contains one copy of the maturation protein, which is implicated in the 
attachment of MS2 to the F-pilus of E. coli and is essential for infectivity (Kozak 
and Nathans, 1971, Krahn et al., 1972).  
 
 
 
 
 
Figure 1.12. Components of the MS2 bacteriophage. (A) A map of the MS2 genome 
(GenBank: NC_001417). (B) Structure of the MS2 capsid (PDB: 2ms2). (C) Structures of the 
two quasi-equivalent MS2 coat protein dimers (PDB: 1zdh). Binding of TR to the symmetrical 
C/C-like dimer triggers a conformational switch, principally in the highlighted FG loops (which 
connect the F and G β-strands in each monomer), to yield an asymmetrical A/B-like dimer. Both 
C/C and A/B-like dimers are required for efficient MS2 capsid assembly in vitro. (D) Structure of 
the TR RNA stem loop, which encompasses 19 nt of the MS2 genome. Adapted from 
Borodavka et al. (2012). (Borodavka et al., 2012). 
 
MS2 has a positive-sense RNA genome, which can either directly serve as 
mRNA for translation into viral proteins, or as a template for RNA replication by 
the viral replicase. Secondary structures within the genome provide a 
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mechanism to regulate the expression of each of the four viral proteins, 
ensuring an appropriate number of copies are made (van Duin, 1988). For 
instance, the gene encoding the CP, which is required in large quantities, is 
highly accessible to ribosomes and can be immediately translated; whereas the 
translation start of the gene encoding A-protein is only transiently accessible 
during replication of the RNA, to limit its expression. Similarly, the start codon 
for the replicase gene – normally hidden within RNA secondary structure – is 
transiently accessible as ribosomes traverse the CP gene (Fiers et al., 1976). 
Lastly, the lysis protein gene is translated upon a +1 ribosomal frameshift during 
translation of the upstream CP gene, which occurs at a very low frequency. 
These frameshifted ribosomes terminate at one of two nonsense codons just 
before the lysis protein cistron, and subsequently initiate translation of the lysis 
protein gene (Kastelein et al., 1982). 
MS2 viral assembly is triggered by a high affinity interaction between a CP 
dimer (CP2) and TR (Figure 1.12D), a 19 nt stem loop encompassing the start 
codon of the replicase gene that acts as a packaging signal. TR binding 
prevents further translation of the replicase gene, and results in a 
conformational change in the CP2, from a symmetrical C/C-like conformation to 
an asymmetrical A/B-like conformation (Figure 1.12C) (Stockley et al., 2007). 
This conformational switch is required for the efficient assembly of MS2 T=3 
capsids (Rolfsson et al., 2008, Stockley et al., 2007), which comprise of 30 C/C-
like and 60 A/B-like CP2. There is a growing body of evidence supporting the 
presence of multiple packaging signals within numerous viral genomes, which 
facilitate their efficient and high-fidelity packaging into assembling capsids 
(Bunka et al., 2011, Qin et al., 2003, Goto et al., 2013, Qu and Morris, 1997).  
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Figure 1.13. Construction of an MS2 VLP-based drug delivery system. VLPs can be 
assembled in vitro by mixing CP2 with TR at neutral pH. Drug cargos (X) conjugated to TR can 
be packaged inside VLPs during assembly. The VLP surface can then be chemically modified to 
display ligands for immunomasking, endosomal escape or tumour targeting. Examples 
presented include PEG, a nucleic acid aptamer, Tf and an antibody (Ab). These are not drawn 
to scale. 
 
MS2 VLPs offer many advantages as a drug delivery system, including (i) they 
are extremely well-characterised, (ii) the MS2 CP can be recombinantly 
expressed in large quantities in E. coli, (iii) VLPs can be efficiently assembled in 
vitro by mixing dissociated CP2 with TR oligonucleotides at neutral pH; any 
cargo attached to TR can be packaged inside during assembly (Figure 1.13), 
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(iv) VLPs are pH-sensitive and can disassemble in the acidic environment of the 
endosome, thus facilitating drug release, (V) with a diameter of 26 nm, MS2 
VLPs fully benefit from EPR, (vi) VLPs have a zeta potential of -25 mV (Pang et 
al., 2009) and therefore are unlikely to have strong electrostatic interactions with 
cells; this may also be adjusted via surface modifications if required, and (vii) 
abundant amines are present on the VLP surface (Figure 1.14) to facilitate 
multivalent display of useful ligands (Figure 1.13).  
Initial work on MS2 VLP-mediated drug delivery began in the Stockley 
laboratory in the 1990s. TR-conjugated ricin A chain (RAC) was packaged into 
VLPs during in vitro assembly, before Tf was attached to the VLP surface as a 
tumour-targeting ligand (Wu et al., 1995). RAC is the ribosome-inactivating 
component of ricin, though its cytotoxicity is limited without the B chain which is 
required for cellular uptake. VLP(RAC)-Tf successfully delivered RAC to HL-60 
promyelocytic leukemia and HeLa cervical cancer cells via Tf receptor-mediated 
endocytosis, and induced significant levels of cell death with an LD50 in the sub 
nM range (Wu et al., 1995). Other combinations of drugs and targeting ligands 
were subsequently tested, including the use of the nucleoside analogue, 5-
fluorouridine, as the therapeutic cargo and antibodies targeting DF3, a breast 
cancer marker, as the tumour-targeting ligand (Brown et al., 2002). The 
resulting VLP particles delivered 5-fluorouridine to ZR-75-1 breast carcinoma 
cells, and enhanced its cytotoxic effects compared to free 5-fluorouridine. In 
2005, VLP-Tf was used to deliver an antisense oligodeoxynucleotide (ODN) to 
leukemia and bladder cancer cell lines (Wu et al., 2005). The ODN targeted the 
mRNA encoding P120, a proliferation-linked nucleolar protein overexpressed in 
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many human tumours. When delivered by VLP-Tf, the ODN induced 8-fold 
enhanced cytotoxicity in Tf-targeted cancer cells compared to the free ODN.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14. Amine groups exposed on the VLP surface. Ribbon diagram of an A/B-like MS2 
CP2 (A subunit in green, B in blue) is shown. Each monomer consists of three amines 
(highlighted in red) which are exposed on the surface of assembled VLPs, two present on lysine 
side chains (K106, K113) and one present at the N-terminus. Therefore, 540 amines are 
displayed on the surface of each VLP. These amines facilitate N-hydroxysuccinimide (NHS)-
based chemistry, which can be used to modify the VLP surface with a range of useful ligands. 
The same amine groups are also present on C/C-like dimers, which are not shown.  
 
More recently, VLP-Tf was used to deliver therapeutic siRNAs targeted against 
the mRNA of the apoptotic factor BCL2, and PLK1 (Galaway, 2011, Galaway 
and Stockley, 2013). The siRNAs were chosen as they were previously 
demonstrated to retain their function despite being covalently attached to an 
RNA aptamer (McNamara et al., 2006), and thus should tolerate TR coupling to 
facilitate their packaging inside VLPs. VLP-Tf successfully delivered the siRNAs 
                                                                                                    ___   _ _                      Page 67 
 
to HeLa cells in a Tf receptor-dependent manner, produced knockdown of the 
targeted mRNAs and their protein products, and induced significant cytotoxicity 
at sub nM siRNA concentrations (Galaway, 2011, Galaway and Stockley, 2013).  
One potential problem which emerged from these studies was the cellular 
uptake of unmodified VLPs, possibly due to the presence of VLP surface 
epitopes that interact with the cell surface and allow internalisation (Wu et al., 
1995, Brown et al., 2002, Wu et al., 2005, Galaway, 2011). Although surface 
modification with Tf improved uptake via Tf receptor-mediated endocytosis, 
some level of non-specific uptake was still evident – shown through inhibition 
assays in which high concentrations of free Tf only partially reduced VLP-Tf 
uptake (Galaway, 2011, Galaway and Stockley, 2013). It was hypothesised that, 
due to the relatively low levels of surface modification (~15.2 Tf per VLP) 
(Galaway, 2011) and the lack of control over their spatial distribution, there 
might be ‘naked’ regions on the VLP surface with exposed epitopes that allow 
non-specific uptake. Non-specific uptake is a highly undesirable feature for drug 
delivery systems, and can severely limit their effectiveness in vivo (Peer et al., 
2007). High levels of uptake by healthy cells can induce dose-limiting side 
effects, and also reduce the amount of drugs taken up by cancer cells, thus 
increasing the effective dosage. Furthermore, prolonged exposure of cancer 
cells to low levels of drugs can facilitate the development of drug resistance 
(Holohan et al., 2013). Ultimately, these effects can significantly limit the 
therapeutic window and efficacy of delivered drugs, therefore non-specific 
uptake is an important issue that needs to be addressed for the MS2 VLP drug 
delivery system.  
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Other groups have since also contributed to the development of this drug 
delivery system. In 2011, the Peabody group reported the use of MS2 VLPs for 
the targeted delivery of cargos to hepatocellular carcinoma (HCC) cells (Ashley 
et al., 2011). A cocktail of siRNAs targeting the mRNA of several cyclins, whose 
overexpression is associated with hepatocarcinogenesis (Masaki et al., 2003), 
were packaged inside MS2 VLPs. The VLP surface was then decorated with (i) 
PEG for immunomasking, (ii) SP94, a targeting peptide previously identified by 
affinity selection from a phage display library against HCC cell surface targets 
(Lo et al., 2008), and (iii) a histidine-rich peptide to promote endosomal escape. 
Gene silencing of targeted cyclins, growth arrest and apoptosis were observed 
at pM siRNA concentrations in HCC cells, but not in normal hepatocyte cells. 
Additionally, these VLPs have successfully delivered other cargos, including 
quantum dots, and a drug cocktail containing doxorubicin, cisplatin and 5-
fluorouracil to SP94-targeted HCC cells, selectively killing them at drug 
concentrations <1 nM (Ashley et al., 2011). This highlighted the potential of 
MS2 VLPs to facilitate combinatorial therapy, delivering multiple drugs which 
may demonstrate good synergy in vitro, but are severely limited by their 
different pharmacokinetics and biodistribution in vivo. 
Preliminary in vivo testing of MS2 VLP drug delivery has been carried out by the 
Wang group (Pan et al., 2012a, Pan et al., 2012b, Li et al., 2013). MS2 VLPs 
packaging a pre-miRNA, pre-miR146a, were surface-decorated with HIV Tat 
peptides for cell penetration; no cell-targeting ligands were used. Upon 
intravenous administration in mice, VLP(pre-miR146a)-Tat particles displayed 
widespread biodistribution in the plasma, lung, spleen and kidney, where high 
levels of mature miR146a were detected and knockdown of known targets of 
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miR146a was observed (Pan et al., 2012b). Systemic lupus erythematosus is 
an autoimmune disease characterised by the production of pathogenic 
autoantibodies. Administration of MS2 VLP-delivered miR146a, which is known 
to act as an inhibitor of autoimmunity and cancer, to lupus-prone mice 
significantly reduced the expression of autoantibodies and total IgG (Pan et al., 
2012a). More recently, MS2 VLPs were adapted for the delivery of mRNA 
vaccines, which successfully protected mice from prostate cancer, and delayed 
tumour growth in prostate cancer mice models (Li et al., 2013).  Importantly, no 
off-target toxicities were observed in VLP-treated mice in these studies.  
VLPs based on other viruses have also been explored for the delivery of 
diagnostic or therapeutic agents. It has been reported that  VLPs of the cowpea 
mosaic virus (CPMV) display natural tumour targeting via vimentin (Steinmetz et 
al., 2011), a type III intermediate filament associated with tumour growth and 
invasiveness, which is overexpressed on endothelial cells in tumour tissue (van 
Beijnum et al., 2006). The cellular uptake of fluorescently-labelled CPMV VLPs 
correlated positively with vimentin expression in four different cancer cell lines; 
successful targeting was also demonstrated using human tumour xenografts 
(Steinmetz et al., 2011).  
Recently, a non-covalent infusion technique has been utilised to stably package 
fluorescent and therapeutic cargos which have an affinity for nucleic acids, 
including 4',6-diamidino-2-phenylindole (DAPI), propidium iodide, acridine 
orange and proflavin, inside RNA-encapsidated CPMV VLPs (Yildiz et al., 
2013). The vimentin-targeted uptake of dye-loaded VLPs by HeLa, HT-29 and 
PC-3 cancer cells was visualised. VLPs loaded with proflavin, a bacteriostatic 
agent with known anti-proliferative activity in tumours, demonstrated 
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comparable IC50 to the free drug in the three cancer cell lines; empty CPMV 
VLPs did not produce an effect on cell viability, indicating the absence of off-
target cytotoxicity. 
Filamentous VLPs of another plant virus, the Potato virus X, have also been 
tested as a delivery system. These VLPs exhibited notably enhanced tissue 
penetration and tumour homing properties compared to the spherical CPMV 
VLPs (Shukla et al., 2013). This study highlighted the potential of exploiting the 
shapes of VLPs to achieve better delivery efficiencies. 
 
1.4 Summary and aims 
More than a century after Ehrlich established the foundations of chemotherapy, 
several generations worth of effort have failed to fulfil his vision of a magic bullet 
therapeutic – a chemotherapia specifica. One current focus in cancer therapy is 
the development of nanoparticulate drug delivery systems, which have been 
shown to improve many aspects of traditional and novel chemotherapeutics; 
some formulations have already received FDA approval and many more are 
emerging from laboratories and clinical trials. Despite these advancements, 
there is a need for more targeted approaches to drug delivery, to enhance 
tumour selectivity and drug efficacy.  
The aim of this project was to build upon a targeted drug delivery system based 
on MS2 VLPs previously established in the Stockley laboratory. Specific goals 
were to: (i) mitigate non-specific cellular uptake of VLPs, (ii) test a relatively 
novel class of targeting ligands, nucleic acid aptamers, to promote tumour-
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specific uptake, and (iii) incorporate different drug cargos inside VLPs for 
delivery. 
Chapter 3 explores whether the incorporation of a layer of PEG to the MS2 VLP 
surface can reduce non-specific cellular uptake. The synthesis and analysis of 
VLPs surface modified with PEG24 (VLP-PEG24), or PEG24 and Tf (VLP-PEG24-
Tf), are described. Using HeLa cells, the uptake of VLP, VLP-PEG24 and VLP-
PEG24-Tf are compared. Finally, the cellular effects of siRNA delivery by VLP-
PEG24-Tf are assessed.  
In Chapter 4, the RNA aptamer, A9L, is tested for use as a targeting ligand in 
the MS2 VLP drug delivery system. A9L specifically binds the prostate cancer 
marker, PSMA, and allows internalisation into PSMA-expressing prostate 
cancer cells. The construction and analysis of VLP-PEG24-A9L is described. 
Using two prostate cancer cell lines, PSMA+ve LNCaP and PSMA-ve PC-3, the 
cellular effects of siRNA delivery by VLP-PEG24-A9L are assessed. 
Chapter 5 describes the testing of the anthracycline chemotherapeutic, 
doxorubicin (Dox), as a drug cargo for targeted delivery by VLP-PEG24-A9L. 
The packaging of Dox inside TR-Cy5 encapsidated VLPs is described. The 
uptake and cytotoxic effects of VLP-PEG24-A9L delivered Dox are assessed in 
LNCaP, PC-3 and HeLa cells.   
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Chapter 2 
Materials and Methods 
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2.1 Materials 
2.1.1 General reagents 
All chemicals were purchased from Sigma-Aldrich (Gillingham, UK), unless 
otherwise stated. DEPC-treated water was purchased from Severn Biotech 
(Kidderminster, UK). Protease/Phosphatase Inhibitor Cocktail (100X) was 
purchased from Cell Signalling Technology (Leiden, Netherlands). Amicon Ultra 
0.5 mL 100 kDa molecular weight cut-off (MWCO) spin concentrators were 
purchased from Millipore (Feltham, UK). 
 
2.1.2 Reagents for the synthesis of surface-modified VLPs 
Crosslinking reagents 
N-succinimidyl S-acetylthioacetate (SATA) and sulfosuccinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) were purchased 
from Pierce (Paisley, UK). SM(PEG)24 was from Fisher Scientific 
(Loughborough, UK). EZ-Link NHS-PEG12-biotin was purchased from Thermo 
Scientific (Hemel Hempstead, UK). 
 
Protein 
Recombinant human holo-Tf was purchased from Alpha laboratories (Eastleigh, 
UK).  
 
Nucleic acids 
A9L-thiol RNA aptamers were purchased from DNA Technology (Risskov, 
Denmark). Other RNAs were synthesised at the University of Leeds (with the 
help of Amy Barker). Syntheses were carried out on an ABI Model 394 DNA 
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Synthesizer, using UltraMILD reagents purchased from Link Technologies 
(Bellshill, UK). 
 
RNA Sequence (5′->3′) Modifications Target 
TR ACAUGAGGAUUACC
CAUGU 
Cy5 (5′) - 
TR-Bcl2 sense TR-
AAAAGUGAAGUCAA
CAUGCCUGCUU 
Cy5 (5′) - 
Bcl2 antisense GCAGGCAUGUUGAC
UUCACUU 
Cy5 (5′) BCL2 mRNA 
TR-Control sense TR-
AAAAUUCUCCGAAC
GUGUCACGUUU 
Cy5 (5′) - 
Control antisense ACGUGACACGUUCG
GAGAAUU 
Cy5 (5′) - 
U6 UUUUUU 6-FAM (5′),  
Thiol-C3 (3′) 
- 
A9L GGGCCGAAAAAGAC
CUGACUUCUAUACU
AAGUCUACGUCCC 
Thiol-C3 (3′) PSMA 
 
Table 2.1. List of RNA oligonucleotides used along with their sequences, modifications, 
and molecular targets (where relevant). 
 
2.1.3 Biochemical assay reagents 
Gel filtration chromatography 
The Superose 6 10/300 GL size exclusion column, and Sephadex G25 NAP-5, 
NAP-10 and NAP-25 columns were purchased from GE Healthcare (Chalfont St 
Giles, UK).  
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Gel electrophoresis 
Fermentas PageRuler Plus Prestained Protein Ladder was purchased from 
Thermo Scientific. 10 bp DNA Step Ladder was from Promega (Southampton, 
UK). Hyperladder I was from Bioline (London, UK). Ethidium bromide was from 
Severn Biotech. 
 
Western blotting 
The anti-MS2 CP antibody was purchased from Millipore. The anti-PSMA 
antibody was purchased from Abgent Europe Ltd (Maidenhead, UK). Enhanced 
chemiluminescent Western blotting substrate was purchased from Amersham 
(Amersham, UK). Nitrocellulose membrane was purchased from Whatman 
(Little Chalfont, UK). Dried milk powder was from Marvel (St. Albans, UK). 
 
Transmission electron microscopy (TEM) 
Ultra-thin carbon coated copper grids were from Agar Scientific (Stansted, UK). 
Uranyl acetate in pH 4.0 water was provided by Martin Fuller at the University of 
Leeds.  
 
2.1.4 Cell biology reagents 
Cell culture 
HeLa cervical cancer cells were purchased from ATCC (Manassas, VA, USA) 
(Galaway, 2011).  The prostate cancer cell lines, LNCaP and PC-3, were a gift 
from Prof. Norman Maitland at the University of York. Dulbecco’s Phosphate 
Buffered Saline (DPBS), Dulbecco’s Modified Eagles Medium (DMEM), poly-L-
lysine hydrobromide, human serum type AB from male plasma, T75 flasks, and 
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6 well and 24 well plates were purchased from Sigma-Aldrich. Foetal Bovine 
Serum (FBS), Penicillin Streptomycin (Pen Strep), Ham's F-12K medium, RPMI-
1640 medium, and TrypLE Express were from Life Technologies (Paisley, UK). 
HiPerFect Transfection Reagent was purchased from Qiagen (Manchester, 
UK). 
 
Fluorescent dyes  
Propidium iodide, FITC-labelled Annexin V and 4,6-diamino-2-phenylindole 
(DAPI) were purchased from Life Technologies.  
 
Fluorescent dye Excitation max (nm) Emission max (nm) 
DAPI 358 463 
FITC 495 517 
Fluorescein 495 517 
Propidium iodide 538 617 
Cyanine 3 549 562 
Cyanine 5 646 664 
 
Table 2.2. List of fluorescent dyes used, along with their spectral properties. 
 
Antibodies 
FITC-labelled anti-human BCL2 antibody and FITC-labelled isotype control 
antibody were purchased from BD Biosciences (Oxford, UK). The anti-PSMA 
antibody was from Abgent Europe Ltd. 
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2.1.5 Buffers 
Buffers were prepared with ddH2O and filter sterilised (0.2 μm filtration). 
For the purification of MS2 VLPs: 
 λ buffer: 10 mM HEPES, 100 mM NaCl, 1 mM EDTA, adjusted to pH 7.2 
with NaOH, 
 Ω buffer: 50 mM HEPES, 100 mM NaCl, 10 mM dithiothreitol, 5 mM 
EDTA, adjusted to pH 7.2 with NaOH. 
 
For the surface modification of MS2 VLPs: 
 HEPES buffer: 50 mM HEPES, 100 mM NaCl, adjusted to desired pH with 
NaOH, 
 Iron(III) citrate buffer: 10 mM iron(III) citrate, 200 mM citric acid, adjusted 
to pH 7.8 with sodium bicarbonate. 
 
For biochemical assays: 
 Laemmli loading buffer (2x): 125 mM Tris base, 20% (v/v) glycerol, 4% 
(w/v) SDS, 10% (v/v) β-mercaptoethanol, 0.02% (w/v) bromophenol blue, 
adjusted to pH 6.8 with HCl, 
 SDS-PAGE Running buffer (10x): 248 mM Tris base, 1.92 M glycine, 1% 
(w/v) SDS, 
 SDS-PAGE Resolving buffer: 1.5 M Tris base, 0.4% (w/v) SDS, adjusted 
to pH 8.8 with HCl, 
 SDS-PAGE Stacking buffer: 0.5 M Tris base, 0.4% (w/v) SDS, adjusted to 
pH 6.8 with HCl, 
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 Western blotting transfer buffer: 25 mM Tris base, 190 mM glycine, 0.1% 
(w/v) SDS, 20% (v/v) methanol, 
 Tris-buffered saline (TBS): 50 mM Tris base, 150 mM NaCl, adjusted to 
pH 7.5 with HCl, 
 TBS Tween (TBST): TBS with 0.1% (v/v) Tween, 
 BLOCK (5x): TBS with 3.75% (w/v) milk powder, 
 TBE: 89 mM Tris base, 89 mM boric acid, 2 mM EDTA, adjusted to pH 8.0 
with NaOH. 
 
For cell biology assays: 
 Annexin binding buffer: 100 mM HEPES, 1.4 M NaCl, 25 mM CaCl2, 
adjusted to pH 7.5 with NaOH, 
 DPBS/FBS: DPBS with 4% (v/v) FBS, 
 DPBS Tween (DPBST): DPBS with 0.1% (v/v) Tween, 
 FIX: DPBS with 1% (w/v) paraformaldehyde, 
 Permeabilisation buffer: DPBS with 1% (v/v) Triton X-100, 4% (v/v) FBS 
and 2.5 mM EDTA, 
 PSMA Binding buffer: 20 mM HEPES, 150 mM NaCl, 2 mM CaCl2, 0.01% 
(w/v) BSA, pH 7.4. 
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2.2 Methods 
2.2.1 Preparation and modification of VLPs 
Annealing and purification of TR-siRNAs 
Double-stranded siRNAs were prepared by mixing the TR-sense strand (10 µM) 
and the anti-sense strand (10 µM) in DEPC-treated water. The mixture was 
briefly heated to 95oC, and was allowed to cool to room temperature. The 
annealing reaction was analysed by gel electrophoresis on a native 15% (w/v) 
polyacrylamide gel, visualised by ethidium bromide staining and by 
fluorescence scanning on a Fujifilm FLA-5000. The band corresponding to 
annealed TR-siRNA was excised, from which the RNA was extracted via 
electro-elution (80 V for 60 min). The TR-siRNA was then concentrated by 
isopropanol precipitation, and resuspended in DEPC-treated water. 
 
Purification of MS2 VLPs 
Recombinant MS2 VLPs were previously expressed in E. coli in the Stockley 
laboratory, stored as a frozen cell paste. The cell paste was resuspended at 
room temperature in Ω buffer, and lysed via sonication, with a pulse sequence 
of 10 on, 10 off for 3 cycles. The cell lysate was centrifuged at 10,000 RCF for 
30 min at 4oC. The VLP-containing supernatant was collected, treated with 
DNase I (10 µg.mL-1) for 1 h at room temperature, and then centrifuged again at 
10,000 RCF for 30 min at 4oC. The supernatant was collected, to which 
ammonium sulfate was slowly added to reach 60% saturation, before it was 
centrifuged at 10,000 RCF for 30 min at 4oC. The precipitate was resuspended 
in λ buffer, and centrifuged through a 15-45% (w/v) linear sucrose density 
gradient at 47,000 RCF, 4oC for 17 h. Fractions were collected and analysed by 
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SDS-PAGE to check for MS2 CP content. Fractions containing MS2 CPs 
(hence VLPs) were pooled, ammonium sulfate precipitated, and purified through 
a second round of sucrose density gradient centrifugation as before. Pure MS2 
VLP-containing fractions were pooled and stored at 4oC. 
 
Preparation of MS2 CP2 
Purified MS2 VLPs were concentrated using a 100 kDa MWCO spin 
concentrator, into pH 7.3 HEPES buffer. Concentrated VLPs were dissociated 
by diluting 1:3 in glacial acetic acid for 1 h at 4oC, before brief centrifugation to 
pellet precipitated nucleic acid material. The supernatant was eluted into 20 mM 
acetic acid using a Sephadex G-25 NAP-10 column; fractions were collected 
and analysed by UV spectroscopy and SDS-PAGE for CP content. Fractions 
with an A260/A280 ratio of ≤ 0.8 were considered to contain sufficiently pure CP2; 
these were pooled, and the concentration was estimated using ε280nm = 33,240 
M-1.cm-1. When stored in 20 mM acetic acid at 4oC, CP2 remain stable and 
assembly competent for up to 2 months.  
 
VLP assembly and cargo packaging 
Trial experiments to establish optimal reassembly and packaging conditions 
were performed in 10 µL volumes. Acid dissociated CP2 were mixed with TR-
Cy5 at molar ratios of 1:1, 2:1, 10:1, 15:1, 25:1 and 50:1 in pH 7.3 HEPES 
buffer at room temperature for 5 h. A 10 μM CP2-only control was also used. 
The concentration of TR-Cy5 was fixed at 1 μM, and that of CP2 varied 
accordingly. The assembly reactions were then analysed by TEM and native 
2% (w/v) agarose gel electrophoresis. The agarose gel was run in TBE buffer at 
90 V for 90 min, and then visualised by ethidium bromide and Coomassie 
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Brilliant Blue R-250 staining. Larger scale assemblies were carried out in 1 mL 
volumes, in which acid dissociated CP2 (10 μM) were mixed with TR-X (1 μM) in 
pH 7.3 HEPES buffer at room temperature for 5 h, before the mixture was 
incubated at 4oC overnight. The reactions were analysed by TEM, size 
exclusion chromatography and native 2% (w/v) agarose gel electrophoresis. 
Assembled VLPs were concentrated and buffer exchanged into pH 8.3 HEPES 
using 100 kDa MWCO spin concentrators, then stored at 4oC. 
 
Quantification of siRNA and CP content in RNA encapsidated VLPs 
To determine the concentration of Cy5-labelled TR or TR-siRNA encapsidated 
inside VLPs, the Cy5 fluorescence was measured at 649 nm using a Nanodrop 
1000 (ε649nm Cy5 = 250,000 M
-1.cm-1). To estimate the protein content, the 
absorbance at 260 nm and 280 nm were measured using a Nanodrop 1000 and 
the following formula was used (Groves et al., 1968):  
1.55 x A280 – 0.76 x A260 = [Proteins] (mg.mL
-1)  
 
From this, the concentration of CP2 was calculated using:  
Mw (CP2) = 27,800 g.mol
-1. 
 
Synthesis of VLP-Tf 
In a 1 mL reaction in pH 8.3 HEPES, TR-Cy5 encapsidated VLPs (333 nM) 
were reacted with SATA (166.5 µM) at room temperature for 1 h. To deacetylate 
SATA-modified VLPs, hydroxylamine-HCl (50 mg.mL-1 in 100 μL pH 8.3 
HEPES) was added to the mixture, and left to react at room temperature for 1 h. 
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In a separate 1 mL reaction in pH 8.3 HEPES, human apo-Tf (10 μM) was 
reacted with sulfo-SMCC (1 mM) at room temperature for 1 h. The two reaction 
mixtures were separately eluted from NAP-25 columns into pH 7.3 HEPES, 
mixed at room temperature for 2 h, then at 4oC overnight. Apo-Tf in the solution 
was converted to holo-Tf by the addition of 5 μL iron(III) citrate buffer. The 
mixture was purified by size exclusion chromatography on a Superose 6 10/300 
column, equilibrated and eluted with DPBS at a flow rate of 1 mL.min-1. The 
absorbance at 260 nm, 280 nm and 465 nm were monitored and recorded using 
the ÄKTA FPLC system (GE healthcare). The fraction containing VLP-Tf was 
collected and concentrated using 100 kDa MWCO spin concentrators into 
DPBS. VLP-Tf was analysed by size exclusion chromatography, TEM, Western 
blotting and native 2% (w/v) agarose gel electrophoresis. 
 
Synthesis of VLP-PEG12-biotin 
In a 200 µL reaction in pH 8.3 HEPES, TR-Cy5 encapsidated VLPs (55.56 nM) 
were mixed with EZ-Link NHS-PEG12-biotin (0.5 mM) at room temperature for 
30 min. The mixture was eluted through a NAP-5 column into DPBS – fractions 
were collected and checked for A260, A280 and A649 using a Nanodrop 1000, 
those containing VLP-PEG12-biotin were pooled and concentrated using a 100 
kDa MWCO spin concentrator. VLP-PEG12-biotin was then analysed by SDS-
PAGE, TEM and native 2% (w/v) agarose gel electrophoresis to confirm 
successful conjugation and the intact nature of particles.  
 
Synthesis of VLP-PEG24 
In a 200 µL reaction in pH 8.3 HEPES, TR-X encapsidated VLPs (55.56 nM) 
were mixed with SM(PEG)24 (0.3 mM, 3 mM, 15 mM, 30 mM, or 60 mM) at 
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room temperature for 30 min. The SM(PEG)24 to VLP surface amine molar ratio 
was 10, 100, 500, 1000 or 2000 to 1, respectively. The mixture was eluted 
through a NAP-5 column into pH 7.3 HEPES. Fractions were collected and 
checked for A260, A280 and A649 using a Nanodrop 1000. Those containing VLP-
PEG24-maleimide were pooled. To quench unreacted maleimide groups, β-
mercaptoethanol (7 μL of 14.3 M stock) was added to VLP-PEG24-maleimide, 
and left to react at room temperature overnight. Quenched VLP-PEG24 was 
eluted through a NAP-5 column into DPBS and concentrated using a 100 kDa 
MWCO spin concentrator. VLP-PEG24 was then analysed by SDS-PAGE, TEM, 
linear 15-45% (w/v) sucrose density gradient centrifugation, size exclusion 
chromatography and native 2% (w/v) agarose gel electrophoresis to confirm 
successful conjugation and the intact nature of particles.  
 
Synthesis of VLP-PEG24-Tf 
In a 200 µL reaction in pH 8.3 HEPES, Tf (1.67 µM) was mixed with SATA (1.4 
mM) at room temperature for 30 min. To deacetylate SATA-modified Tf, 
hydroxylamine-HCl (50 mg.mL-1 in 50 μL pH 8.3 HEPES) was added to the 
mixture, and left to react at room temperature for 1 h. In a separate 200 µL 
reaction in pH 8.3 HEPES, TR-X encapsidated VLPs (55.56 nM) were mixed 
with SM(PEG)24 (15 mM) at room temperature for 30 min. The SM(PEG)24 to 
VLP surface amine molar ratio was 500 to 1. The two reaction mixtures were 
separately eluted from NAP-5 columns into pH 7.3 HEPES, fractions were 
collected and checked for A260, A280 and A649 using a Nanodrop 1000, those 
containing Tf and VLP-PEG24-maleimide were pooled, and mixed together at 
room temperature for 2 h. β-mercaptoethanol (7 μL of 14.3 M stock) and iron(III) 
citrate buffer (5 µL) were added to VLP-PEG24-Tf to quench unreacted 
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maleimide groups and to convert apo-Tf to holo-Tf, respectively. The mixture 
was allowed to react at room temperature overnight.  
Quenched VLP-PEG24-Tf was purified by linear 15-45% (w/v) sucrose density 
gradient centrifugation. The fraction containing VLP-PEG24-Tf was collected, 
and then concentrated using a 100 kDa MWCO spin concentrator. VLP-PEG24-
Tf was analysed by Western blotting, TEM, size exclusion chromatography and 
native 2% (w/v) agarose gel electrophoresis to confirm successful conjugation 
and the intact nature of particles.  
 
Synthesis of VLP-PEG24-U6-FAM 
In a 100 µL reaction in pH 7.3 HEPES, U6-FAM (8.33 µM) was mixed with 
TCEP (20 mM) at 70oC for 2 min, and then at room temperature for 2 h. In a 
separate 200 µL reaction in pH 8.3 HEPES, TR-Cy5 encapsidated VLPs (55.56 
nM) were mixed with SM(PEG)24 (15 mM) at room temperature for 30 min. The 
SM(PEG)24 to VLP surface amine molar ratio was 500 to 1. The two reaction 
mixtures were separately eluted from NAP-5 columns into pH 7.3 HEPES, 
fractions were collected and checked for A260, A280, A494 and A649, using a 
Nanodrop 1000, those containing U6-FAM and VLP-PEG24-maleimide were 
pooled, and mixed together at room temperature for 2 h, to allow conjugation. 
To quench unreacted maleimide groups, β-mercaptoethanol (7 μL of 14.3 M 
stock) was added to VLP-PEG24-U6-FAM, and left to react at room temperature 
overnight. Quenched VLP-PEG24-U6-FAM was eluted through a NAP-25 
column, and concentrated into DPBS using a 100 kDa MWCO spin 
concentrator. VLP-PEG24-U6-FAM was then analysed by UV-visible 
spectroscopy, SDS-PAGE, and native 2% (w/v) agarose gel electrophoresis to 
confirm successful conjugation.  
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Synthesis of VLP-PEG24-A9L 
In a 100 µL reaction in pH 7.3 HEPES, A9L (8.33 µM) was mixed with TCEP 
(20 mM) at 70oC for 2 min, and then at room temperature for 2 h. In a separate 
200 µL reaction in pH 8.3 HEPES, TR-X encapsidated VLPs (55.56 nM) were 
mixed with SM(PEG)24 (15 mM) at room temperature for 30 min. The 
SM(PEG)24 to VLP surface amine molar ratio was 500 to 1. The two reaction 
mixtures were separately eluted from NAP-5 columns into pH 7.3 HEPES, 
fractions were collected and checked for A260, A280 and A649 using a Nanodrop 
1000, those containing A9L-SH and VLP-PEG24-maleimide were pooled, and 
mixed together at room temperature for 2 h. To quench unreacted maleimide 
groups, β-mercaptoethanol (7 μL of 14.3 M stock) was added to VLP-PEG24-
A9L, and left to react at room temperature overnight. Quenched VLP-PEG24-
A9L was eluted through a NAP-25 column, and concentrated into DPBS using a 
100 kDa MWCO spin concentrator. VLP-PEG24-A9L was then analysed by TEM 
and native 2% (w/v) agarose gel electrophoresis to confirm successful 
conjugation and the intact nature of particles.  
 
Doxorubicin spectroscopic analysis 
Doxorubicin in ddH2O was analysed by UV spectroscopy to determine the 
wavelength of maximum absorbance (486 nm). Using this, the absorbance of 
varying concentrations of doxorubicin was measured to construct a calibration 
graph, from which the extinction coefficient was calculated. This facilitated the 
quantification of doxorubicin in downstream packaging experiments.   
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Doxorubicin packaging inside VLPs 
Trial doxorubicin packaging experiments were firstly carried out. In a 10 µL 
volume, doxorubicin (15 µM, 30 µM, 60 µM, 120 µM, 240 µM, 480 µM or 960 
µM) was mixed with VLP(TR-Cy5) (0.278 µM) in pH 8.3 HEPEs for 1 h at room 
temperature. Two controls were doxorubicin only (960 µM) and VLP(TR-Cy5) 
only (0.278 µM). The mixtures were concentrated through 100 kDa MWCO spin 
concentrators three times, washing in between with pH 8.3 HEPES, to 20 µL 
final volumes. Concentrated solutions were analysed by UV-visible 
spectroscopy: the absorbance at 649 nm was measured to estimate the 
concentration of VLP(TR-Cy5) present; the absorbance at 486 nm was 
measured to estimate the concentration of doxorubicin present. The doxorubicin 
retained after spin concentration was assumed to be bound to TR-Cy5 within 
VLPs. For the preparation of VLP(TR-Cy5/Dox)-PEG24-A9L, the above protocol 
was scaled up to using 480 µM doxorubicin and 0.278 µM VLP(TR-Cy5) in a 
100 µL volume. VLP(TR-Cy5/Dox) was eluted through a NAP-5 column, and 
concentrated into pH 8.3 HEPES using a 100 kDa MWCO spin concentrator, 
prior to surface modification with SM(PEG)24 and A9L (as previously described).  
 
2.2.2 Biochemical assays 
Sucrose density gradient centrifugation (SDC) 
Samples were loaded onto a 12 mL (SW 40 rotor) or 38 mL (SW 32 rotor) 15-
45% (w/v) linear sucrose gradient made using a Biocomp Instruments gradient 
station. The gradients were centrifuged in a Beckman Coulter Optima L-80 XP 
ultracentrifuge at 47,000 RCF, 4oC for 17 h. Fractions were collected using a 
Biocomp Instruments piston gradient fractionator either by 260 nm absorbance 
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Pharmacia UVM II detector or by eye. Photographs were taken on a camera 
phone, at a fixed position in front of the gradients. 
 
Western blotting 
Protein samples were resolved by SDS-PAGE (15%) in Tris glycine buffer at 
160 V for 60 min, and transferred to a 0.2 µm nitrocellulose membrane at 80 V 
for 60 min. The membrane was washed with TBS, incubated with BLOCK (5x) 
for 1 h at room temperature, and washed twice with TBST. The primary 
antibody was incubated with the membrane in TBST for 45 min, before washing 
once with BLOCK (1x) and twice with TBST. The membrane was incubated with 
the HRP-conjugated secondary antibody in TBST for another 45 min, and 
washed once with BLOCK (1x) and twice with TBST. After brief incubation with 
enhanced chemiluminescent substrate, peroxidase activity was detected using 
X-ray film. Ghost bands on the film left by a pre-stained protein ladder allowed 
estimation of the molecular weight of the protein bands  
 
2D Densitometry 
The intensities of the bands from SDS-PAGE or Western blotting were 
measured using AIDA (Astronomical Image Decomposition and Analysis) image 
analysing software. A mock sample lane containing only loading buffer was 
used to measure the background intensity, using which the other band 
intensities were corrected. For VLP-PEG24-Tf visualised with anti-MS2 CP 
antibody, the intensity of the unmodified CP band was compared to the total 
intensity of the bands to calculate the percentage of CPs that were (not) 
conjugated to PEG24. Likewise, the intensity of the CP-PEG24-Tf conjugate band 
was compared to the total intensity to calculate the percentage of CPs coupled 
                                                                                                    ___   _ _                      Page 89 
 
to PEG24 and Tf. For VLP-PEG24-Tf visualised with anti-Tf antibody, the 
intensity of the CP-PEG24-Tf conjugate band was compared to that of the free Tf 
band. As the molarity of free Tf loaded onto the gel was known, the molarity of 
Tf present in CP-PEG24-Tf conjugates was extrapolated. The same method was 
used to estimate the total molarity of CPs (and hence VLPs) present. These 
were then used to estimate the average number of Tf coupled to each VLP.  
 
TEM 
Samples were applied to the shiny side of charged carbon-coated copper grids 
and left for 1 min. After gently removing the sample with filter paper, two drops 
of 2% (w/v) uranyl acetate solution were briefly applied to the shiny side of the 
grid, and allowed to run off. A third drop of uranyl acetate was then applied to 
the grid, and allowed to sit for 45 s. A wedge of filter paper, wetted in sterile 
water, was used to gently remove the uranyl acetate to leave a thin sheen of 
stain on the surface. The grid was allowed to dry at room temperature for 1 h, 
before it was visualised using a JEOL 1400 transmission electron microscope at 
120 keV. 
 
Ribonuclease digest assay 
TR-Cy5, either free in solution or encapsidated in VLPs, were incubated with 50 
ng.mL-1 RNase A for 30 min at 37°C. Reaction mixtures were analysed by 
native 2% (w/v) agarose gel electrophoresis, run at 100 V for 90 min. Bands 
were visualised by ethidium bromide or Coomassie Brilliant Blue R-250 staining. 
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Antibody binding assay 
TR-Cy5 encapsidated VLP or VLP-PEG24–A9L were mixed with rabbit 
polyclonal anti-MS2 CP antibody (0, 1 or 5 µL), and left at room temperature for 
30 min. The mixture was analysed by native 2% (w/v) agarose gel 
electrophoresis, run at 100 V for 90 min. Bands representing VLP or VLP-
PEG24–A9L were visualised by Cy5 fluorescence scanning, and their intensities 
quantitated using 2D densitometry. 
 
VLP stability assay in media and human serum 
VLP-PEG24-A9L was incubated in either of the prostate cancer cell medium 
(Ham's F-12K or RPMI 1640), or in human serum at 37oC for up to 48 h. The 
mixtures were buffer exchanged into HEPES (pH 7.3) buffer using 100 kDa 
MWCO spin concentrators, before they were analysed by TEM or native 2% 
(w/v) agarose gel electrophoresis.  
 
2.2.3 Cell biology assays 
Cell culture 
All cells were cultured in T75 flasks at 37°C with 5% (v/v) CO2, and passaged 
with TrypLE Express. HeLa cervical cancer cells were grown in Dulbecco’s 
Modified Eagles Medium that was supplemented with 10% (v/v) FBS, penicillin 
(50 U.mL-1) and streptomycin (50 µg.mL-1). PC-3 cells were grown in Ham's F-
12K Medium supplemented with 7% (v/v) FBS. LNCaP cells were grown in 
RPMI-1640 Medium supplemented with 10% (v/v) FBS. Cell cultures were 
discarded and renewed from frozen stock roughly once every month.  
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Poly-L-lysine plate spreading 
Poly-L-lysine was dissolved in tissue culture grade water to a final concentration 
of 0.1 mg.mL-1. The cell culture surface was aseptically and evenly coated with 
40 µL poly-L-lysine solution per cm2. After 5 min, the solution was removed and 
the surface rinsed with sterile water, before drying for at least 2 h prior to cell 
seeding.  
 
Deconvolution microscopy internalisation assay 
Cells were seeded on glass coverslips in a 24 well plate and grown to ~70% 
confluence. After washing with medium, cells were incubated in fresh medium 
at 4oC for 20 min. The medium was then replaced by fresh 4oC medium 
containing up to 100 nM encapsidated TR-Cy5, in which cells were incubated at 
4oC for 1 h. The cells were washed three times with 4oC medium, and incubated 
with fresh medium at 37oC for 1 h to allow internalisation of cell surface bound 
VLPs. Cells were washed three times with DPBST, and incubated in FIX for 15 
min at room temperature. After washing with DPBST, cells were incubated in 
200 μL DPBS containing DAPI (2 µg.mL-1) at room temperature for 10 min. The 
DPBS/DAPI was removed; coverslips were mounted onto slides using 
Fluoromount-G and allowed to dry, before visualisation on a Delta Vision 
deconvolution microscope. Images were acquired using a 60x magnification 
objective lens. SoftWoRx was used to acquire a Z stack of images for 
deconvolution analysis. 
 
Flow cytometry analysis 
Flow cytometry was carried out on a Becton Dickinson BD-LSRFortessa Cell 
Analyzer. From each sample, 104 cell events were collected for analysis. The 
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355 nm laser was used with a 450/40 detector for DAPI; the 488 nm laser was 
used with a 525/10 detector for FITC, a 585/15 detector for doxorubicin, and a 
630/30 detector for PI; the 633 nm laser was used with a 660/20 detector for 
Cy5. Compensations were set using Becton Dickinson fluorescent beads in 
accordance with the manufacturer’s instructions. Several gates were 
established to separate desired and undesired events, and to measure relative 
cell populations. An initial gate, based on forward and side scatters of untreated 
cells, was used to distinguish cell events from non-cell events. A second gate 
was set to distinguish between cells that have taken up TR-X and cells that 
have not. Untreated cells were used to set the upper Cy5 fluorescence intensity 
for non-transfected cells – cells with fluorescence higher than 99% of these 
cells were designated ‘transfected’. For the apoptosis assays, a third gate was 
set up to sort cells into one of four populations, including live, early apoptotic, 
late apoptotic and necrotic, based on their FITC (Annexin V) and propidium 
iodide fluorescence emissions.     
 
VLP uptake analysis in test tubes 
Cells were harvested using TrypLE at 37oC, washed three times with 500 μL 
DPBS, and counted using a hemocytometer. Following dilution to 0.5 × 105 cells 
per mL in cell medium, 400 μL cells were pipetted into test tubes, to which 100 
μL medium containing encapsidated TR-Cy5 (to make a final concentration of 
10 nM) was added. After brief vortexing, cells were incubated at 37oC for up to 
24 h. Cells were washed three times with DPBST, and incubated in FIX at room 
temperature for 10 min. Fixed cells were pelleted with brief centrifugation, then 
resuspended in 200 μL DPBS and analysed by flow cytometry. 
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VLP uptake analysis on plates 
Cells were harvested using TrypLE at 37oC, and counted using a 
hemocytometer. After diluting to 0.5 x 105 cells.mL-1 in cell medium, 340 µL cells 
were seeded onto wells of a 24 well plate. TR-Cy5 packaged inside various VLP 
formulations was diluted in cell medium to a total volume of 10 µL, and a 
concentration of 350 nM. This was added to the seeded cells; hence a final 
concentration of 10 nM TR-Cy5 was achieved. Cells were incubated in a CO2 
incubator at 37oC for up to 48 h. Cells were harvested with TrypLE at 37oC, and 
washed three times with 500 μL DPBS. After fixing with 200 μL FIX at room 
temperature for 10 min, cells were finally resuspended in 200 μL DPBS before 
analysis by flow cytometry.  
 
Cellular delivery of siRNA by VLPs 
Cells were harvested using TrypLE at 37oC, and counted using a 
hemocytometer. After diluting to 0.5 x 105 cells.mL-1 in cell medium, 340 µL cells 
were seeded onto wells of a 24 well plate. TR-siRNA (BCL2 or Control) 
packaged inside various VLP formulations was diluted in cell medium to a total 
volume of 10 µL, to a concentration which is 35x the desired final concentration. 
This was added to the seeded cells. Cells were incubated in a CO2 incubator at 
37oC for up to 72 h, and prepared for downstream assays. 
 
Liposomal delivery of siRNA 
TR-Cy5 or TR-siRNA was mixed with 3 μL HiPerFect Transfection Reagent. 
The mixture was vortexed and left at room temperature for 10 min, and then 
added to PC-3 cells in 24 well plates. The cells were incubated for up to 48 h 
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before flow cytometry analysis of uptake, relative BCL2 expression and 
apoptosis. 
 
Intracellular anti-BCL2 antibody staining 
The cell medium was collected and retained. Cells were washed twice with 
DPBS and harvested with TrypLE at 37oC. Harvested cells were collected with 
the original medium and centrifuged at 1,000 RCF for 5 min. The cell pellet was 
resuspended in FIX for 5 min at room temperature, and washed with DPBS, 
before it was transferred into a clean tube and incubated in permeabilisation 
buffer at 4oC for 20 min. FITC-labelled anti-BCL2 antibody (30 µL per 106 cells) 
was added to the cell suspension, and left at 4oC for 1 h. The cells were 
pelleted and resuspended in 200 µL DPBS, before flow cytometry analysis. A 
FITC-labelled isotype control antibody was also used to stain untreated cells to 
determine the background fluorescence, which was subtracted from the mean 
fluorescence values of anti-BCL2 antibody stained cells. Relative percentage 
BCL2 expressions were calculated by comparing the mean FITC fluorescence 
of treated cells with that of untreated cells, assuming 100% expression for the 
untreated cells. 
 
Apoptosis assay 
After siRNA delivery, the cell medium was collected and retained. Cells were 
washed twice with DPBS and harvested with TrypLE at 37oC. The harvested 
cells were collected with the original growth medium, washed twice with DPBS 
and once with annexin binding buffer. Cells were then resuspended in 200 µL 
annexin binding buffer containing annexin V (2 μg.mL−1) and propidium iodide 
(4 μg.mL−1), incubated at 4oC for 15 min, and analysed by flow cytometry. For 
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HeLa cells, controls included untreated cells stained with annexin V and 
propidium iodide; cells exposed to UV radiation for 2 h, stained with propidium 
iodide (necrotic control); and cells treated with 50 μM cisplatin for 24 h, stained 
with annexin V (apoptotic control). 
 
PSMA expression on prostate cancer cell lines 
The cell surface expression of PSMA on LNCaP and PC-3 cells was determined 
by flow cytometry. Cells were harvested using TrypLE at 37oC, washed three 
times with 500 μL DPBS, and counted using a hemocytometer. Cells were then 
resuspended in 500 μL DPBS/FBS (1 x 106 cells.mL-1), incubated at room 
temperature for 15 min. After brief centrifugation, pelleted cells were 
resuspended in 100 μL of DPBS/FBS and 20 μg.mL-1 primary rabbit anti-PSMA 
antibody, incubated at room temperature for 1 h. Cells were then washed three 
times with 500 μL DPBS/FBS, and incubated in DPBS/FBS containing a 1:500 
dilution of secondary antibody (anti-rabbit IgG-FITC conjugate) at room 
temperature for 30 min. Cells were washed three times with 500 μL DPBS/FBS, 
resuspended in 200 μL DPBS/FBS and analysed by flow cytometry. Cellular 
PSMA expression was also analysed by Western blotting. LNCaP and PC-3 
cells were collected as described above, resuspended in 1x RIPA buffer 
containing 1x Protease/Phosphatase Inhibitor Cocktail, and incubated at 4oC for 
20 min. Cells were pelleted with brief centrifugation, and 25 μg protein from the 
supernatant was analysed by Western blotting. Antibodies used include a 
primary rabbit anti-PSMA antibody and a HRP-conjugated secondary anti-rabbit 
IgG antibody. 
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PSMA cell surface binding assay 
TrypLE harvested LNCaP and PC-3 cells were washed twice with 500 μL 
DPBS, incubated in 200 μL FIX solution for 10 min at room temperature. Fixed 
cells were washed twice with 500 μL DPBS, resuspended in PSMA binding 
buffer, then incubated at 37oC for 20 min. Cells were then pelleted, 
resuspended in 50 μL PSMA binding buffer containing 25 nM encapsidated TR-
Cy5, and incubated at 37°C for 1 h. After washing three times in 500 μL PSMA 
binding buffer, cells were finally resuspended in 200 μL DPBS and analysed by 
flow cytometry. 
 
Doxorubicin delivery assays 
LNCaP, PC-3 and HeLa cells were harvested using TrypLE at 37oC, and 
counted using a hemocytometer. After diluting to 0.5 x 105 cells.mL-1 in cell 
medium, 340 µL cells were seeded onto wells of a 24 well plate. Free or 
encapsidated doxorubicin was diluted in cell medium to a total volume of 10 µL, 
to a concentration which is 35x the desired final concentration. This mix was 
added to the cells. Cells were incubated in a CO2 incubator at 37
oC for 24 h, 
and analysed by flow cytometry to assess the doxorubicin uptake and cytotoxic 
effects (as previously described for siRNA treated cells). One variation from the 
aforementioned apoptosis assay was the substitution of propidium iodide for 
DAPI as the cell viability dye. 
 
 
 
 
 
  
 
 
Chapter 3 
Mitigating non-specific cellular uptake of VLPs 
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3.1 Introduction 
3.1.1 Polyethylene glycol and drug delivery 
Polyethylene glycol (PEG) is one of the most widely used synthetic polymers 
(Figure 3.1A). It can be made via the polymerisation of ethylene oxide – a range 
of different molecular weights can be achieved, from 300 Da to 10,000,000 Da, 
to suit a myriad of applications (Yue et al., 2012). They can also be prepared 
with chemical groups on one or both termini to facilitate conjugation to 
biomolecules. Some examples, including the commercially available hetero-
bifunctional SM(PEG)24, and NHS-(PEG)12-biotin, are shown in Figure 3.1BC.  
 
 
 
 
 
 
 
 
Figure 3.1. Structure of polyethylene glycol and some possible derivatives. (A) Structure 
of polyethylene glycol (PEG). PEG is commercially available over a wide range of molecular 
weights, with n repeats of ethylene oxide (O-CH2-CH2) resulting in different lengths to suit a 
myriad of applications. (B) Structure of SM(PEG)24. The presence of an NHS group and a 
maleimide group facilitates amine-to-thiol conjugations, whilst incorporating a PEG24 linker. (C) 
Structure of NHS-(PEG)12-biotin. PEG12-biotin can be conjugated to amine presenting 
molecules.  
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PEG is highly water soluble, biocompatible, chemically inert, and displays low 
immunogenicity as well as low toxicity. The versatility and usefulness of PEG 
has been demonstrated across a range of applications (Yue et al., 2012), for 
example, it is used in mass spectrometry studies as a calibration compound, in 
DNA preparations to facilitate precipitation, in food as an anti-foaming agent, 
and in toothpastes as a humectant.  
The first reports of conjugating PEG to proteins emerged in 1977, which 
revealed that PEGylation could mask bovine serum albumin from the immune 
system in rabbits (Abuchowski et al., 1977b), and also significantly increase the 
plasma retention of bovine liver catalase from 12 h to 48 h in mice whilst, 
importantly, not affecting its enzyme activity (Abuchowski et al., 1977a). These 
results sparked a huge interest in the therapeutic applications of PEG. Since 
then, many PEGylated drugs (proteins, nucleic acids and small molecules) have 
been synthesised and shown to exhibit more favourable properties compared to 
the non-PEGylated versions (Knop et al., 2010); several of these formulations 
are now FDA approved for treating a range of diseases (Table 3.1). It is now 
known that PEG can improve the drug efficacy through multiple mechanisms 
(Knop et al., 2010), including (i) increasing the hydrodynamic size of small 
molecule drugs or drug delivery systems, to reduce rapid renal clearance, and 
enhance their plasma half-lives and passive accumulation in tumour tissues via 
EPR, (ii) improving drug solubility, (iii) enhancing drug stability and protection 
from degradation by endogenous proteases or nucleases, (iv) altering their 
biodistribution, (v) mitigating non-specific cellular uptake, and (vi) reducing 
immunogenicity by masking surface epitopes. 
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Drug 
 
 
Description 
 
Indication 
 
Approval 
 
Oncospar 
 
mPEG-L-asparaginase 
 
 
ALL 
 
1994 
Doxil 
 
 
PEG-liposome Breast cancer, Kaposi’s sarcoma,  
MM, ovarian cancer 
1995 
PEG-Intron 
 
mPEG-interferon α2a 
 
Chronic hepatitis C 2001 
Neulasta 
 
mPEG-GCSF Febrile neutropenia 2002 
Pegasys 
 
mPEG-interferon-α-2b Chronic hepatitis C 2002 
Macugen 
 
mPEG-anti-TNFα Age-related macular degeneration 2004 
Peginesatide PEG-peptide Anaemia associated with  
chronic kidney disease  
2012 
 
Table 3.1. Selected examples of approved drugs that include PEG. mPEG = methoxy 
polyethylene glycol; GCSF = granulocyte-colony stimulating factor.  
 
The use of PEG in VLP drug delivery systems has been demonstrated for the 
CPMV (Destito et al., 2007). Similar to MS2 VLPs, non-surface modified CPMV 
VLPs carrying fluorescent cargo displayed some levels of non-specific uptake, 
which was significantly reduced by decorating the VLP surface with PEG chains 
(Mw ~ 500 Da). Upon further addition of the targeting ligand, folic acid, specific 
folate receptor-mediated uptake was observed in targeted HeLa and KB cancer 
cells. Furthermore, the addition of a PEG layer markedly improved folic acid-
mediated cell binding and uptake compared to VLPs directly conjugated to folic 
acid, which was attributed to the added flexibility conferred to the ligands 
(Destito et al., 2007). More recently, MS2 VLPs surface decorated with PEG24 
and a tumour-targeting peptide successfully delivered cargos to targeted 
hepatocellular carcinoma cells, but not normal hepatocyte cells (Ashley et al., 
2011). These results suggest that PEGylation might be a suitable strategy for 
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mitigating the previously observed non-specific uptake of MS2 VLPs (Galaway, 
2011). Further addition of a targeting ligand, such as Tf, to the PEG termini 
should promote tumour-specific delivery of encapsidated cargo.  
 
 
 
 
Figure 3.2. General schematic showing the synthesis of siRNA encapsidated, surface 
modified VLPs. Mixing TR-coupled siRNA with dissociated MS2 CP2 at neutral pH triggers VLP 
assembly and the packaging of siRNA inside. VLPs can then be surface modified using NHS-
based conjugative chemistry, to incorporate useful ligands. The modifications used in this 
chapter are shown (not to scale), including (i) Tf, (ii) PEG12-biotin, (iii) PEG24 and (iv) PEG24-Tf. 
 
A generalised schematic for VLP construction is shown in Figure 3.2. The 
previously used anti-BCL2 siRNA will be used as the model drug cargo; 
conjugation to TR (‘TR-BCL2’) facilitates its encapsidation within MS2 VLPs 
during in vitro assembly, which can then be surface modified. Five different MS2 
VLPs are used in this Chapter, including unmodified VLP, VLP-Tf, VLP-PEG12-
biotin, VLP-PEG24 and VLP-PEG24-Tf (Figure 3.2). 
 
 
                                                                                                    ___   _ _                      Page 102 
 
3.1.2 Aims 
The aims of the work described in this chapter were to: 
1. Synthesise RNA-encapsidated VLP, VLP-PEG and VLP-PEG-Tf. 
2. Compare the uptake of VLP, VLP-PEG and VLP-PEG-Tf by HeLa cells. 
3. Assess the cellular effects of siRNA delivery by VLP-PEG-Tf to HeLa 
cells. 
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3.2 Results and discussion 
3.2.1 Purification of MS2 VLPs 
The MS2 CP was previously recombinantly expressed in E. coli in the Stockley 
laboratory (Mastico et al., 1993). These CP readily assembled into capsids in 
vivo, typically packaging random E. coli nucleic acids. These structures are 
referred to as VLP(E.coli).  
VLP(E. coli) was purified through two rounds of sucrose density gradient 
centrifugation (SDC), and analysed (Figure 3.3). SDS-PAGE indicated the 
presence of a large amount of E. coli protein contaminants in the unpurified 
sample, which was removed through SDC (Figure 3.3A). 2D densitometry 
analysis of the bands determined that a CP purity of ~90% and >99% was 
achieved after one or two rounds of SDC, respectively. Analysis on a native 2% 
(w/v) agarose gel revealed that SDC was also able to purify VLP(E. coli) from 
nucleic acid contaminants, most likely the E. coli genome (Figure 3.3B). The 
contaminants migrated much slower than the VLP(E. coli) band, which is 
consistent with VLP(E. coli) having a more compact structure compared to the 
large E. coli genome. Furthermore, the VLP(E. coli) bands were visualised by 
ethidium bromide staining, suggesting that nucleic acids were encapsidated 
within VLP(E. coli) – this is supported by the A260/A280 ratio of purified VLP(E. 
coli), typically ~1.7. Size exclusion chromatography of purified VLP(E. coli) 
revealed a major peak representing VLP(E. coli), and a negligible amount of 
smaller species that were likely dissociated CP or assembly intermediates 
(Figure 3.3C). The intact nature of VLP(E. coli) was confirmed by TEM, Figure 
3.3C inset).   
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Figure 3.3. Purification and analysis of VLP(E. coli). After two rounds of purification by 15-
45% (w/v) linear SDC, VLP(E. coli) was analysed by (A) SDS-PAGE. 1: Fermentas prestained 
ladder; 2: VLP(E. coli) after one round of SDC; 3: unpurified VLP(E. coli); 4: VLP(E. coli) after 
two rounds of SDC. Arrow indicates CP monomers. (B) Native 2% (w/v) agarose gel 
electrophoresis. 1: Unpurified VLP(E. coli); 2: VLP(E. coli) after one round of SDC; 3: VLP(E. 
coli) after two rounds of SDC. Arrow indicates VLP(E. coli). (C) Size exclusion chromatography. 
Absorbance traces at 260 nm (red) and 280 nm (black) are displayed. A TEM image of purified 
VLP(E. coli) is shown as an inset. Scale bar = 25 nm. 
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3.2.2 TR-siRNA design, synthesis and preparation 
To be compatible with the MS2 VLP drug delivery system, the therapeutic 
siRNA must remain functional when attached to TR, and must not contain 
sequences complementary to TR, which might interfere with siRNA strand 
annealing as well as TR-mediated VLP assembly. Furthermore, it should also 
tolerate the terminal attachment of fluorescent dyes, which are required for 
quantifying siRNA packaging and cellular uptake. Two siRNAs have previously 
demonstrated to fulfill these requirements (Galaway, 2011, Galaway and 
Stockley, 2013): one targeted against the mRNA of the anti-apoptotic factor, 
BCL2; the other targeted against the mRNA of polo-like kinase 1 (PLK1). Both 
siRNAs were originally studied as aptamer-siRNA conjugates, and were shown 
to retain their ability to induce target knockdown and apoptosis in cells despite 
being coupled to a tumour-targeting RNA aptamer (McNamara et al., 2006). 
This prompted the use of these siRNAs as TR-siRNA conjugates in the MS2 
VLP delivery system (Galaway, 2011).  
Of the two siRNAs, the anti-BCL2 siRNA showed better efficacy in HeLa cells 
(Galaway, 2011), and was chosen for the present study as the model 
therapeutic cargo. BCL2 is an anti-apoptotic factor, whose overexpression is 
associated with numerous human cancers and also their development of 
resistance to chemotherapeutics (Cory and Adams, 2002). The two strands of 
the siRNA (TR-BCL2, Figure 3.4B) were synthesised separately and then 
annealed, as shown previously (Galaway, 2011). The antisense strand is 
complementary to nucleotides 1208 to 1228 within the coding region of the 
BCL2 mRNA; the sense strand is synthesised with TR as a single chain, and is 
situated on the 3' end of TR. This siRNA could be considered a second 
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generation siRNA. It differs from a previous version only in the sense strand, in 
which a 3′ uracil overhang and two adenines between the siRNA and TR are 
incorporated; these modifications were shown to confer enhanced siRNA 
effects in vitro (Dassie et al., 2009, Galaway, 2011).      
 
A control siRNA was also used to ensure that any cellular effects observed is 
siRNA sequence-dependent (Figure 3.4C). This siRNA has the same nucleotide 
composition as the BCL2 siRNA, but its sequence was scrambled using siRNA 
Wizard v3.1, and is not complementary to any known human mRNA. Cyanine 5 
(Cy5) phosphoramidites (Figure 3.4D) were incorporated to the 5′ end of both 
strands of the TR-siRNAs during RNA synthesis to facilitate the quantification of 
siRNAs. In addition to the two TR-siRNAs, a sequence composed of only TR 
coupled to Cy5 (TR-Cy5, Figure 3.4A) was used to test for VLP assembly 
conditions and in cellular uptake experiments.  
All RNAs were synthesised by Amy Barker using an ABI 394 DNA Synthesizer, 
prior to purification by reverse phase HPLC (Figure 3.5A). Typically three 
fractions were observed, containing unincorporated phosphoramidites (fraction 
1), non-Cy5 coupled RNA (fraction 2) and Cy5 coupled RNA (fraction 3). The 
Cy5 phosphoramidite coupling efficiency ranged from ~40% to 70%.  
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Figure 3.4. Structures of the RNA sequences and fluorescent dye used. The RNAs used 
include (A) TR, (B) TR-BCL2 and (C) TR-Control. TR is a known MS2 packaging signal. The 
TR-siRNAs, TR-BCL2 and TR-Control, are composed of two annealed strands, with the sense 
strand and TR as one chain. The TR-BCL2 antisense strand is complementary to BCL2 mRNA, 
whereas that of TR-Control has no complementary mRNA. (D) Cyanine 5 (Cy5) 
phosphoramidites were incorporated to the 5′ end of both strands of the TR-siRNAs during RNA 
synthesis. 
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Figure 3.5. Typical reverse-phase HPLC elution profile of synthesised RNAs. Absorbance 
traces at 260 nm (black), 280 nm (blue) and 649 nm (magenta) are shown. The dotted blue line 
represents an increasing gradient of acetonitrile. Green shaded regions indicate fractions 
collected.  
 
 
 
 
 
 
 
Figure 3.6. Gel purification of annealed siRNAs. Annealed TR-siRNAs were analysed on a 
native 15% (w/v) polyacrylamide gel, visualised by ethidium bromide staining (left) or Cy5 
fluorescence scanning (right). 1: 10 bp DNA ladder; 2: TR-BCL2 sense; 3: BCL2 antisense; 4: 
TR-BCL2 annealed; 5: TR-Control sense; 6: Control antisense; 7: TR-Control annealed. 
Positions of bands representing annealed siRNAs, TR-sense or antisense strands are indicated. 
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The siRNAs were annealed as previously described (Galaway, 2011). 
Complementary TR-sense and antisense strands were mixed at a 1:1 molar 
ratio in DEPC-treated water, and briefly heated to 95oC before it was cooled to 
room temperature. The products were analysed on a 15% (w/v) polyacrylamide 
gel (Figure 3.6). Three distinct bands were observed for each annealing 
reaction, representing the antisense strand, TR-sense strand, or annealed TR-
siRNA. Bands corresponding to annealed TR-siRNAs (TR-BCL2 and TR-
Control) were excised and extracted via electro-elution. The siRNAs were then 
concentrated by isopropanol precipitation, and resuspended in DEPC-treated 
water prior to use in VLP assembly. 
 
3.2.3 VLP reassembly and cargo packaging 
To adapt VLP(E. coli) for drug delivery, the encapsidated random nucleic acids 
must be replaced by TR-siRNAs. To achieve this, VLP(E. coli) was firstly 
dissociated into CP2 by mixing with 66% (v/v) glacial acetic acid for 1 h at 4
oC. 
Following acid dissociation, a brief centrifugation step was sufficient to remove 
the encapsidated nucleic acids; the CP2-containing supernatant was eluted into 
20 mM acetic acid through a NAP-10 column. Fractions were collected and their 
A260/A280 ratios assessed; those with a ratio of <0.8 were designated as pure 
CP fractions and were used in subsequent reassembly experiments. The 
concentration of CP2 was estimated using the A280 and its molar extinction 
coefficient (ε280nm = 33,240 L.mol
−1.cm−1). A typical yield of dissociated CP2 from 
VLP(E.coli) was ~75%. 
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Figure 3.7. Analysis of TR-Cy5 packaging and in vitro VLP assembly. TR-Cy5 was mixed 
with dissociated CP2 at various molar ratios at neutral pH. The reassemblies were subsequently 
analysed. (A) Native 2% (w/v) agarose gel electrophoresis. (1)  HyperLadder I; (2) TR-Cy5; (3) 
VLP(E.coli); (4) CP2-only control; and reassemblies with CP2 : TR-Cy5 ratios of  (5) 1:1; (6) 2:1; 
(7) 10:1; (8) 15:1; (9) 25:1 and (10) 50:1. The gel was visualised by ethidium bromide or 
Coomassie staining. (B) TEM. Scale bar = 50 nm.  
 
Trial VLP reassembly experiments were carried out using TR-Cy5. CP2 was 
mixed with TR-Cy5 in pH 7.3 HEPEs at room temperature for 5 h. Different CP2 
to TR molar ratios (1:1, 2:1, 10:1, 15:1, 25:1, 50:1) were tested, alongside a 10 
µM CP2-only control. The reassembly reactions were then analysed by native 
2% (w/v) agarose gel electrophoresis (Figure 3.7A). For the CP2-only control 
(lane 4), a band resembling VLP was observed with Coomassie staining, 
indicative of some TR-independent VLP formation – which has been previously 
reported (Wu et al., 1995). A smear was also observed above the band, 
suggesting that the reassembly efficiency was low and some aberrant or 
aggregated species were formed. Using its amino acid sequence, the isoelectric 
point of MS2 CP2 was estimated to be slightly higher than the pH of the TBE 
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running buffer – thus, free CP2 should run towards the cathode (seen on lanes 9 
and 10), and hence could not account for the smear observed.   
For the TR-mediated reassemblies, more intense VLP bands were observed 
with increasing CP2 concentrations – up to the 10:1 molar ratio (lanes 5-8), with 
both ethidium bromide and Coomassie staining. As the ratio increased further to 
15:1, 25:1 and 50:1, significant amounts of smear could be seen above the VLP 
bands, which were visualized by TEM as aggregate species (Figure 3.7B). 
These suggest that higher efficiency reassembly was achieved with greater CP2 
: TR ratios, up to 10:1, beyond which significant amounts of aberrant species 
were formed. This result was expected: at low CP2 to TR molar ratios, CP2 are 
saturated with TR and undergo conformational change to A/B-like dimers, and 
the availability of C/C-like dimers becomes limiting thus VLP formation is 
restricted (Stockley et al., 2007); at high CP2 concentrations (>10 μM), VLPs 
can form independent of TR, as observed in the CP2 only control, albeit is 
inefficient and results in high levels of aberrant species.  
To achieve optimal reassembly and packaging efficiency, a compromise must 
be made between good TR-Cy5 incorporation and the avoidance of aberrant 
species. Whilst a CP2 : TR-Cy5 molar ratio of 2:1 (lane 6) produced a relatively 
clean VLP band, free TR-Cy5 was still present indicating incomplete 
incorporation. For this reason, it appeared that a molar ratio of 10:1 is the best 
choice for cargo packaging and VLP assembly. This is consistent with previous 
results (Galaway, 2011). Additionally, the intact nature of VLP(TR-Cy5) formed 
from the reassembly reactions was confirmed by TEM (Figure 3.7B).  
VLP(TR-Cy5) assembled using a 10:1 ratio were purified via linear 15-45% 
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(w/v) SDC, and concentrated using 100 kDa MWCO spin concentrators. The 
absorbance at 260 nm and 280 nm was measured, and used to estimate the 
concentration of CP2 with the following equation: 
Concentration (mg/ml) = 1.55 x A280 – 0.76 x A260 
Given 90 MS2 CP2 assemble into one VLP, the concentration of VLP was 
derived. Furthermore, the absorbance at 649 nm was also measured to 
calculate the concentration of TR-Cy5 (Cy5 ε649 nm = 250,000 L.mol
-1.cm-1). 
Using these, the average number of TR-Cy5 packaged per VLP was calculated 
to be 9.9±1.6 from three repeats. The CP content in the purified VLP(TR-Cy5) 
was typically ~50% of the starting material.  
 
3.2.4 Nuclease protection of packaged cargo 
An ideal drug delivery system can protect its cargo from undesired interactions 
with cellular proteins, in particular endogenous proteases or nucleases, which 
can degrade the therapeutics into an inactive form. The in vivo instability of 
nucleic acid-based therapeutics, including siRNAs, has greatly hindered their 
clinical progress. The encapsidation of siRNAs within MS2 VLPs should solve 
this problem.  
To assess the capacity of MS2 VLPs to protect its nucleic acid cargo from 
nuclease degradation, digest assays were carried out, in which TR-Cy5 – either 
free or packaged inside VLPs – were incubated with or without RNase A at 
37oC for 30 min, before the products were analysed on a native 2% (w/v) 
agarose gel (Figure 3.8). The bands corresponding to encapsidated TR-Cy5 did 
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not vary in intensity after either ethidium bromide or Coomassie staining (lanes 
4 and 5), suggesting that encapsidated TR-Cy5 as well as the VLP particle 
remained stable after incubation with RNase A. However, the ethidium bromide 
signal of free TR-Cy5 disappeared upon RNase A treatment, suggesting 
complete degradation of the RNA (lanes 2 and 3). These results imply that 
encapsidation inside VLPs protected TR-Cy5 from RNase degradation.  
 
 
 
 
 
 
 
 
Figure 3.8. RNA digest assay. TR-Cy5, free or packaged inside VLP, was incubated with 
RNase A for 30 min at 37
o
C. The reactions were analysed by 2% (w/v) agarose gel 
electrophoresis, visualised by ethidium bromide or Coomassie staining. 1: HyperLadder I; 2: TR-
Cy5; 3: TR-Cy5 plus RNase A; 4: VLP(TR-Cy5); 5: VLP(TR-Cy5) plus RNase A.   
 
3.2.5 Preparation and analysis of VLP-Tf 
Human Tf is one of the most used targeting ligands in drug delivery (Daniels et 
al., 2012, Daniels et al., 2006a). Not only does it facilitate the cell entry of drug 
delivery systems through a natural pathway (Tf receptor-mediated endocytosis), 
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Tf also confers tumour-preferential targeting, as Tf receptors are known to be 
overexpressed on the surface of various cancer cells (Qian et al., 2002). In 
addition, it is biocompatible, non-immunogenic,  and its mechanism of action is 
extremely well characterised (Daniels et al., 2006b). 
Multivalent display of Tf on MS2 VLP was achieved by adapting a previously 
used protocol (Figure 3.9) (Wu et al., 1995, Galaway, 2011, Galaway and 
Stockley, 2013). Three surface accessible amines are present in each CP 
monomer: two presented by lysines at positions 106 and 113, and one by the N-
terminus (Figure 1.12). This means that up to 540 copies of a ligand may be 
attached to the VLP surface for targeting – although this is significantly limited 
by factors such as the low efficiency of conjugative chemistry and steric 
constraints. Likewise, there are also amines on the surface of human Tf. The 
availability of these amines gives rise to the possibility of using NHS chemistry 
for conjugation.  
VLP(TR-Cy5) was reacted with SATA to introduce thiol groups to the surface 
(Figure 3.9a, b); Tf was reacted with sulfo-SMCC, to introduce maleimide 
groups to its surface (Figure 3.9c). Both reactions were carried out at pH 8.3 – a 
compromise to ensure sufficient deprotonation of amines for the reaction to take 
place, whilst limiting the rate of hydrolysis of the NHS esters. These two 
reactions were separately eluted from NAP columns to remove excess 
crosslinking reagents, and mixed to allow the formation of amide bonds 
between the thiol and maleimide groups, resulting in VLP-Tf conjugates (Figure 
3.9d). 
                                                                                                    ___   _ _                      Page 115 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.9. Schematic depicting the conjugative chemistry used to synthesise VLP-Tf. (a) 
Amines (NH2) on the surface of MS2 VLPs are reacted with N-succinimidyl-S-acetylthioacetate 
(SATA), which incorporates a protected thiol group. (b) The thiol groups are deprotected by the 
addition of hydroxylamine hydrochloride. (c) NH2 on the surface of Tf are reacted with 
sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC), which 
incorporates a maleimide group. (d) The two reactions are purified separately through NAP 
columns, and then mixed to allow conjugation between the thiol and maleimide groups.  
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As before (Galaway, 2011), Fe3+-binding sites within Tf were saturated by 
adding an iron(III) citrate buffer, the products were then analysed by size 
exclusion chromatography on a Superose 6 column (Figure 3.10A). Fe3+-bound 
Tf, or holo-Tf, has a characteristic absorption peak at 465 nm, which arises as a 
result of the phenolate-to-iron charge transfer transition as iron binds to two 
tyrosine ligands (Patch and Carrano, 1981). The A465 curve suggests the 
presence of holo-Tf in the first two peaks. Taking this into account, and using 
the A260 and A280 readings, the first two peaks observed in the chromatogram 
were designated, in order of elution: VLP-Tf conjugates (~7 mL) and free holo-
Tf (~15 mL). VLP-Tf had a markedly reduced retention time compared to VLP 
(dotted curve, Figure 3.10A), as expected of a larger particle. The third peak 
(~20 mL) might have contained a mixture of excess crosslinking reagents and 
dissociated CP2.  
Using the A260, A280 and A465 readings of the VLP-Tf containing peak, an 
average of 13.5±3.1 Tf per VLP was calculated from three repeats, which is 
similar to the previously obtained ratio of 15.2±2.3 (Galaway, 2011). The CP 
content in VLP-Tf was ~20% of the starting material used for conjugation, which 
is also comparable to previous results (Galaway, 2011).  
TEM analysis of the VLP-Tf fraction revealed the presence of intact surface-
modified VLPs; no aggregate species were observed (Figure 3.10B). 
Aggregates were previously encountered (Galaway, 2011), and were thought to 
be a result of the crosslinking of multiple VLPs via Tf: multivalently displayed 
maleimide groups on the surface of one molecule of Tf might react with thiols 
from multiple VLPs. The protocol was slightly modified in the present 
experiment, using less SATA : VLP, SMCC : Tf, and Tf : VLP molar ratios than 
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before in their respective reactions, and might be the reason for the reduced 
frequency of aggregate formation observed. Additional purification steps that 
were previously necessary to remove the aggregates are no longer required. 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. Analysis of VLP-Tf. (A) Superose 6 size exclusion chromatogram of VLP (dotted) 
and the product of the VLP-Tf conjugation reaction (solid). Absorbance measurements were 
taken at 260 nm, 280 nm and 465 nm for VLP-Tf, and at 280 nm for VLP. (B) TEM image of 
VLP-Tf. Scale bar = 50 nm. (C) Western blot analysis of VLP and VLP-Tf. Anti-MS2 CP 
antibodies (left) or anti-human Tf antibodies (right) were used as primary antibodies. (D) Native 
2% (w/v) agarose. 1: HyperLadder I; 2: VLP; 3: VLP-SATA; 4: VLP-Tf. The gel was visualised 
by ethidium bromide or Coomassie staining. 
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Successful conjugation of Tf to VLP was confirmed by Western blotting (Figure 
3.10C). A band was present in the VLP-Tf lane, which was higher than Tf (~77 
kDa), and could be visualised with both anti-MS2 CP and anti-Tf primary 
antibodies, suggesting the co-presence and covalent attachment of CP and Tf. 
Native agarose gel electrophoresis was also used to analyse VLP-Tf (Figure 
3.10D). The band representing VLP-SATA displayed a minor increase in 
electrophoretic mobility compared to VLP, possibly due to the removal of 
positive charges from the surface lysines. VLP-Tf had a lower electrophoretic 
mobility compared to both VLP and VLP-SATA, likely due to the increased size 
of the particle. Furthermore, the band resembling VLP-Tf was a smear, which 
suggests different levels of Tf conjugation for different VLPs. Due to the nature 
of the conjugation chemistry used, there was little control over some aspects of 
the conjugation, including the number of Tf per VLP and the orientation of Tf 
relative to the VLP surface. Therefore, it is likely that some level of 
heterogeneity was present in the resulting VLP-Tf population, which could be a 
limiting factor for its use as a drug delivery system.  
 
3.2.6 Preparation of VLP-PEG12-biotin and analysis of cellular uptake 
To assess whether coating the VLP surface with PEG can reduce non-specific 
VLP uptake by cells, NHS-PEG12-biotin was used to prepare VLP-PEG12-biotin. 
The selection of NHS-PEG12-biotin was due to its compatibility with the VLP 
surface amines and also its availability within the laboratory. VLP(TR-Cy5) was 
reacted with NHS-PEG12-biotin in pH 8.3 HEPES at room temperature for 30 
min, before the product was eluted through a NAP-5 column and concentrated 
using a 100 kDa MWCO spin concentrator.  
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Figure 3.11. Analysis of VLP-PEG12-biotin. VLP(TR-Cy5) was reacted with NHS-(PEG)12-
biotin at a PEG : surface amine ratio of 100 : 1. The product was purified through NAP-5 
columns and then analysed. (A) SDS-PAGE. 1: Fermentas PageRuler prestained ladder; 2: 
VLP; 3: 1 µL VLP-PEG12-biotin; 4: 5 µL VLP-PEG12-biotin. The gel was visualised by silver 
nitrate staining. Putative bands resembling CP attached to one (CP1), two (CP2), three (CP3) or 
four (CP4) molecules of PEG12-biotin are indicated on the right. (B) TEM. Scale bar = 50 nm.  
(C) Native 2% (w/v) agarose gel electrophoresis. 1: HyperLadder I; 2: VLP; 3: 1 µL VLP-PEG12-
biotin; 4: 5 µL VLP-PEG12-biotin. The gel was visualised by ethidium bromide or Coomassie 
staining. Bands representing VLP and VLP-PEG12-biotin are indicated on the right. 
 
The product was analysed by SDS-PAGE (Figure 3.11A), which showed three 
high intensity bands just above where the unmodified CP monomer is expected 
(13.7 kDa, lane 2). Three possible sites for conjugation are present on each CP 
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monomer (Figure 1.12). The molecular weights of these species are consistent 
with them being CP conjugated to one, two, or three molecules of PEG12-biotin. 
Low intensity bands were also observed above the three main bands – it is 
possible that a small fraction of VLPs were dissociated or partially assembled, 
exposing internal amines that would otherwise be inaccessible to the NHS 
ester, and thus enabling the conjugation of CP to more than three molecules of 
PEG12-biotin. Another possibility is that the NHS terminus of some NHS-PEG12-
biotin entered VLPs via ~1.7 nm pores that are present on the VLP surface 
(Karin Valegård, 1990), gaining access to internal lysines for conjugation. 
The intact nature of VLP-PEG12-biotin was confirmed by TEM (Figure 3.11B), 
although it did not clearly show particles of an increased size or the presence of 
a PEG layer on the VLP surface. Analysis on a native agarose gel revealed that 
VLP-PEG12-biotin had a notably lower electrophoretic mobility compared to VLP 
(Figure 3.11C), which is consistent with a larger particle.  
The cellular uptake of VLP, VLP-Tf and VLP-PEG12-biotin was then assessed. 
HeLa cells were harvested and pipetted into test tubes, to which 10 nM TR-Cy5 
packaged inside VLP, VLP-Tf or VLP-PEG12-biotin was added and incubated for 
up to 24 h. The cells were washed, fixed and resuspended in DPBS prior to flow 
cytometry analysis (Figures 3.12, 3.13). Two gates were set up, as previously 
described (Galaway, 2011). The first gate used the forward and side scatters to 
distinguish between cell and non-cell events. The second gate determined if a 
cell had taken up TR-Cy5: cells with Cy5 fluorescence greater than that of 99% 
of untreated cells were designated as positive for TR-Cy5 uptake, or 
‘transfected’. This is demonstrated in the sample flow cytometry histograms in 
Figure 3.12.  
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Figure 3.12. Flow cytometry analysis of VLP uptake. Sample flow cytometry histograms 
showing the effects of incubating HeLa cells with VLP(TR-Cy5) on their Cy5 fluorescence. Each 
dot represents an individual cell. Untreated cells are shown in the left-most histogram; these 
were used to draw gates to determine whether a cell was negative (orange box) or positive 
(purple box) for VLP(TR-Cy5) uptake. 
 
Information extracted from the flow cytometry histograms, including the 
percentage cell uptake (Figure 3.13A) and the mean Cy5 fluorescence of cells 
(Figure 3.13B), are presented as scatter plots with respect to incubation time. 
The percentage uptake for both VLP and VLP-Tf increased with time (Figure 
3.13A), although it saturated at 100% much quicker for VLP-Tf (~30 min) than 
for VLP (~180 min). This is consistent with previous reports (Galaway, 2011), 
and likely due to the faster uptake of VLP-Tf via Tf receptor-mediated 
endocytosis. VLP-PEG12-biotin was still taken up by HeLa cells, but significantly 
slower than unmodified VLPs – only saturating in percentage uptake at ~350 
min. Markedly different profiles were also observed for the mean Cy5 
fluorescence of cells incubated with VLP and VLP-Tf over 24 h (Figure 3.13B).  
Although the two profiles shared similarly shaped curves – peaking at 10 h, the 
Cy5 fluorescence of VLP-Tf transfected cells was significantly greater than that 
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of VLP transfected cells at all time points. There was a reduction in mean Cy5 
fluorescence after 10 h for all three transfections. This might be the result of a 
dilution of TR-Cy5 due to cell division.  
An interesting observation was that, although the VLP and VLP-Tf curves 
almost converge at 960 min, a significant difference was seen again at 1440 
min – as the mean Cy5 fluorescence of VLP transfected cells kept decreasing, 
but that of VLP-Tf transfected cells increased again. This might be due to the 
faster rate of uptake of VLP-Tf by newly divided HeLa cells compared to VLP, 
and also suggests that the concentration of TR-Cy5 used was not limiting in this 
time frame. Further, the mean Cy5 fluorescence of VLP-PEG12-biotin 
transfected cells peaked at only 488.3±100.9, which was a ~2-fold reduction 
compared to VLP (Figure 3.13B). Again, a decrease in mean Cy5 fluorescence 
was observed after 10 h, suggesting dilution due to cell division. The reduced 
rate of VLP-PEG12-biotin uptake suggests that PEGylation successfully 
mitigated non-specific VLP uptake by HeLa cells. The low level of uptake of 
VLP-PEG12-biotin observed might be due to interactions between biotin and cell 
surface receptors.  
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Figure 3.13. Time-dependent cellular uptake of VLP, VLP-Tf and VLP-PEG12-biotin. Scatter 
plots showing the (A) percentage of HeLa cells positive for uptake, and (B) mean Cy5 
fluorescence intensity (MFI) of HeLa cells after incubation with 10 nM TR-Cy5 packaged inside 
VLP, VLP-Tf or VLP-PEG12-biotin for up to 24 h. Error bars indicate the standard deviation of 
three repeats. 
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3.2.7 Preparation and analysis of VLP-PEG24-Tf 
Although the surface attachment of PEG12-biotin significantly mitigates non-
specific uptake of VLPs, the main problem with its use is the difficulty of 
attaching targeting ligands to the PEG terminus via biotin. One possibility was to 
couple streptavidin to the targeting ligands, which could then be non-covalently 
attached to VLP-PEG12-biotin via high affinity interactions between biotin and 
streptavidin. The use of the streptavidin-biotin system for conjugating two 
molecules has been utilised for a range of chemical and biological applications 
(Dundas et al., 2013). However, streptavidin is relatively large (~53 kDa), and its 
coupling to the targeting ligands would add unwanted complexity to the VLP 
delivery system. Furthermore, streptavidin is composed of four identical 
monomers and can bind to four molecules of biotin, this would likely result in the 
formation of large aggregates with the crosslinking of multiple VLPs. 
The use of SM(PEG)24 as a crosslinker between MS2 VLP and targeting ligands 
has previously been reported (Ashley et al., 2011). It is a hetero-bifunctional 
linker, ~9.5 nm in length, and facilitates amine-to-thiol conjugations with an NHS 
terminus and a maleimide terminus. The availability of amines of the MS2 VLP 
surface, and the possibility of modifying the Tf surface with the previously used 
SATA meant that SM(PEG)24 should be suitable for their coupling. First, a range 
of SM(PEG)24 to VLP surface amine molar ratios from 10 : 1 to 2,000 : 1 were 
tested to identify optimal conditions for PEGylation. VLP(TR-Cy5) was reacted 
with different amounts of SM(PEG)24 in pH 8.3 HEPES at room temperature for 
30 min; the product was eluted through a NAP-5 column and concentrated 
using a 100 kDa MWCO spin concentrator, before analysis (Figure 3.14). 
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Figure 3.14. Analysis of VLP-PEG24. VLP(TR-Cy5) was reacted with SM(PEG)24 at various 
PEG : surface amine molar ratios, including 10:1, 100:1, 500:1, 1000:1 and 2000:1. The 
resulting particles were eluted through NAP-5 columns and then analysed. (A) SDS-PAGE 
visualised by Coomassie staining. Positions of 15 kDa and 25 kDa protein markers are 
indicated on the left. Putative bands resembling unmodified CP, and CP attached to one (CP1), 
two (CP2), three (CP3) or four (CP4) molecules of PEG24 are indicated on the right. (B) Native 
2% (w/v) agarose gel visualised by Cy5 fluorescence scanning. (C) TEM. Scale bar = 50 nm. 
 
The successful coupling of SM(PEG)24 to MS2 CP was confirmed by SDS-
PAGE (Figure 3.14A), which showed bands above the unmodified CP band, 
with molecular weights corresponding to CP modified with one, two or three 
molecules of PEG24. The distribution of intensity shifted towards the higher 
bands, indicating a greater extent of PEGylation, with greater SM(PEG)24 to 
amine ratios. As observed previously with NHS-PEG12-biotin (Figure 3.11A), a 
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fourth band was observed which was likely CP conjugated to four PEG 
molecules. This species only appeared at higher SM(PEG)24 : amine ratios, at 
1,000 : 1 and 2,000 :1, suggesting that high levels of PEGylation might 
destabilise VLPs to expose additional interior amines for conjugation. The 
products were also analysed by native agarose gel electrophoresis (Figure 
3.14B), which showed that as the SM(PEG)24 : amine ratio increased, the 
electrophoretic mobility of the products decreased, consistent with larger 
particles. The ratio of 500 : 1 seemed to be suitable – this was a good 
compromise between maximising the extent of VLP surface PEGylation and 
minimising the coupling of PEG to interior amines. Finally, TEM analysis of the 
products showed intact VLP particles and no evidence of aggregate formation, 
even at the higher SM(PEG)24 : amine ratios used (Figure 3.14C).  
A strategy for conjugating Tf to the VLP surface via SM(PEG)24 was devised 
(Figure 3.15). VLP(TR-Cy5) was first reacted with SM(PEG)24 – at a molar ratio 
of 500 PEG : 1 amine – in pH 8.3 HEPEs at room temperature for 30 min. Tf 
was reacted with the previously used SATA to introduce thiol groups to its 
surface (Figure 3.15B). As before, the thiols were deprotected via the addition 
of hydroxylamine hydrochloride. The two reactions were eluted through NAP-5 
columns to remove excess reagents, and then pooled to allow maleimide and 
thiol groups to react, resulting in the production of VLP(TR-Cy5)-PEG24-Tf. 
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Figure 3.15. Schematic depicting the preparation of VLP-PEG24-Tf. (A) Surface decoration 
of loaded VLPs with SM(PEG)24 and the targeting ligand, Tf. (B) Conjugation chemistry used for 
VLP surface modification. SM(PEG)24 is a hetero-bifunctional crosslinker, with an NHS terminus 
that reacts with VLP surface amines, and a maleimide terminus that reacts with SATA-modified 
Tf.  
 
The product was incubated with β-mercaptoethanol overnight to quench 
unreacted maleimide groups. This was not done previously in the synthesis of 
VLP-Tf (Galaway and Stockley, 2013) – although maleimide groups readily 
hydrolyse (Hermanson, 2013), it is unknown whether hydrolysed maleimide 
groups can interact with the cell surface, thus they might have contributed to the 
non-specific uptake previously observed. The quenched product was purified by 
linear 15-45% (w/v) SDC, the fluorescent band resembling VLP(TR-Cy5)-
PEG24-Tf was collected and concentrated using 100 kDa MWCO spin 
concentrators, prior to analysis (Figure 3.16). The A649 of the sample was 
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measured to calculate the concentration of Cy5 present, which was used to 
estimate the yield (~25% of starting material). 
Size exclusion chromatography analysis revealed different elution volumes for 
VLP (11 mL), VLP-PEG24 (10.5 mL) and VLP-PEG24-Tf (10 mL) (Figure 3.16A), 
suggesting an increase in particle size with additional components. This was 
consistent with the linear 15-45% (w/v) sucrose gradients (Figure 3.16B), which 
showed that VLP-PEG24-Tf migrated faster through the gradient relative to VLP-
PEG24, suggesting the presence of larger and denser particles. Additionally, 
Cy5 fluorescence could be seen at the top of the VLP-PEG24-Tf gradient, 
suggesting the presence of free TR-Cy5. These might be the result of the 
destabilisation of some VLPs caused by the conjugation reactions.  
Successful conjugation was confirmed by Western blotting (Figure 3.16C): a 
band was present in the VLP-PEG24-Tf lane, which was larger than Tf and 
visualised by both anti-MS2 CP and anti-Tf primary antibodies, indicating the 
co-presence of CP and Tf. The bands were analysed by 2D densitometry, which 
estimated that 96.7±2.0% of CPs were conjugated to at least one molecule of 
PEG24, and that 8.0±1.5% of CPs were conjugated to PEG24 and Tf. 
Additionally, on average each VLP was coupled to 7.4±3.3 molecules of Tf. This 
was relatively low compared to the previously observed 13.5±3.1 Tf per VLP for 
VLP-Tf, even though the same Tf : VLP ratios were used in both conjugation 
reactions. The discrepancy might be due to the number estimated using 
Western blotting / 2D densitometry being an underestimate, as conjugation to 
PEG24 and CP might affect the capacity of some Tf to bind antibodies, resulting 
in a lower intensity band.  
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Figure 3.16. Biochemical analysis of VLP-PEG24-Tf. (A) Superose 6 size exclusion 
chromatogram of VLP, VLP-PEG24, and VLP-PEG24-Tf; absorbance curves at 280 nm are 
displayed. (B) Linear 15-45% (w/v) sucrose gradients of VLP-PEG24 (left) and VLP-PEG24-Tf 
(right). Photos were taken at a fixed position in front of the gradients. (C) Western blot analysis. 
1: VLP; 2: VLP-PEG24; 3: VLP-PEG24-Tf; 4: Tf. Anti-MS2 CP antibodies (left) or anti-human Tf 
antibodies (right) were used as primary antibodies. (D) Native 2% (w/v) gel electrophoretic 
analysis. 1: HyperLadder I; 2: VLP; 3: VLP-PEG24; 4: VLP-PEG24-Tf. The gel was visualised by 
ethidium bromide staining or Cy5 fluorescence scanning. (E) TEM images of VLP, VLP-PEG24 
and VLP-PEG24-Tf. Scale bar = 50 nm. Red boxes of the same size are shown in each image, 
enclosing individual MS2 VLPs; these are scaled up in the bottom right corners for clarity. 
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Native 2% (w/v) agarose gel electrophoresis revealed a decrease in 
electrophoretic mobility as the PEG24 and Tf layers were added (Figure 3.16D), 
indicating increased particle size after the respective conjugation reactions. 
Finally, TEM analysis showed the intact nature of the VLP-PEG24-Tf products; 
no aggregate structures were observed (Figure 3.16E). Furthermore, a clear 
difference in size could be seen between VLP and VLP-PEG24 / VLP-PEG24-Tf.  
 
3.2.8 Cellular uptake of VLP-PEG24-Tf 
The effects of adding Tf on the cell binding and internalisation of VLP-PEG24-Tf 
were investigated. HeLa cells were grown on glass coverslips, and incubated 
with 100 nM TR-Cy5, packaged inside VLP, VLP-PEG24 or VLP-PEG24-Tf at 4
oC 
for 1 h, to enable cell surface binding but minimise receptor-mediated 
endocytosis (Klausner et al., 1983). The cells were washed with DPBS to 
remove unbound or weakly bound particles, and incubated at 37oC for 1 h to 
allow internalisation of surface-bound particles. They were then washed and 
visualised by deconvolution microscopy (Figure 3.17A). Cy5 fluorescence was 
only observed in cells incubated with VLP-PEG24-Tf, suggesting that Tf allowed 
tight binding of VLP-PEG24-Tf to the cell surface via Tf receptors, which were 
not removed with DPBS wash steps and subsequently internalised at 37oC. It is 
interesting that different levels of Cy5 fluorescence were observed in the cells 
visualised. This might reflect heterogeneity in the cell population in their surface 
Tf receptor expression. Contrastingly, no Cy5 fluorescence was observed for 
the VLP or VLP-PEG24 incubations, suggesting that neither could bind to nor 
internalise into HeLa cells under the experimental conditions used. 
                                                                                                    ___   _ _                      Page 131 
 
Flow cytometry was also used to assess cellular uptake as before. However, 
cells were grown on 24 well plates (instead of test tubes), and then incubated 
with 10 nM TR-Cy5 packaged inside VLP, VLP-PEG24, or VLP-PEG24-Tf for 2 h 
or 18 h, before they were harvested and processed for flow cytometry analysis 
(Figure 3.17B). At 2 h, PEGylation resulted in a 4-fold reduction in the mean 
Cy5 fluorescence of transfected cells (25.7±8.3 AU for VLP-PEG24; 109.0±33.7 
AU for VLP); addition of the targeting ligand, Tf, resulted in a 9-fold increase in 
mean Cy5 fluorescence (222.3±19.2 AU). Further addition of 100 nM free Tf 
reduced mean Cy5 fluorescence 3-fold (71.7±11.4 AU), suggesting a Tf-
dependent mechanism of cell entry via Tf receptor-mediated endocytosis. 
Intriguingly, this was still higher than the Cy5 fluorescence of VLP-PEG24 – 
similar results were also previously observed with VLP-Tf (Galaway, 2011). Two 
possible reasons for this are: (i) Tf receptors were rapidly recycled to the cell 
surface (Ciechanover et al., 1983), and could not be fully saturated by the free 
Tf used, (ii) multivalent display of Tf on VLP-PEG24-Tf favoured, to some extent, 
Tf receptor-binding and receptor mediated endocytosis over free Tf. Similar 
results were observed at the 18 h time point (Figure 3.17B): PEGylation 
significantly reduced the mean Cy5 fluorescence of transfected cells 
(251.0±76.4 AU for VLP-PEG24; 657.7±45.8 for VLP), whilst Tf-targeting led to 
notably enhanced uptake (1020.0±67.6 AU).  
These results suggest that, although VLP could not tightly bind to nor quickly 
internalise into HeLa cells, at longer incubation times, they were still taken up 
non-specifically by cells. This is consistent with previous results (Figure 3.13). 
Importantly, this non-specific uptake could be significantly reduced by surface 
coating VLPs with PEG24, likely due to the ability of PEG to mask VLP surface 
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epitopes that enable non-specific cell interactions. The further addition of a layer 
of targeting ligands, Tf, on the PEG termini led to significantly higher uptake, 
likely via Tf receptor-mediated endocytosis. 
 
 
 
 
 
 
 
 
 
Figure 3.17. Analysis of VLP-PEG24-Tf binding and internalisation by HeLa cells. (A) Cells 
were incubated with 100 nM TR-Cy5 packaged inside VLP, VLP-PEG24 or VLP-PEG24-Tf at 4
o
C 
for 1 h. After washing with DPBS, cells were incubated at 37
o
C for 1 h, and visualised by 
deconvolution microscopy. DAPI staining (nuclei) is depicted in blue; Cy5 fluorescence (siRNA) 
is depicted in red. Scale bar = 15 µm. (B) Flow cytometry analysis of cells incubated with 10 nM 
siRNA packaged inside VLP (blue), VLP-PEG24 (green), VLP-PEG24-Tf (black) or VLP-PEG24-Tf 
plus 100 nM free Tf (red). 2 h and 18 h time points are represented by solid and dotted lines, 
respectively. Grey shaded curves depict untreated cells. Freq. = frequency; AU = arbitrary units. 
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                                                                                                    ___   _ _                      Page 133 
 
3.2.9 Effects of siRNA delivery on BCL2 expression 
The capacity of VLP-PEG24-Tf to deliver siRNAs to HeLa cells was then 
investigated. TR-siRNA (either TR-BCL2 or TR-Control) encapsidated VLP-
PEG24-Tf was prepared using the same protocol as for TR-Cy5 encapsidated 
VLP-PEG24-Tf, described above.  
Firstly, the effect of siRNA delivery on cellular BCL2 protein expression was 
assessed, using intracellular antibody staining and flow cytometry. HeLa cells 
were incubated with TR-siRNA packaged inside various VLP formulations for up 
to 72 h, before they were fixed and washed with DPBS. Cells were incubated 
with FITC-conjugated anti-BCL2 antibodies in a permeabilisation buffer at 4oC 
for 1 h, and then analysed by flow cytometry. The mean FITC fluorescence of 
untreated cells were assumed to represent 100% BCL2 expression, to which 
the fluorescence of siRNA treated cells were compared to calculate relative 
percentage BCL2 expressions. In addition, a FITC-conjugated isotype control 
antibody, which does not bind human BCL2, was used to stain untreated cells 
to determine non-specific background fluorescence, which was subtracted from 
the mean fluorescence of anti-BCL2 antibody stained cells for baseline 
correction.  
HeLa cells were incubated with 10 nM TR-BCL2 packaged inside VLP-PEG24-Tf 
for 0 h, 24 h, 48 h or 72 h, and assayed for BCL2 expression. Delivered siRNAs 
reduced BCL2 expression in a time-dependent manner (Figure 3.18A): 24 h 
incubation resulted in a slight decrease in BCL2 expression compared to the 0 h 
control (90.0±11.9%), whereas more significant reductions were observed at 48 
h (53.6±6.8%) and 72 h (28.0±13.6%) time points. The relatively small effect at 
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24 h might allude to the time needed for VLP-PEG24-Tf to be internalised into 
HeLa cells, for the acid-triggered dissociation of VLPs and, importantly, the 
endosomal escape of siRNA into the cytosol, before entry into the RNAi 
pathway. VLP-PEG24-Tf delivered siRNAs also induced BCL2 knockdown in a 
concentration-dependent manner (Figure 3.18B): 69.8±10.5%, 53.6±6.8%, and 
39.7±10.9% BCL2 expressions were observed following 48 h incubations with 5 
nM, 10 nM and 25 nM siRNA, respectively.  
Significant knockdown was observed with 10 nM siRNA and 48 h incubation 
time, which was chosen as the condition for assessing relative BCL2 expression 
following siRNA delivery by different VLP formulations (Figure 3.19C). TR-BCL2 
delivered by VLP, VLP-PEG24 and VLP-PEG24-Tf reduced BCL2 expression in 
HeLa cells to 45.3±10.3%, 75.8±7.7% and 53.6±6.8%, respectively. This is 
consistent with the cellular uptake results, and suggests that the knockdown 
effects correlated positively with the uptake of siRNAs. Further addition of 100 
nM free Tf to VLP-PEG24-Tf increased BCL expression to 88.9±14.6%, 
suggesting that VLP-PEG24-Tf delivered siRNAs via Tf receptor-mediated 
endocytosis. Lastly, negligible changes in BCL2 expression were observed 
when cells were incubated with TR-Control packaged inside VLP-PEG24-Tf 
(97.2±9.1%). The control siRNA sequence is a scrambled version of the anti-
BCL2 siRNA sequence, and does not have complementarity to any known 
human mRNA. This result suggests that the observed knockdown of BCL2 were 
siRNA sequence-dependent.  
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Figure 3.18. Relative BCL2 expression in HeLa cells after siRNA delivery. After treatment 
with either (A) 10 nM TR-BCL2 packaged inside VLP-PEG24-Tf for 0, 24, 48 or 72 h, or (B) 0 
nM, 5 nM, 10 nM or 25 nM TR-BCL2 siRNA packaged inside VLP-PEG24-Tf for 48 h, cells were 
stained with FITC-conjugated anti-BCL2 antibodies, washed, and analysed by flow cytometry. 
The mean FITC fluorescence of untreated cells (0 h and 0 nM siRNA) were designated as 
100% BCL2 expression, to which the FITC fluorescence of treated cells were compared to 
calculate relative percentage BCL2 expressions. Error bars indicate standard deviation of three 
repeats. Corresponding flow cytometry histograms are displayed under the bar charts. Black 
curves represent 0 h and 0 nM controls; grey shaded curves show the background 
fluorescence, determined by staining cells with a FITC-labelled isotype control antibody. 
 
It is notable that, because RNAi occurs in the cytosol, the successful 
knockdown of BCL2 by delivered siRNAs could serve as indirect evidence that 
siRNAs were able to escape from VLP-PEG24-Tf as well as the endosome to 
mediate their effect.  
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Figure 3.19. Comparative BCL2 expression in HeLa cells after siRNA delivery. HeLa cells 
were incubated with 10 nM TR-BCL2 packaged inside (from left) VLP, VLP-PEG24, VLP-PEG24-
Tf, or VLP-PEG24-Tf plus 100 nM free Tf, or with 10 nM TR-Control packaged inside VLP-
PEG24-Tf for 48 h, and then assayed for BCL2 expression. Error bars indicate standard 
deviation of three repeats. 
 
3.2.10 Cytotoxic effects of siRNA delivery  
To assess the cytotoxic effects of TR-BCL2 delivery by VLP-PEG24-Tf, a flow 
cytometry assay was used, based on established protocols (Galaway, 2011). 
HeLa cells were incubated with various treatments on 24 well plates. After 
harvesting with TrypLE, cells were washed, resuspended into annexin binding 
buffer and then stained with FITC-conjugated annexin V and propidium iodide, 
before flow cytometry analysis. Annexin V binds with high affinity to the 
apoptotic marker, phosphatidylserine; propidium iodide intercalates with nucleic 
acids but is only taken up by cells undergoing late stage apoptosis or necrosis, 
due to the loss of membrane integrity.  
0
20
40
60
80
100
120
Relative
%BCL2
                                                                                                    ___   _ _                      Page 137 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20. Flow cytometry analysis of cell toxicity. As a necrotic control, HeLa cells were 
exposed to UV radiation for 2 h, and stained with propidium iodide (PI). As an apoptotic control, 
HeLa cells were incubated with 50 µM cisplatin for 24 h, and stained with annexin V-FITC. (A) 
Flow cytometry histograms of (un)treated cells. Gates were drawn using untreated cells, stained 
with both PI and annexin V-FITC, which resembles a quadrant. Cells negative for PI and FITC 
fluorescence were designated live (green box); cells positive for FITC fluorescence only were 
designated early apoptotic (blue box); cells positive for PI and FITC fluorescence were 
designated late apoptotic (red box); and cells positive for PI fluorescence only were designated 
necrotic (black box). (B) Bar charts displaying the relative percentage of cell populations that 
were live (green), early apoptotic (blue), late apoptotic (red), or necrotic (black). The 
percentages shown represent the average of three repeats. Numbers indicate mean percentage 
cell viability ± SD. 
 
Initial controls were set up as follows. Untreated cells were stained with annexin 
V-FITC and propidium iodide, and analysed by flow cytometry. A scatter plot of 
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propidium iodide fluorescence against FITC fluorescence is shown (Figure 
3.20A); this was used to establish gates to determine if cells were positive for 
staining by the two fluorescent dyes relative to untreated cells. The gates 
resemble a quadrant, which divide the cells, based on their fluorescence 
emissions, into live, early apoptotic, late apoptotic and necrotic populations. 
Cells negative for both annexin V and propidium iodide staining were 
designated live (green); those positive for annexin V staining only were 
designated early apoptotic (blue); those positive for propidium iodide staining 
only were designated necrotic (black); and those positive for both annexin V 
and propidium iodide staining were designated late apoptotic (red). Each cell 
population was then presented as a percentage of the total cell population, 
shown in Figure 3.20B. As expected, the majority of untreated HeLa cells were 
viable (95±6%); a small population of cells were positive for FITC or propidium 
iodide staining, thus showing evidence of background cytotoxicity. It is unclear 
whether these cells were naturally present in the cell population or a result of 
the conditions used in the assay. 
As a necrotic control, HeLa cells were exposed to UV radiation for 2 h and 
stained with propidium iodide. As an apoptotic control, cells were treated with 
50 µM cisplatin for 24 h, and stained with annexin V-FITC. The percentage of 
live cells after these treatments decreased to 65±4% and 48±5%, respectively, 
with cells taking up propidium iodide or binding annexin V-FITC (Figure 3.20B). 
The conditions used in these controls did not completely eliminate the live cell 
populations. A smear was observed for both treatments, possibly suggesting 
heterogeneity within the cell population in their sensitivity to the treatments or to 
the assay used. Comparison between untreated cells stained with both annexin 
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V-FITC and propidium iodide with UV-exposed cells only stained with propidium 
iodide shows that there was background binding of annexin V-FITC by 
untreated live cells (Figure 3.20A). A smaller background uptake of propidium 
iodide by untreated cells was also observed by comparing the untreated and 
apoptotic controls (Figure 3.20A). 
BCL2 is an anti-apoptotic factor, thus its siRNA-mediated knockdown should 
trigger apoptosis in cells. Although apoptotic cells can progress to necrosis 
(Kravchenko-Balasha et al., 2009), the apoptotic state should still be detectable 
under the experimental conditions, as siRNA effects take 24-72 h. It has been 
reported that cells can persist in an apoptotic state with a duration that largely 
correlates with BCL2 protein levels in the cell, and that a longer duration 
increases the chance of cells escaping apoptosis (Skommer et al., 2010).  
HeLa cells were incubated with 10 nM TR-BCL2 packaged inside VLP-PEG24-Tf 
for 0 h, 24 h, 48 h or 72 h, stained with annexin V-FITC and propidium iodide, 
and analysed by flow cytometry (Figure 3.21A). Significant toxicity was 
observed at 48 h and 72 h, with 39±9% and 26±4% of the cell population 
remaining viable, respectively. Little change in percentage cell viability was 
observed at 24 h (86±6%) compared to the 0 h control (88±5%). These results 
indicate a correlation between BCL2 expression and cytotoxicity: at 24 h, TR-
BCL2 delivered by VLP-PEG24-Tf only reduced BCL2 protein expression by 
~10%, whereas more significant knockdown occurred after 48 h (~46%) and 72 
h (~70%). There was a diminishing return on the cytotoxic effects of siRNA 
delivery as the incubation time increased, which might be caused by the dilution 
of siRNAs from cell division (HeLa cells have a doubling time of ~24 h). Other 
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factors also cannot be ruled out, such as heterogeneity within the cell 
population – some cells might be more sensitive to BCL2 knockdown than 
others, and the development of resistance to the treatment in a subset of cells.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21. Time- and concentration-dependent toxicity of siRNA delivery. (A) HeLa cells 
were incubated with 10 nM TR-BCL2 packaged inside VLP-PEG24-Tf for 0, 24, 48 or 72 h, and 
assessed for toxicity. (B) HeLa cells were incubated with 0, 5, 10 or 25 nM TR-BCL2 packaged 
inside VLP-PEG24-Tf for 48 h, and assessed for toxicity. The percentages shown represent the 
average of three repeats. Numbers indicate mean percentage cell viability ± SD. 
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Distinct populations of cells were observed after the 48 and 72 h treatments, 
with the majority of cells designated as live (negative for annexin V-FITC and 
propidium iodide) or late apoptotic (positive for both dyes). A large portion of 
necrotic cells was only observed at 48 h (23±7%), which interestingly 
disappeared at 72 h (3±1%). It is possible that a subset of cells progressed 
quickly through necrosis, resulting in cell swelling and membrane rupture, and 
thus was not counted at 72 h.  
The siRNA concentration dependence of cytotoxicity was also investigated: 
HeLa cells were incubated with 0 nM, 5 nM, 10 nM or 25 nM TR-BCL2 
packaged inside VLP-PEG24-Tf for 48 h. Delivered siRNA reduced cell viability 
in a concentration-dependent manner – with 85±5%, 82±7%, 39±9% and 
33±4% of cells remaining viable following incubation with 0 nM, 5 nM, 10 nM 
and 25 nM siRNA, respectively (Figure 3.21B). Although there seems to be a 
correlation between BCL2 knockdown and cytotoxicity, this is not a simple linear 
relationship. For instance, a knockdown of BCL2 by ~30% at 5 nM siRNA only 
reduced percentage cell viability by ~3%, whilst BCL2 knockdown by ~46% at 
10 nM reduced percentage viability by ~46%. It is possible that apoptosis is 
triggered in cells only at a given threshold of BCL2 expression. An increase of 
siRNA concentration from 10 nM to 25 nM produced a small change in 
percentage cell viability compared to from 5 nM to 10 nM siRNA. This might be 
due to the saturation of RNAi components in the cell: the intracellular siRNA 
concentration resulting from a 10 nM transfection might be close to saturating 
limiting components, such as the Argonaute-2 protein (Diederichs et al., 2008, 
Grimm et al., 2010), thus further increases in siRNA concentration will see 
diminishing returns on its cytotoxic effects. 
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Figure 3.22. Comparative toxicity of siRNA delivery. HeLa cells were (from left) untreated, 
incubated with 10 nM TR-BCL2 siRNA delivered by VLP, VLP-PEG24, VLP-PEG24-Tf, or VLP-
PEG24-Tf plus 100 nM free Tf, or 10 nM TR-Control delivered by VLP-PEG24-Tf for 48 h, and 
then assayed for cytotoxicity. The percentages shown represent the average of three repeats. 
Numbers indicate mean percentage cell viability ± SD. 
 
As before, 10 nM siRNA and 48 h were selected as the condition for comparing 
the cytotoxic effects of siRNA delivery by various VLP formulations (Figure 
3.22). Background toxicity unrelated to siRNA treatments was again observed, 
with 84.8±2.8% of untreated cells designated as live. In comparison, treatment 
with TR-BCL packaged inside VLP, VLP-PEG24 and VLP-PEG24-Tf reduced the 
percentage cell viability to 58±7%, 80±2% and 39±9%, respectively. This is 
consistent with the BCL2 expression data (Figure 3.18), and correlates the 
observed cytotoxicity with siRNA-mediated BCL2 knockdown. The lack of 
cytotoxic effect of siRNA delivery by VLP-PEG24 was surprising, as it was 
observed to reduce BCL2 expression by ~25% (Figure 3.19). One possible 
explanation is that apoptosis is triggered below a given threshold of BCL2 
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expression, which was not achieved by the effects of VLP-PEG24 mediated 
siRNA delivery. Interestingly, TR-BCL2 delivery by VLP-PEG24-Tf was notably 
more effective at inducing cytotoxicity within cells compared to delivery by VLP, 
despite producing comparable BCL knockdowns (Figure 3.19). One possible 
explanation for this is that VLP-PEG24-Tf particles triggered off-target toxicity 
that was unrelated to BCL2 knockdown. 
Further addition of 100 nM free Tf to VLP-PEG24-Tf increased the percentage 
cell viability to 65±1%, which supports a Tf receptor-dependent mechanism for 
the cellular uptake of VLP-PEG24-Tf. Interestingly, this is somewhat 
contradictory to the previous assumption that a threshold of BCL2 knockdown 
was required for triggering cell death, as free Tf inhibition only produced an 
~11% reduction in BCL2 expression. One possibility is that the apoptosis 
observed here was, at least in part, caused by the uptake of large amounts of 
free holo-Tf. The cytotoxic potential of iron overload and the subsequent 
production of reactive oxygen species in cells have been documented 
(Allameha et al., 2008, Dixon and Stockwell, 2014). 
Finally, the delivery of TR-Control by VLP-PEG24-Tf produced no change in 
percentage cell viability (86±3%). This suggests that the cellular uptake of VLP-
PEG24-Tf particles did not produce off-target toxicities, and that the cytotoxicity 
observed when TR-BCL2 was delivered by VLP-PEG24-Tf can be largely 
attributed to the siRNA-mediated knockdown of BCL2. It has been reported that 
off-target toxicity can also result from robust RNAi expression in mammalian 
cells, as limiting components like exportin-5 and Argonaute proteins become 
saturated and natural miRNAs are outcompeted (Grimm, 2011, Grimm et al., 
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2006). The lack of cytotoxic effect of the control siRNA rules out this possibility, 
at least for the siRNA concentration used.  
 
3.3 Summary of Chapter 3 
1. Previous protocols (Galaway, 2011) were adapted to construct TR-Cy5 
encapsidated VLP and VLP-Tf. The resulting particles packaged on average 
~10 molecules of TR-Cy5 each, and protected them from nuclease degradation. 
For VLP-Tf, a Tf valency of ~14 was achieved, which was comparable to 
previous results (Galaway, 2011). Notably fewer aggregates were formed than 
before, eliminating the necessity of additional purification steps. TR-Cy5 
encapsidated VLP-PEG24 and VLP-PEG24-Tf were also synthesised using the 
hetero-bifunctional crosslinker, SM(PEG)24, and amine-to-maleimide 
conjugation chemistry. Extensive PEGylation of the VLP surface was achieved 
(~97% of CPs); each VLP-PEG24-Tf particle displayed on average ~7 molecules 
of Tf on the termini of PEG24.  
 
2. Consistent with previous results (Galaway, 2011), Tf targeting resulted in 
significantly higher uptake of VLP-Tf by HeLa cells compared to VLP, whilst 
some level of non-specific VLP uptake was still observed. PEGylation of the 
VLP surface (VLP-PEG24) was able to significantly mitigate non-specific uptake 
by HeLa cells, likely by masking viral epitopes. Further addition of Tf (VLP-
PEG24-Tf) led to markedly increased uptake, likely via Tf receptor-mediated 
endocytosis.  
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3. TR-BCL2 encapsidated VLP-PEG24-Tf were constructed. VLP-PEG24-Tf 
successfully delivered the siRNA to HeLa cells. Significant cellular responses, 
including ~50% BCL2 protein knockdown and a ~45% decrease in cell viability, 
were achieved at just 10 nM TR-BCL2 concentrations. The uptake of VLP-
PEG24-Tf did not trigger any off-target toxicity in cells. 
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RNA aptamers as a novel tumour-targeting VLP 
ligand 
 
 
 
 
 
 
 
  
                                                                                                    ___   _ _                      Page 148 
 
4.1 Introduction 
4.1.1 Nucleic acid aptamers 
A major development in nucleic acid research came in the early 1980s, with the 
discovery of RNAs with catalytic activities, termed ribozymes (Kruger et al., 
1982, Guerriertakada et al., 1983). This ground-breaking finding not only 
shattered the long-held paradigm that only proteins could catalyse chemical 
reactions, but also the belief that nucleic acids were mere passive carriers of 
genetic information. Based on this idea that RNAs can fold into complex, three 
dimensional structures which enable specific interactions with biomolecules and 
confer functions, it was hypothesised that RNA ligands could be isolated against 
specific targets by in vitro selection from a library of random nucleotide 
sequences. 
Three laboratories independently provided proof-of-principle for this in 1990. 
The Gold laboratory coined the term to a selection method ‘Systematic 
Evolution of Ligands by Exponential Enrichment’, or SELEX, and used it to 
select for high affinity RNA ligands against the bacteriophage T4 DNA 
polymerase (Tuerk and Gold, 1990). The Szostak laboratory used a similar 
protocol to select RNA ligands against poly-thymine oligonucleotides and 
organic dyes that mimicked metabolic co-factors (Ellington, 1990), and 
subsequently coined the resulting ligands ‘aptamers’, derived from the Latin 
word apto, meaning ‘to fit’. In addition, the Joyce laboratory developed an in 
vitro selection method to identify RNA ligands capable of efficiently cleaving 
ssDNA (Robertson and Joyce, 1990). 
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Figure 4.1. In vitro nucleic acid aptamer selection via SELEX. (a) A large random 
oligonucleotide library is incubated with the target molecule. The library consists of sequences 
with a randomised region, flanked by constant 5' and 3' ends which serve as primer-binding 
regions. (b) Nucleic acids bound to the target molecule are partitioned from those not bound. (c) 
Nucleic acids which are unbound to the target molecules are removed. (d) Nucleic acids which 
are bound to the target molecules are eluted. (e) Bound nucleic acids are then amplified by 
(RT)PCR and used as the starting nucleic acid pool in subsequent cycles. Through successive 
rounds of SELEX, higher affinity aptamers are selected as they outcompete low affinity species 
for target binding and amplification – this is akin to Darwinian evolution. Typically 10 to 20 
cycles are performed, before the resulting aptamers are characterised. 
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The process of SELEX is illustrated in Figure 4.1. The starting point of SELEX is 
a synthetic library of oligonucleotides, containing sequences with a randomised 
region flanked by constant 5' and 3' regions for primer binding. The random 
region is typically 20-80 (n) nt in length, with the number of possible sequences 
being 4n. The pool of oligonucleotides is incubated with a target molecule for 
binding, before unbound or weakly bound species are removed through 
partitioning (e.g. affinity chromatography) and wash steps. Species which are 
bound are eluted and then amplified by (RT-)PCR to create an enriched pool for 
subsequent rounds of selection. To select for the tightest binders, the stringency 
of selection conditions is increased with successive SELEX rounds. This can be 
achieved by varying the conditions for the binding and washing steps, and by 
decreasing the concentration of target molecules used. Typically, 10 to 20 
rounds of SELEX are carried out before the final enriched aptamer pool is 
cloned, sequenced and characterised.  
Aptamer sequences identified from SELEX can fold into unique higher order 
structures – with a combination of bulges, hairpins, quadruplexes, pseudoknots, 
stems or loops (Patel et al., 1997) – through intramolecular base-pairing. These 
structures enable specific binding to target molecules through a series of 
intermolecular interactions, including hydrogen bonding, electrostatic 
interactions as well as van der Waal forces. Aptamers typically display high 
affinity for their targets, with dissociation constants (Kd) ranging from mM to pM 
values, which rival the affinities between antibodies and their corresponding 
antigens. Although analogous in function, aptamers offer numerous advantages 
over antibodies as targeting agents (Bunka and Stockley, 2006), including (i) 
they can be isolated in vitro, (ii) they can bind to a wider range of target 
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molecules including nucleic acids, proteins, peptides, organics, metal ions or 
even toxic species, (iii) they are amenable to large-scale chemical synthesis 
with minimal batch-to-batch variations, (iv) they elicit little or no immunogenicity 
in vivo, (v) their smaller size enables binding to epitopes which might be 
inaccessible to antibodies, and (vi) they are tolerant of chemical modifications 
that can enhance their stability or binding.  
The original SELEX reports used RNA libraries. Subsequent work revealed that 
DNA libraries could also be used to isolate DNA aptamers against specific 
target molecules, such as human thrombin (Bock et al., 1992). DNA aptamers 
are functionally similar to their RNA counterparts, although RNA aptamers 
require the extra steps of (reverse) transcription during SELEX. 
The process of SELEX has constantly evolved since its first reported use, due 
to rapid technological advances. One key development came in 2001, when 
Cox and coworkers demonstrated the automation of SELEX using Biomek 2000 
liquid-handling robots, which significantly reduced the duration of selection from 
six weeks to just three days (Cox and Ellington, 2001). The efficiency of the 
partitioning steps has also been improved with advances in techniques such as 
surface plasmon resonance (Misono and Kumar, 2005) and capillary 
electrophoresis (Mendonsa and Bowser, 2004). The nuclease resistance of 
aptamers can be significantly improved by the incorporation of 2'-modified 
pyrimidines (Beigelman et al., 1995), or by the use of unnatural L-ribose 
nucleotides to synthesise Spiegelmers (Klussmann et al., 1996). In addition to 
modified sugar groups, the use of modified bases for SELEX has been 
demonstrated by Somalogic (Ochsner et al., 2014, Ostroff et al., 2010) – 
resulting aptamers have extremely high affinity to their targets, with Kd typically 
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in the low nM range. Furthermore, advances in next-generation sequencing and 
computer programming have enabled more efficient, high-throughput aptamer 
characterisation (Cho et al., 2010, Lu et al., 2014).  
Hundreds of nucleic acid aptamers have now been isolated against a myriad of 
targets – including small molecules (Niazi et al., 2008), peptides (Vater et al., 
2003), proteins (Svobodova et al., 2013), bacteria (Duan et al., 2013), viruses 
(Wang et al., 2013) and even whole cells (Shangguan et al., 2006). These 
aptamers are catalogued online in the Aptamer Database 
(http://aptamer.icmb.utexas.edu/), and have been adapted to a range of 
applications, such as biotechnological, therapeutic, diagnostic and bio-sensing.   
 
4.1.2 Therapeutic applications of nucleic acid aptamers 
Nucleic acid aptamers have attracted major clinical interest due to their ability to 
tightly and specifically bind to target molecules. Development began as early as 
1994, when Jellinek and coworkers reported the use of an n=30 random RNA 
library to select aptamers against the 165 isoform of vascular endothelial growth 
factor (VEGF165) (Jellinek et al., 1994). VEGF165 is a signalling protein that 
stimulates angiogenesis, and is implicated in the formation of abnormal blood 
vessels that impair the retina in age-related macular degeneration. Following 13 
rounds of SELEX, six structural families of sequences were obtained; each 
containing conserved sequences that shared a defined secondary structure. 
Importantly, the aptamers effectively blocked the interaction between VEGF165 
and the VEGF receptor on cells, with a Kd of ~30 nM.  
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Figure 4.2. Structure and binding mechanism of pegaptanib. (A) Predicted secondary 
structure of pegaptanib. Highlighted in black are unmodified nucleotides; in red are 2′-OMe 
purines; in blue are 2′-F pyrimidines. A 40 kDa PEG is conjugated to the 5′ end of the aptamer. 
An inverted deoxythymidine cap is attached at the 3′ end. (B) Binding of pegaptanib (right) to 
the heparin-binding domain of VEGF165 (left). Disulfide bonds in the heparin-binding domain are 
highlighted in yellow. Helical stems in the aptamer are highlighted in teal. Shown in red is 
nucleotide U-14 on the aptamer, which interacts with cysteine-137 of VEGF165. Adapted from Ng 
et al. (2006). (Ng et al., 2006). 
 
The instability of RNA and their susceptibility to nuclease degradation hindered 
the clinical progress of these VEGF165-targeting aptamers. This prompted the 
same group to introduce chemical modifications, by using SELEX libraries 
containing 2′-modified sequences for selection against VEGF165 (Ruckman et 
al., 1998). After 10 rounds of selection, 46 aptamer sequences were identified, 
which were characterised into 3 structural families and all displayed high affinity 
binding to VEGF165 (Kd~5 nM). The consensus sequence from each family was 
truncated, yielding three minimal sequences 23-29 nt in length, which retained 
their VEGF165 binding. The capacity of these aptamers to inhibit the activity of 
VEGF was then investigated in guinea pig models (Ruckman et al., 1998). 
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Intradermal injection of one of the aptamers, t44-OMe, inhibited the vascular 
permeability response to VEGF by up to ~58%. Additionally, coupling of the t44-
OMe aptamer to a 40 kDa PEG was shown to dramatically prolong its plasma 
half-life, from a few minutes to 9 h in rhesus monkeys (Tucker et al., 1999). This 
PEG-aptamer conjugate was named pegaptanib (Figure 4.2).  
 
 
Aptamer 
 
 
Target  
 
Therapeutic application 
 
Development 
 
AS1411 
 
 
Nucleolin 
 
 
Renal cell carcinoma/NSCLC 
 
 
Phase III 
 
ARC1779 von Willebrand factor von Willebrand’s disease Phase III 
 
ARC1905 
 
 
Complement component 5 
 
 
Neovascular AMD 
 
 
Phase I 
 
Macugen VEGF 
 
AMD, DME, PDR Approved 
NOX-A12 
 
Stromal cell-derived factor 1 
 
CLL, MM, glioblastoma 
  
Phase II 
 
NOX-E36 
 
CCL2 Type II diabetes mellitus Phase II 
 
RB006 Factor IXa Coronary artery disease Phase II 
 
  
Table 4.1. Selected examples of DNA and RNA aptamers in clinical development. NSCLC 
= non-small cell lung carcinoma; AMD = age-related macular degeneration; VEGF = vascular 
endothelial growth factor; DME = diabetic macular edema; PDR = proliferative diabetic 
retinopathy; CLL = chronic lymphocytic leukaemia; MM = multiple myeloma; CCL2 = chemokine 
(C-C motif) ligand 2. 
 
 
Pegaptanib entered clinical trials for treating wet age-related macular 
degeneration in 1998 (Trujillo et al., 2007). Following intraocular administration 
of the drug, a high response rate was achieved, with 80% of patients 
experiencing improved vision after 3 months of treatment. Moreover, the doses 
used were well tolerated and no significant off-target effects were observed 
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even at 3 mg/eye doses. In 2004, pegaptanib became the first nucleic acid 
aptamer to be FDA approved, and was trademarked as Macugen. Although to 
date, pegaptanib remains the only FDA approved aptamer drug, many more 
candidates are beginning to emerge from the clinical pipelines, for treating a 
variety of diseases. Selected examples are highlighted in Table 4.1; many more 
exist (Keefe, 2010). 
As well as direct therapeutics, nucleic acid aptamers have also been developed 
as targeting ligands against cancer cell surface markers. In 2002, Lupold and 
coworkers performed SELEX against the extracellular portion of prostate 
surface membrane antigen (PSMA) (Lupold, 2002). PSMA is a membrane 
protein that catalyses the hydrolysis of N-acetylaspartylglutamate. Although low 
levels of PSMA are found in the salivary glands, small intestine and brain, it is 
predominantly a prostate-specific protein, and is highly overexpressed on 
prostate cancer cells (O'Keefe et al., 2004, Israeli et al., 1994). Six rounds of 
selection from a 40mer RNA library of ~6x1014 random sequences led to the 
identification of two unique sequences, named A9 and A10 (Lupold, 2002). Both 
aptamers inhibited the enzyme activity of PSMA with low nM Kis; though non-
competitive inhibition was observed with A9, and competitive inhibition with 
A10. The different modes of inhibition suggested that A9 and A10 bound to 
distinct epitopes on the extracellular portion of PSMA. Furthermore, systematic 
3'-truncation of the A10 aptamer produced a smaller version which displayed 
comparable affinity, and bound specifically to PSMA+ve LNCaP prostate cancer 
cells, but not to PSMA-ve PC-3 cells. 
The A10 aptamer was subsequently utilised by McNamara and coworkers, who 
coupled it to two therapeutic siRNAs, targeted against BCL2 and PLK1 
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(McNamara et al., 2006). Aptamer targeting specifically delivered the siRNAs to 
PSMA+ve LNCaP cells, which induced significant knockdown of the target 
mRNA and protein, as well as apoptosis at sub nM doses. These effects were 
not observed in the PSMA-ve PC-3 cell line. In addition, it was shown that the 
cellular uptake of aptamer-siRNA conjugates did not trigger a substantial type I 
interferon response, suggesting the absence of any non-specific inflammatory 
response. This work was previously mentioned in Chapter 3: the fact that the 
siRNAs remained functional despite being coupled to another oligonucleotide 
prompted their use as model drug cargos for the MS2 VLP delivery system 
(Galaway, 2011).  
The A10-PLK1 siRNA sequence was then optimised by adding 2-nucleotide 
overhangs at the 3' end, and tested in athymic mice bearing tumours derived 
from PSMA+ve 22RV1 or PSMA-ve PC3 cells (Dassie et al., 2009). Following 
systemic administration, significant tumour regression was observed in mice 
with 22RV1-derived tumours, but not those bearing PC3-derived tumours. 
Addition of the 3'-overhang enhanced RISC loading of the guide strand. 
Furthermore, the addition of a ~20kDa PEG to the 5' end of the PLK1 
passenger strand enhanced the circulating half-life of the aptamer-siRNA 
conjugate from 35 min to >30 h, and also induced tumour progression at lower 
doses. 
More recently, computer modelling was used to rationally truncate A9 (70mer) 
to A9L (41mer) (Figure 4.3), which demonstrated comparable PSMA binding 
(Kd~5 nM) as well as specific uptake by PSMA expressing cells (Rockey et al., 
2011). The yield of chemically synthesised RNA decreases significantly with 
increasing nucleotide length, as the efficiency of each coupling step is typically 
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~98% (Caruthers, 2011). For this reason, sequence truncation greatly facilitates 
the large-scale chemical synthesis of aptamers: the expected yield of a 41mer 
(0.9840=45%) is almost double that of a 71mer (0.9869=25%).   
Since the original work on aptamers A9 and A10, many more aptamers have 
been identified which target overexpressed cancer cell surface markers such as 
Tf receptor (Chen et al., 2008), epidermal growth factor receptor (Mi et al., 
2010), and protein tyrosine kinase-7 (Huang et al., 2009).  
 
4.1.3 MS2 VLPs and nucleic acid aptamers as targeting ligands 
The MS2 VLP drug delivery system is highly modular in that a variety of 
targeting ligands and drug cargos can be combined, to potentially treat a 
diverse range of cancers. Coupled with a flexible targeting ligand, such as 
nucleic acid aptamers that can be selected against any target, MS2 VLPs could 
be a powerful platform for targeted drug delivery. For a model targeting 
aptamer, A9L seems suitable as it is relatively short (41 nt) and is amenable to 
chemical synthesis, and it has been well characterised. Furthermore, the 
relevant prostate cancer cell lines (PSMA+ve LNCaP and PSMA-ve PC-3) are 
relatively simple to maintain. The use of two cell lines would provide the benefit 
of an extra negative control, which was lacking in the previous experiments 
(Galaway, 2011) and in Chapter 3.  
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Figure 4.3. Schematic showing the synthesis of siRNA encapsidated, PEG-aptamer 
modified VLP. Cargo packaging is achieved by mixing TR-siRNA with dissociated MS2 CP2 at 
roughly neutral pH. Packaged VLPs can be surface modified with PEG24, as described in 
Chapter 3, and with the RNA aptamer A9L as a tumour-targeting ligand. The sequence and 
predicted secondary structure of A9L is shown. The resulting particles are denoted as VLP-
PEG24-A9L.  
 
It is notable that aptamer targeting had been previously attempted by Galaway 
(Galaway, 2011). Aptamer A10-3.2, a truncated version of A10, was directly 
conjugated to the surface of MS2 VLPs using thiol-to-amine conjugation 
chemistry. However, when tested in vitro on LNCaP and PC-3 cells, aptamer-
mediated specific targeting was not observed. Two likely explanations include: 
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(1) aptamer conjugation was not sufficient to cover viral epitopes that enabled 
high levels of non-specific uptake, and (2) steric effects of the direct conjugation 
of aptamers to a rigid surface prevented the correct folding of aptamers, or 
interfered with their PSMA binding. The addition of PEG24 as an intermediary 
layer (as shown in Chapter 3) between MS2 VLPs and the targeting aptamer 
should solve these problems. A schematic of the preparation of VLP-PEG24-Apt 
is shown in Figure 4.3.  
 
4.1.4 Aims 
The aims of the work described in this chapter were to: 
1. Conjugate aptamer A9L to the surface of VLP-PEG24. 
2. Assess the stability and immunogenicity of VLP-PEG24-A9L. 
3. Evaluate VLP-PEG24-A9L binding and uptake in LNCaP and PC-3 
prostate cancer cell lines, and assess the cellular effects of TR-BCL2 
delivery by VLP-PEG24-A9L. 
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4.2 Results and discussion 
4.2.1 Preparation and analysis of VLP-PEG24-A9L 
The protocol for synthesising VLP-PEG24-Tf in Chapter 3 was adapted for the 
preparation of VLP-PEG24-A9L (Figure 4.4). The 41 nt RNA aptamer, A9L, was 
synthesised by DNA Technology using 3'-Thiol-Modifier C3 Controlled Pore 
Glass columns, and purified by reverse-phase high-performance liquid 
chromatography. The resulting aptamer contained a protected disulfide linker at 
the 3' end, which could be reduced to a thiol group and thus was compatible 
with the amine-to-thiol conjugation chemistry used (Figure 4.4B). One 
advantage of using aptamers over Tf as a targeting ligand, from a conjugation 
perspective, is that the 1:1 thiol to aptamer ratio results in aptamers being 
presented in a defined orientation, with the regions responsible for PSMA 
recognition and binding fully exposed to the exterior. This level of control was 
not possible for Tf, as the introduction of thiol groups by SATA utilised NHS 
chemistry to randomly incorporate them to exposed amines on Tf. 
Although a fluorescent dye would facilitate aptamer quantification as well as the 
assessment of cellular binding and uptake, it was not incorporated because (i) it 
would reduce the efficiency of RNA synthesis, significantly raising its cost, and 
more importantly (ii) it might affect aptamer folding and its ability to bind PSMA. 
Therefore, a second RNA oligonucleotide, U6-FAM, was synthesised to test for 
conjugation conditions. U6-FAM is a short oligonucleotide composed of 6 
uridines, a 3'-thiol modification, and a 5'-fluorescein modification to facilitate 
quantification.  
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Figure 4.4. Schematic depicting the preparation of VLP-PEG24-A9L. (A) Surface decoration 
of VLP with SM(PEG)24 and subsequently the 41 nt RNA aptamer, A9L. (B) Conjugation 
chemistry used for VLP surface modification. SM(PEG)24 is a hetero-bifunctional crosslinker, 
with an NHS terminus that can react with VLP surface amines, and a maleimide terminus that 
can react with thiol-modified A9L. 
 
To expose terminal thiol groups for conjugation, U6-FAM was reduced via 
incubation with TCEP. TR-Cy5 encapsidated VLPs were reacted with 
SM(PEG)24 as previously described. The two reaction mixtures were separately 
eluted through NAP-5 columns to remove excess reagents; the fractions 
containing U6-FAM or VLP-PEG24 were pooled, and then mixed to allow 
conjugation to take place. A molar ratio of 75 U6-FAM to 1 VLP was used. The 
final reaction mixture was incubated with excess β-mercaptoethanol overnight 
to quench unreacted maleimide groups, and eluted through a NAP-25 column 
before it was concentrated using a 100 kDa MWCO spin concentrator.  
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Figure 4.5. Analysis of VLP-PEG24-U6-FAM. (A) SDS-PAGE. 1: Fermentas Prestained 
Ladder; 2: VLP; 3: VLP-PEG24; 4: VLP-PEG24-U6-FAM. The gel was visualised by silver staining 
(left) or FAM fluorescence scanning (right). (B) Native 2% (w/v) agarose gel electrophoresis. 1: 
VLP; 2: VLP-PEG24; 3: VLP-PEG24-U6-FAM. The gel was visualised via Cy5 or FAM 
fluorescence scanning. 
 
The products were firstly analysed by UV-visible spectroscopy. The absorbance 
at 649 nm was measured to calculate the concentration of Cy5 in solution (Cy5 
ε649 nm = 250,000 L.mol
-1.cm-1). From this, the concentration of MS2 VLPs was 
estimated using the previously observed ratio from Chapter 3 (~10 TR-Cy5 to 1 
VLP). The absorbance at 495 nm was also measured to calculate the 
concentration of U6-FAM present in solution (FAM ε495 nm = 75,000 L.mol
-1.cm-1). 
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Using these, an average U6-FAM to VLP ratio of 15.7±2.1 was calculated from 
three repeats. 
SDS-PAGE analysis revealed bands which were only visualised by fluorescein 
fluorescence scanning for the putative VLP-PEG24-U6-FAM lane, but not for the 
VLP or VLP-PEG24 lanes (Figure 4.5A). This confirms the successful 
conjugation of U6-FAM to PEGylated MS2 CP. Analysis by native 2% (w/v) 
agarose gel electrophoresis revealed that, whilst the VLP-PEG24 displayed a 
lower electrophoretic mobility relative to VLP, reflecting their larger particle size, 
addition of U6-FAM increased the mobility (Figure 4.5B). This might be due to 
the conjugated RNA imparting more negative charge, which outweighed the 
effects of their relatively small mass contribution on the electrophoretic mobility 
of the particle. Hence, VLP-PEG24-U6-FAM migrated further towards the 
positive anode. Moreover, FAM fluorescence was only observed for the VLP-
PEG24-U6-FAM band, and not for the VLP or VLP-PEG24 bands, confirming the 
successful conjugation of U6-FAM.   
The same protocol was used to synthesise VLP-PEG24-A9L, again, using an 
aptamer to VLP ratio of 75 to 1. VLP-PEG24-A9L was eluted through a NAP-25 
column, and then concentrated using a 100 kDa MWCO spin concentrator. The 
A649nm of the sample was measured to calculate the concentration of Cy5 
present, which was used to estimate the yield (~40% of the starting material). 
Analysis on a native 2% (w/v) agarose gel revealed the previously observed 
characteristic shift in electrophoretic mobility towards the anode for VLP-PEG24-
A9L, relative to VLP-PEG24, which suggests successful conjugation (Figure 
4.6A). TEM analysis of VLP-PEG24-A9L did not clearly show evidence of larger 
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particles (Figure 4.6B). However, it did show that the VLP particles remained 
intact after the conjugation reactions. No aggregate structures were observed.  
 
 
 
 
 
 
 
Figure 4.6. Analysis of VLP-PEG24-A9L. The same protocol for the preparation of VLP-PEG24-
U6-FAM was used for synthesising VLP-PEG24-A9L, which was then analysed. (A) Native 2% 
(w/v) agarose gel electrophoresis. 1: HyperLadder I; 2: VLP; 3: VLP-PEG24; 4: VLP-PEG24-A9L. 
The gel was visualised by ethidium bromide scanning or Cy5 fluorescence scanning. (B) TEM 
analysis of VLP-PEG24-A9L. Scale bar = 50 nm. 
 
4.2.2 Stability of VLP-PEG24-A9L 
Various modifications are typically made to RNA aptamers to stabilise them 
against hydrolysis and nuclease degradation, such as 2'-OH substitutions and 
phosphodiester backbone modifications (Shigdar et al., 2013). However, the 
A9L aptamer used here did not contain any stabilising modifications. To assess 
the stability of VLP-PEG24-A9L in cell medium, the nanoparticles were 
incubated in either the PC-3 medium (Ham’s F-12k with 7% (v/v) FBS) or the 
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LNCaP medium (RPMI-1640 with 10% (v/v) FBS) at 37oC for up to 48 h, before 
they were concentrated through 100 kDa MWCO spin concentrators.  
 
 
 
 
 
 
 
 
 
Figure 4.7. Stability analysis of VLP-PEG24-A9L in cell media. VLP-PEG24-A9L was 
incubated in either the PC-3 or LNCaP cell medium at 37
o
C for 0 h, 1 h, 2 h, 6 h, 12 h, 24 h or 
48 h, and spin concentrated into HEPES before analysis. (A) Native 2% (w/v) agarose gel 
electrophoresis. L = HyperLadder I. The gel was visualised by ethidium bromide staining or Cy5 
fluorescence. (B) TEM analysis. Scale bar = 50 nm. Selected individual particles were scaled up 
in size and shown in red boxes (bottom right) for clarity.  
 
The products were analysed on a native 2% (w/v) agarose gel (Figure 4.7A). 
Increasing the incubation time did not produce changes in the VLP-PEG24-A9L 
bands in either cell medium, which remained constant in electrophoretic mobility 
as well as intensity. This suggests that, under the conditions used for growing 
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PC-3 and LNCaP cells, (i) A9L remain stable, (ii) VLP-PEG24-A9L particles 
remain intact, and (iii) there is no non-specific binding to components in the cell 
media. TEM analysis also revealed intact particles, indicating that VLP-PEG24-
A9L was not destabilised under the cell growth conditions (Figure 4.7B). The 
poor quality of the TEM images might be due to the presence of components of 
the cell media, which could not be removed via 100 kDa MWCO spin 
concentrators. 
 
 
 
 
 
 
Figure 4.8. Stability analysis of VLP-PEG24-A9L in human serum. VLP-PEG24-A9L was 
incubated in human serum at 37
o
C for 0 h, 1 h, 2 h, 6 h, 12 h, 24 h or 48 h, and spin 
concentrated into HEPES before analysis. (A) Native 2% (w/v) agarose gel electrophoresis. L = 
HyperLadder I. The gel was visualised by ethidium bromide staining or Cy5 fluorescence. (B) 
TEM analysis. Scale bar = 50 nm. Selected individual particles were scaled up in size and 
shown in red boxes (bottom left) for clarity. 
 
The same assay was then carried out using human serum instead of cell 
medium, to investigate the stability of VLP-PEG24-A9L under conditions more 
similar to those found in vivo. After incubation at 37oC for up to 48 h, VLP-
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PEG24-A9L was concentrated using 100 kDa MWCO spin concentrators, and 
analysed on a native 2% (w/v) agarose gel (Figure 4.8A). Bands representing 
VLP-PEG24-A9L remained relatively unchanged in intensity with increasing 
incubation times, suggesting that the VLP-PEG24-A9L particles remained stable 
(Figure 4.8A). This was supported by TEM images showing the presence of 
intact VLP particles, indicating that prolonged exposure to human serum did not 
disrupt particle stability (Figure 4.8B). However, the bands appeared more 
diffuse with increasing incubation times, resembling smears with slightly lower 
electrophoretic mobility most notably at 24 h and 48 h (Figure 4.8A). Given the 
relative electrophoretic mobility observed for VLP-PEG24 and VLP-PEG24-A9L 
(Figure 4.6A), this result suggests that some A9L on VLP-PEG24-A9L became 
degraded after prolonged incubation in human serum. One possibility is that the 
RNA aptamers were degraded by nucleases present in the serum used. 
Altogether, these results indicate that both VLP-PEG24-A9L particles and A9L 
remained stable after prolonged incubation at 37oC with cell media, and thus 
should be compatible with the in vitro experiments used in Chapter 3 to 
investigate cellular uptake, BCL2 knockdown and cytotoxicity. However, the 
unmodified RNA aptamers on VLP-PEG24-A9L appeared to degrade when 
incubated in human serum in a time-dependent manner, therefore future in vivo 
testing of RNA aptamer targeted VLPs should utilise chemically modified 
aptamers, which can better tolerate such conditions. 
 
                                                                                                    ___   _ _                      Page 168 
 
4.2.3 Antibody binding of VLP-PEG24-A9L 
As shown in the previous Chapter, PEGylation significantly mitigates the non-
specific uptake of VLPs by cells, which was assumed to be due to the masking 
of viral epitopes on the VLP surface that interact with cells. To assess this idea, 
an experiment was carried out to compare the antibody-binding capacity of 
VLP-PEG24-A9L to that of unmodified VLPs. An ideal drug delivery system 
should elicit minimal immunogenicity when administered in vivo, thus this assay 
could provide a good indication of the likely immunogenicity of aptamer 
targeted, PEGylated MS2 VLPs. 
VLP and VLP-PEG24-A9L were mixed with increasing quantities of rabbit 
polyclonal anti-MS2 CP antibodies that were previously raised in the Stockley 
laboratory. The mixtures were left at room temperature for 30 min to allow 
antibody binding, and then analysed on a native 2% (w/v) agarose gel (Figure 
4.9A). TR-Cy5 encapsidated VLP and VLP-PEG24-A9L were used, thus bands 
on the gel could be visualised by Cy5 fluorescence scanning. The intensities of 
the bands were quantitated by 2D densitometry, and compared to calculate the 
relative % bound VLP or VLP-PEG24-A9L; bands representing VLP and VLP-
PEG24-A9L in the absence of antibodies were assumed to be 0% bound (Figure 
4.9B).  
The addition of 1 µL and 5 µL anti-MS2 antibodies resulted in the binding of 
58.3±3.6% and 86.7±8.1% of VLP, respectively. The diminishing intensity of the 
VLP band coincided with the increasing intensity of a band at the top of the gel, 
which likely represented complexes of VLPs bound to multiple anti-MS2 
antibodies that were too large to migrate through the gel. In comparison, only 
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7.9±3.1% and 43.9±10.8% of VLP-PEG24-A9L became bound with the addition 
of 1 µL and 5 µL antibodies, respectively, indicating a 7-fold and 2-fold 
reduction in antibody binding compared to VLP. This suggests that PEGylation 
masked VLP surface epitopes and mitigated their recognition and binding by 
anti-MS2 antibodies.  
 
 
 
 
 
 
 
Figure 4.9. Antibody binding analysis of VLP-PEG24-A9L. VLP or VLP-PEG24-A9L was 
mixed with 0, 1 or 5 µL rabbit polyclonal anti-MS2 CP antibodies at room temperature for 30 
min, and then analysed. (A) Native 2% (w/v) agarose gel electrophoresis. 1: HyperLadder I; 2: 
VLP; 3: VLP with 1 µL antibody; 4: VLP with 5 µL antibody; 5: VLP-PEG24-A9L; 6: VLP-PEG24-
A9L with 1 µL antibody; 7: VLP-PEG24-A9L with 5 µL antibody. The gel was visualised by Cy5 
fluorescence scanning. (B) 2D densitometry analysis of the bands. The intensities of the bands 
were compared to calculate relative % bound VLP or VLP-PEG24-A9L. Error bars indicate the 
standard deviation of three repeats. 
 
It is unclear why some level of antibody binding was still observed for VLP-
PEG24-A9L at higher antibody concentrations. From the SDS-PAGE analysis of 
PEGylated VLP (Figure 3.16, Figure 4.5), it appears that a small portion of MS2 
CP was not conjugated to PEG24 at the VLP to SM(PEG)24 molar ratios used. It 
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is therefore likely that certain regions on some particles were insufficiently 
covered by PEG, to prevent antibodies binding. Another possibility is that, due 
to the polyclonal nature of the anti-MS2 antibodies used, some non-specific 
antibodies might have been present, which bound to other parts of VLP-PEG24-
A9L, such as quenched maleimide groups or A9L. Obviously the immune 
system is highly complex, which is not reflected in the simple in vitro antibody 
binding assay. Therefore, in vivo work must be carried out to accurately assess 
the true immunogenicity of MS2 VLPs. There are currently few reports of the in 
vivo testing of MS2 VLPs – the Wang laboratory systemically administered non-
PEGylated MS2 VLPs to mice, to deliver nucleic acid-based cargos, such as 
miRNAs and mRNA vaccines (Li et al., 2013, Pan et al., 2012b, Pan et al., 
2012a). No significant immune responses were observed in those studies. 
 
4.2.4 Cellular binding and uptake of VLP-PEG24-A9L 
Two prostate cancer cell lines were used to assess VLP-PEG24-A9L uptake, 
including PC-3 and LNCaP. PC-3 cells differ from LNCaP cells in their high 
metastatic potential and, importantly, in their lack of PSMA expression (Kaighn 
et al., 1979, Carter et al., 1996). Since aptamer A9L targets PSMA, PC-3 can 
serve as the negative cell line and LNCaP as the positive cell line.  
To confirm the relative PSMA expression levels, PC-3 and LNCaP cell lysates 
were analysed by Western blotting (Figure 4.10A). When probed with anti-
PSMA antibodies, a ~100 kDa band was observed for the LNCaP cell lysate but 
not for the PC-3 cell lysate, indicating their differential PSMA expression. As a 
control, anti-GADPH antibodies were also used, which produced a ~37 kDa 
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band for both LNCaP and PC-3 cell lysates. This was expected, as GADPH is a 
housekeeping protein.  
 
 
 
 
 
 
 
 
 
Figure 4.10. Analysis of the PC-3 and LNCaP prostate cancer cell lines. (A) Western blots 
of PC-3 and LNCaP cell lysates, using either anti-PSMA or anti-GADPH antibodies as the 
primary antibody. (B) Flow cytometry analysis of PC-3 and LNCaP cells stained with primary 
anti-PSMA antibodies and secondary FITC-labelled antibodies (black curves). Grey shaded 
curves represent cells incubated with the secondary FITC-labelled antibodies only.  
 
The surface display of PSMA in each cell line was also assessed using an 
adapted protocol (McNamara et al., 2006). PC-3 and LNCaP cells were 
incubated with an anti-PSMA rabbit antibody for 1 h, washed, then incubated 
with a FITC-labelled anti-rabbit IgG antibody for 30 min. Cells were washed 
again and analysed by flow cytometry (Figure 4.10B). In addition, cells stained 
with only FITC-labelled anti-rabbit IgG antibodies were used to determine the 
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non-specific background fluorescence, shown as grey shaded curves in the flow 
cytometry histograms (Figure 4.10B). An increase in FITC fluorescence was 
only observed for LNCaP cells incubated with both antibodies, whereas the 
fluorescence of PC-3 cells did not change with respect to the control. These 
results suggest that PSMA is expressed in LNCaP, but not in PC-3 cells, and 
also that PSMA is present on the LNCaP cell surface. Therefore, these two cell 
lines should be suitable for investigating PSMA-targeted drug delivery. 
Next, the cell binding capacity of VLP-PEG24-A9L was evaluated using an 
established protocol (McNamara et al., 2006). PC-3 and LNCaP cells were 
harvested and incubated in FIX at room temperature for 10 min. Fixed cells 
were then washed in DPBS, and incubated in a binding buffer containing 25 nM 
TR-Cy5 packaged inside various VLP formulations for 1 h. The binding buffer 
also contained 0.01% (w/v) BSA to minimise any non-specific interactions. The 
cells were washed and analysed by flow cytometry (Figure 4.11). Compared to 
untreated cells, a small increase in Cy5 fluorescence was observed for both 
PC-3 and LNCaP cells incubated with VLP-PEG24, which indicates low levels of 
non-specific cell binding. Incubation with VLP-PEG24-A9L led to a notable 
increase in the Cy5 fluorescence of LNCaP, but not PC-3 cells. In contrast, the 
addition of 100 nM free A9L reduced the Cy5 fluorescence of LNCaP cells to a 
level comparable to VLP-PEG24, suggesting that A9L was mediating cell binding 
by VLP-PEG24-A9L. 
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Figure 4.11. Cell binding analysis of VLP-PEG24-A9L. Flow cytometry histograms of PC-3 
and LNCaP cells incubated with 25 nM TR-Cy5 packaged inside VLP-PEG24, VLP-PEG24-A9L, 
or VLP-PEG24-A9L in the presence of 100 nM free A9L for 1 h. Grey shaded curves represent 
untreated cells. 
 
The cellular uptake of VLP-PEG24-A9L was also evaluated. PC-3 and LNCaP 
cells were grown on 24 well plates, and incubated with 10 nM TR-Cy5 
packaged inside VLP-PEG24, VLP-PEG24-A9L or VLP-PEG24-A9L in the 
presence of 100 nM free A9L, for 2 h or 18 h, before they were processed for 
flow cytometry analysis (Figure 4.12). At 2 h, a significant increase in mean Cy5 
fluorescence was observed for LNCaP cells incubated with VLP-PEG24-A9L 
(90.4±12.5 AU); other treatments did not affect the Cy5 fluorescence of cells 
relative to untreated cells, for both cell lines (Figure 4.12A). At 18 h (Figure 
4.12B), incubation with VLP-PEG24 led to an increase in the mean Cy5 
fluorescence of LNCaP cells (225.3±34.1 AU) compared to untreated cells 
(5.0±1.0 AU), which is indicative of some level of non-specific uptake of VLP-
PEG24. A ~5-fold increase in mean Cy5 fluorescence was observed when 
LNCaP cells were incubated with VLP-PEG24-A9L (1087.7±118.0 AU), whilst 
further addition of 100 nM free A9L led to a ~3-fold decrease in fluorescence 
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(386.7±77.1 AU). For PC-3 cells, an increase in mean Cy5 fluorescence was 
observed (~500 AU), which was comparable for all three treatments, thus it 
likely indicates non-specific uptake.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Cellular uptake analysis of VLP-PEG24-A9L. PC-3 and LNCaP cells were either 
untreated, or incubated with 10 nM TR-Cy5 packaged inside VLP-PEG24, VLP-PEG24-A9L, or 
VLP-PEG24-A9L in the presence of 100 nM free A9L for (A) 2 h or (B) 18 h. Cells were analysed 
by flow cytometry and the mean Cy5 fluorescence of cells were measured. Error bars indicate 
the standard deviation of three repeats. 
 
Altogether, these results suggest that (i) A9L targeting is specific to LNCaP, and 
not PC-3 cells, (ii) there is some level of non-specific uptake for both cell lines 
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with longer incubations, and (iii) the A9L targeted uptake by LNCaP cells and 
the non-specific uptake by both cell lines likely utilise different pathways for cell 
entry, with the former occurring at a markedly faster rate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Analysis of VLP-PEG24-A9L binding and internalisation. Deconvolution 
microscopy images of LNCaP and PC-3 cells either untreated, or incubated with 100 nM TR-
Cy5 packaged inside VLP-PEG24, VLP-PEG24-A9L or VLP-PEG24-A9L in the presence of 1 µM 
free A9L. DAPI staining (nuclei) is depicted in blue; Cy5 fluorescence (siRNA) is depicted in red. 
Scale bar = 20 µM. 
 
The effects of A9L targeting on the cell binding and internalisation of VLP-
PEG24-A9L were further investigated. LNCaP and PC-3 cells were grown on 
glass coverslips, and incubated with 100 nM TR-Cy5 packaged inside VLP-
PEG24, VLP-PEG24-A9L or VLP-PEG24-A9L in the presence of 1 µM A9L at 4
oC 
for 1 h. The cells were washed with DPBS to remove unbound particles from 
the cell surface, and incubated at 37oC for 1 h to enable internalization of 
surface-bound particles. They were then washed and visualized by 
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deconvolution microscopy (Figure 4.13). High Cy5 fluorescence was observed 
in LNCaP cells incubated with VLP-PEG24-A9L, suggesting that A9L enabled 
tight binding of VLP-PEG24-A9L to the LNCaP cell surface via PSMA, which 
were not removed in the wash steps and subsequently internalised at 37oC. 
Addition of excess free A9L aptamers led to a significant decrease in Cy5 
fluorescence, suggesting that free aptamers competed with those present on 
VLP-PEG24-A9L for PSMA binding on the LNCaP cell surface, thus reducing 
VLP-PEG24-A9L uptake. In comparison, no Cy5 fluorescence was observed for 
PC-3 cells, or for LNCaP cells incubated with VLP-PEG24, indicating the lack of 
non-specific cell binding and uptake.  
 
4.2.5 Effects of siRNA delivery on BCL2 expression 
To investigate the effect of siRNA delivery by VLP-PEG24-A9L on cellular BCL2 
expression, intracellular antibody staining was used, as described in Chapter 3. 
Cells were stained with FITC-labelled anti-BCL2 antibodies and analysed by 
flow cytometry. The mean FITC fluorescence of untreated cells were assumed 
to represent 100% BCL2 protein production, to which that of treated cells were 
compared to calculate relative % BCL2 expression.  
LNCaP and PC-3 cells were incubated with 10 nM TR-BCL2 packaged inside 
VLP-PEG24-A9L for 0 h, 24 h, 48 h or 72 h, and assayed for relative BCL2 
expression (Figure 4.14). For LNCaP cells, whilst 24 h incubation led to a small 
reduction in BCL2 expression relative to the 0 h control (89.4±10.1%), more 
significant reductions were observed at 48 h (49.9±6.8%) and 72 h (14.7±9.0%). 
This result is reminiscent of that observed for HeLa cells in Chapter 3 (Figure 
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3.18), in which BCL2 expression was relatively unchanged until the 48 h time 
point. The delay between the start of incubation and the significant BCL2 
knockdown seen at 48 h possibly reflects the cumulative time required for the 
VLP-PEG24-A9L to be taken up, the release of siRNA from the endosome, and 
their entry into the RNAi pathway. In contrast, negligible changes in BCL2 
expression were observed for PC-3 cells at 24 h (94.4±9.6%) and 48 h 
(100.3±15.0%), whilst 72 h incubation produced a noticeable decrease in BCL2 
expression (75.0±8.9%). This ~25.0% BCL2 knockdown might be a result of the 
non-specific uptake previously observed in PC-3 cells (Figure 4.12). The lack of 
effect at earlier time points indicates that the level of non-specific uptake was 
not sufficient to induce BCL2 knockdown at 24 h and 48 h. Another possibility is 
that non-specific uptake by PC-3 cells occurred via a distinct pathway to that 
utilised by A9L targeted uptake by LNCaP cells, which resulted in much smaller 
quantities of siRNAs in the cytoplasm.   
The siRNA concentration dependence of BCL2 knockdown was also 
investigated. LNCaP and PC-3 cells were incubated with 0 nM, 5 nM, 10 nM or 
25 nM TR-BCL2 packaged inside VLP-PEG24-A9L for 48 h, before their relative 
BCL2 expressions were measured (Figure 4.15). The level of BCL2 knockdown 
correlated positively with the concentration of TR-BCL2 used, as the BCL2 
expression decreased to 80.2±13.2%, 49.9±6.8% or 34.2±10.6% following 
incubation with 5 nM, 10 nM or 25 nM siRNA, respectively. For PC-3 cells, a 
relatively small reduction in BCL2 expression was observed with 25 nM siRNA 
(86.8±17.3%), whilst 5 nM and 10 nM did not produce a noticeable change 
compared to untreated cells. 
                                                                                                    ___   _ _                      Page 178 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. Time-dependent BCL2 knockdown after siRNA delivery. After treatment with 
10 nM TR-BCL2 packaged inside VLP-PEG24-A9L for 0 h, 24 h, 48 h or 72 h, LNCaP and PC-3 
cells were stained with FITC-conjugated anti-BCL2 antibodies, washed, and analysed by flow 
cytometry. The mean FITC fluorescence of untreated cells (0 h) was designated as 100% BCL2 
expression, to which the FITC fluorescence of treated cells were compared to calculate relative 
% BCL2 expressions. (A) Bar chart showing relative % BCL2 expressions after siRNA delivery. 
Error bars indicate standard deviation of three repeats. (B) Flow cytometry histograms showing 
the FITC fluorescence of antibody stained cells. Curves in the histograms are colour-coded to 
match the corresponding bar charts above. Black curves represent 0 h controls; grey shaded 
curves show the background fluorescence, determined by staining cells with a FITC-labelled 
isotype control antibody. 
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Figure 4.15. Concentration-dependent BCL2 knockdown after siRNA delivery. After 
treatment with 0 nM, 5 nM, 10 nM or 25 nM TR-BCL2 packaged inside VLP-PEG24-A9L for 48 h, 
LNCaP and PC-3 cells were analysed for relative BCL2 expression. (A) Bar chart showing 
relative % BCL2 expressions after siRNA delivery. Error bars indicate standard deviation of 
three repeats. (B) Flow cytometry histograms showing the FITC fluorescence of antibody 
stained cells. Curves in the histograms are colour-coded to match the corresponding bar charts 
above. Black curves represent 0 h controls; grey shaded curves show the background 
fluorescence, determined by staining cells with a FITC-labelled isotype control antibody. 
 
 
LNCaP and PC-3 cells were then incubated with 10 nM TR-siRNA packaged 
inside various VLP formulations for 48 h, and assayed for relative BCL2 
expression (Figure 4.16). For LNCaP cells, TR-BCL2 delivered by VLP-PEG24 
and VLP-PEG24-A9L led to BCL2 expressions of 94.2±11.9% and 49.9±6.8%, 
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respectively. This is consistent with the cellular uptake data: the relatively low 
level of non-specific uptake of VLP-PEG24 had a minimal impact on BCL2 
expression in LNCaP cells, whilst the much higher uptake of VLP-PEG24-A9L 
produced a significant knockdown in BCL2 expression. Further addition of 100 
nM free A9L to VLP-PEG24-A9L increased the BCL2 expression to 82.1±6.8%, 
confirming that A9L mediates VLP-PEG24-A9L uptake by LNCaP cells.  
 
 
 
 
 
 
 
Figure 4.16. Comparative cellular BCL2 expression after siRNA delivery. LNCaP and PC-3 
cells were incubated with 10 nM TR-BCL2 packaged inside (from left) VLP-PEG24, VLP-PEG24-
A9L, or VLP-PEG24-A9L plus 100 nM free Tf, or with 10 nM TR-Control packaged inside VLP-
PEG24-A9L for 48 h, and then assayed for BCL2 expression. Error bars indicate standard 
deviation of three repeats. 
 
Interestingly, this level of BCL2 expression was lower than that observed for 
VLP-PEG24 treated cells (94.2±11.9%) – similar findings were reported for HeLa 
cells incubated with VLP-PEG24-Tf and free Tf (Figure 3.19). This indicates that 
the presence of 100 nM free A9L was insufficient to fully inhibit the uptake and 
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effects of A9L targeted siRNA delivery. Possible explanations include: (i) the 
multivalent display of A9L to some extent favoured the binding and uptake of 
VLP-PEG24-A9L, due to increased avidity to PSMA on LNCaP cells, (ii) PSMA 
could not be fully saturated by the free A9L due to its recycling to the cell 
surface, and (iii) there was a low level of non-specific uptake of VLP-PEG24-A9L 
which occurred independently of A9L targeting. Furthermore, TR-Control 
delivery by VLP-PEG24-A9L did not produce a significant change in BCL2 
expression (107.3±5.7%), indicating that the observed knockdown was siRNA 
sequence-dependent, and not associated with the uptake of VLP-PEG24-A9L or 
TR-conjugated dsRNAs. For PC-3 cells, none of the treatments produced a 
notable change in BCL2 expression relative to the untreated control. This 
suggests that, despite the previously observed non-specific uptake by PC-3 
cells, the cytoplasmic siRNA concentrations resulting from these transfections 
were insufficient to induce significant BCL2 knockdown.   
 
4.2.6 Cytotoxic effects of siRNA delivery 
The cytotoxicity assay described in Chapter 3 was used to assess whether 
siRNA delivery by VLP-PEG24-A9L could induce toxicity in LNCaP and PC-3 
cells. As a control, LNCaP and PC-3 cells were treated with varying 
concentrations of free cisplatin for 24 h (Skjoth and Issinger, 2006), and stained 
with annexin V-FITC and propidium iodide, before they were analysed by flow 
cytometry (Figure 4.17, Figure 4.18).  
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Figure 4.17. Flow cytometry analysis of cell toxicity in LNCaP cells. LNCaP cells were 
incubated with 0 µM, 50 µM, 125 µM or 250 µM cisplatin for 24 h, and assayed for toxicity. (A) 
Sample flow cytometry histograms showing the 0 µM, 50 µM and 250 µM treatments. (B) Bar 
charts displaying relative % cell populations that were live (green), early apoptotic (blue), late 
apoptotic (red), or necrotic (black). The percentages shown represent the average of three 
repeats. Numbers indicate mean percentage cell viability ± SD. 
 
LNCaP cells exhibited higher annexin V-FITC binding as well as propidium 
iodide uptake with increasing cisplatin concentrations, indicative of increased 
cytotoxicity (Figure 4.17). As described previously, flow cytometry histograms 
were divided into quadrants to determine relative populations of cells that were 
live, early apoptotic, late apoptotic or necrotic (Figure 4.17A). These were then 
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represented as a percentage of the total cell population in stacked bar charts 
(Figure 4.17B). Untreated LNCaP cells largely remained viable (88.6±3.4%); the 
small population of dead cells might be a result of the conditions used for 
incubation, or possibly artefacts produced by the assay. However, significant 
reductions in % cell viability were observed as the cisplatin concentration 
increased to 50 µM (67±6%), 125 µM (43±6%) and 500 µM (24±7%).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18. Flow cytometry analysis of cell toxicity in PC-3 cells. PC-3 cells were 
incubated with 0 µM, 50 µM, 125 µM or 250 µM cisplatin for 24 h, and assayed for toxicity. (A) 
Sample flow cytometry histograms showing the 0 µM, 50 µM and 250 µM treatments. (B) Bar 
charts displaying relative % cell populations that are live (green), early apoptotic (blue), late 
apoptotic (red), or necrotic (black). The percentages shown represent the average of three 
repeats. Numbers indicate mean percentage cell viability ± SD. 
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One interesting observation is that the non-viable cell populations consisted 
mainly of late apoptotic or necrotic cells at all cisplatin concentrations. This 
might be due to LNCaP cells progressing quickly from early to late apoptosis, 
thus very few early apoptotic cells were detected by the assay after 24 h 
incubation. Furthermore, a relatively large necrotic population was observed at 
125 µM cisplatin (34±6%), which interestingly diminished at 250 µM (17±4%). 
One possibility is that higher cisplatin concentrations caused some cells to 
rapidly progress through necrosis, undergoing cell swelling and membrane 
rupture, and thus were not counted at 250 µM.  
Likewise, the % cell viability of PC-3 cells also decreased in a cisplatin 
concentration-dependent manner (Figure 4.18). These results suggest that both 
LNCaP and PC-3 cells are responsive to a conventional chemotherapeutic, and 
that the cytotoxicity assay is compatible with these cells.  
LNCaP and PC-3 cells were incubated with 10 nM TR-BCL2 packaged inside 
VLP-PEG24-A9L for 0 h, 24 h, 48 h or 72 h, stained with annexin V-FITC and 
propidium iodide, and then analysed by flow cytometry (Figure 4.19A). For 
LNCaP cells, a small decrease in % cell viability was observed at 24 h 
(75±10%) compared to the 0 h control (89±1%), whilst more significant 
reductions were observed for the 48 h (35±3%) and 72 h (13±6%) time points. 
This suggests that TR-BCL2 delivery by VLP-PEG24-A9L induced cytotoxicity in 
LNCaP cells in a time-dependent manner, and that there is a strong correlation 
between cytotoxicity and BCL2 expression.  
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Figure 4.19. Time- and concentration-dependent toxicity of siRNA delivery. (A) LNCaP 
and PC-3 cells were incubated with 10 nM TR-BCL2 packaged inside VLP-PEG24-A9L for 0 h, 
24 h, 48 h or 72 h, and assessed for toxicity. (B) LNCaP and PC-3 cells were incubated with 0 
nM, 5 nM, 10 nM or 25 nM TR-BCL2 packaged inside VLP-PEG24-A9L for 48 h, and assessed 
for toxicity. The percentages shown represent the average of three repeats. Numbers indicate 
mean percentage cell viability ± SD. 
 
It was described in Chapter 3 that increasing the incubation time up to 72 h 
produced notable diminishing returns on the cytotoxicity of treated HeLa cells 
(Figure 3.21A). However, this diminishing return effect appeared to be much 
less pronounced in LNCaP cells. This might be due to different rates of cell 
division, as LNCaP cells have a doubling time of ~60 h compared to the ~24 h 
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of HeLa cells. Since cell division is associated with the dilution of internalised 
TR-BCL2, a larger dilution effect was expected in the rapidly dividing HeLa 
cells, hence a greater proportion of HeLa cells were expected to remain viable 
after prolonged treatments compared to LNCaP cells. 
Time-dependent cytotoxicity was also observed in PC-3 cells, although the 
effects were much less significant, with 69±6% of cells still remaining viable 
after 72 h incubation, compared to the 87±1% of untreated cells (Figure 4.19A). 
This mild increase in cytotoxicity correlates with BCL2 expression, as a ~25% 
BCL2 knockdown was observed for PC-3 cells at the same time point (Figure 
4.14). 
The cytotoxic effect of siRNA delivery at different siRNA concentrations was 
also investigated. LNCaP and PC-3 cells were incubated with 0 nM, 5 nM, 10 
nM or 25 nM TR-BCL2 packaged inside VLP-PEG24-A9L for 48 h, before they 
were assayed for cytotoxicity. For LNCaP cells, higher levels of cytotoxicity was 
observed with increasing siRNA concentrations – with 89±3%, 65±9%, 35±3% 
and 27±12% of cells remaining viable after incubation with 0 nM, 5 nM, 10 nM 
and 25 nM siRNA, respectively (Figure 4.19B). The % cell viability seems to 
correlate positively with the BCL2 expression of LNCaP cells treated under the 
same conditions (Figure 4.15). Interestingly, increasing the siRNA concentration 
from 10 nM to 25 nM produced a relatively small change in % cell viability 
compared to that from 5 nM to 10 nM siRNA (Figure 4.19B). It is possible that 
the intracellular siRNA concentration resulting from a 10 nM transfection was 
close to saturating certain RNAi components in the cell, thus further increasing 
the siRNA concentration would yield significant diminishing returns on its 
cytotoxic effects. For PC-3 cells, a similar pattern of concentration-dependent 
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cytotoxicity was observed, albeit the effects were relatively insignificant with 
73±5% of cells still remaining viable after incubation with 25 nM siRNA, 
compared to the 85±3% of untreated cells (Figure 4.19B). The low level of 
cytotoxicity observed might be due to the non-specific uptake of VLP-PEG24-
A9L by some PC-3 cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. Comparative toxicity of siRNA delivery. LNCaP and PC-3 cells were (from left) 
untreated, incubated with 10 nM TR-BCL2 siRNA packaged inside VLP-PEG24, VLP-PEG24-
A9L, or VLP- PEG24-A9L plus 100 nM free A9L, or 10 nM TR-Control packaged inside VLP-
PEG24-A9L for 48 h, and then assayed for cytotoxicity. The percentages shown represent the 
average of three repeats. Numbers indicate mean percentage cell viability ± SD. 
 
 
LNCaP and PC-3 cells were then incubated with 10 nM TR-siRNA packaged 
inside various VLP formulations for 48 h, and assayed for cytotoxicity (Figure 
4.20). For LNCaP cells, a small background level of toxicity was observed, with 
89±3% of untreated cells remaining live. Comparatively, TR-BCL2 delivery by 
VLP-PEG24 and VLP-PEG24-A9L reduced the % cell viability to 77±5% and 
35±3%, respectively. The increased cytotoxicity of VLP-PEG24 treated cells was 
unexpected, as TR-BCL2 delivery by VLP-PEG24 produced a fairly negligible 
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effect on BCL2 expression (94±12%, Figure 4.16). It is possible that uptake of 
small amounts of VLP-PEG24 (Figure 4.12B) led to off-target toxicities in some 
LNCaP cells. Further addition of 100 nM free A9L to VLP-PEG24-A9L increased 
the % cell viability to 73±5%, which is comparable to that observed for VLP-
PEG24 treated cells. This implies that A9L targeted VLP-PEG24-A9L for uptake 
by LNCaP cells, and they were outcompeted by the presence of excess free 
A9L. Delivery of TR-Control by VLP-PEG24-A9L did not produce a significant 
change in % cell viability relative to untreated cells (85±5%). This suggests that 
the uptake of TR-siRNA encapsidated VLP-PEG24-A9L by LNCaP cells did not 
trigger off-target toxicities, and that the cytotoxicity observed for TR-BCL2 
delivery by VLP-PEG24-A9L could be largely attributed to siRNA-mediated BCL2 
knockdown. 
In contrast, negligible effects were observed in PC-3 cells with all treatments 
(Figure 4.20). The biggest effect was observed with TR-BCL2 delivery by VLP-
PEG24-A9L, with 79±7% of cells remaining viable, compared to the 85±3% for 
untreated PC-3 cells. Altogether, these results suggest that VLP-PEG24-A9L 
delivered the TR-BCL2 cargo specifically to LNCaP cells via A9L-mediated 
targeting of PSMA, which subsequently induced cytotoxicity in these cells.  
 
4.2.7 Liposomal siRNA delivery to PC-3 cells 
To ensure the lack of cellular effect seen for PC-3 cells was due to aptamer-
specific targeting, and not their insensitivity to the BCL2 siRNA, HiPerFect 
Transfection Reagent was used to package TR-BCL2 for delivery to PC-3 cells. 
HiPerFect contains a mixture of cationic and neutral lipids, which can interact 
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electrostatically with polyanionic molecules, such as siRNA, to form lipoplexes 
with the siRNA packaged inside. These lipid particles can deliver packaged 
siRNAs to cells indiscriminately.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21. Analysis of liposomal siRNA delivery to PC-3 cells. (A) Flow cytometry 
histogram showing PC-3 cells either untreated (grey), or incubated with 10 nM TR-Cy5 
packaged inside liposomes for 24 h (dotted) or 48 h (solid). (B) Relative % BCL2 expression of 
PC-3 cells after various treatments at 48 h. Error bars indicate the standard deviation of three 
repeats. (C) Relative populations of PC-3 cells that were live (green), early apoptotic (blue), late 
apoptotic (red) or necrotic (black) after various treatments at 48 h. The percentages shown 
represent the average of three repeats. Numbers indicate mean percentage cell viability ± SD. 
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Firstly, the uptake of liposomes by PC-3 cells was investigated. PC-3 cells were 
grown on 24 well plates, incubated with 10 nM TR-Cy5 packaged inside 
HiPerFect for 24 h or 48 h, and processed for flow cytometry analysis (Figure 
4.21A). The mean Cy5 fluorescence of PC-3 cells increased significantly at 24 h 
(651.3±48.9 AU) and 48 h (4037.1±572.3 AU) incubations, which indicates the 
accumulation of TR-Cy5 inside cells with time. The curves in the histogram 
suggest that, whilst a distinct, small portion of cells remained untransfected at 
24 h, the vast majority of cells were transfected by 48 h (Figure 4.21A). The 
untransfected population might reflect newly divided cells that did not take up 
any liposomal TR-Cy5.  
Next, relative cellular BCL2 expressions were assessed using the previously 
used protocol. PC-3 cells were grown on 24 well plates, and were either 
untreated, or incubated with various HiPerFect treatments for 48 h, before they 
were processed for intracellular antibody staining and flow cytometry analysis 
(Figure 4.21B). A HiPerFect (liposome) only control produced a small change in 
% BCL expression (90±14%) compared to untreated cells; likewise, negligible 
change was observed after liposomal delivery of TR-Control (97±13%). 
However, liposomal delivery of TR-BCL2 resulted in a noticeable reduction in 
BCL2 expression (61±15%), somewhat comparable to that observed in LNCaP 
cells after TR-BCL2 delivery by VLP-PEG24-A9L. This suggests that liposomes 
were able to deliver siRNAs to the cytoplasm of PC-3 cells, and trigger siRNA-
mediated knockdown of BCL2.  
Finally, the cytotoxic effects of siRNA delivery were analysed (Figure 4.21C). As 
above, PC-3 cells were grown on 24 well plates, and were untreated, or 
                                                                                                    ___   _ _                      Page 191 
 
incubated with various HiPerFect treatments for 48 h, before they were assayed 
for cytotoxicity. Some background cell death was observed, as 83±4% of 
untreated cells remained viable. The % cell viability was relatively unaffected 
with the addition of liposome (80±11%), or with the liposomal delivery of TR-
Control (77±9%). However, a significant reduction in % cell viability was 
observed with the liposomal delivery of TR-BCL2 (55±12%). This is consistent 
with the relative BCL2 expression data (Figure 4.21B), and indicates a positive 
correlation between BCL2 knockdown and cytotoxicity. The lack of toxicity 
observed for the liposome only control, and for the liposomal delivery of TR-
Control suggests that the treatments did not produce any off-target toxicities. 
 
4.3 Summary of Chapter 4 
1. A thiol-modified, fluorescently labelled RNA ligand, U6-FAM, was 
attached to VLPs via SM(PEG)24 using amine-to-thiol conjugation. Each VLP-
PEG24-U6-FAM particle displayed on average ~16 molecules of U6-FAM. The 
same protocol was then used to conjugate an RNA aptamer, A9L, to VLPs via 
SM(PEG)24, resulting in VLP-PEG24-A9L. A9L binds specifically to PSMA, a 
tumour marker that is prevalently and highly expressed on the surface of 
prostate cancer cells. 
 
2. Both VLP-PEG24-A9L particles and their displayed A9L remained stable 
in cell media. There was evidence of A9L degradation in human serum, 
prompting the use of chemically modified RNA aptamers for future in vivo 
experiments. VLP-PEG24-A9L displayed markedly reduced binding by anti-MS2 
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antibodies compared to unmodified VLP, confirming the immuno-masking effect 
of PEGylation. However, PEGylation could not completely block antibody 
binding at higher antibody concentrations; in vivo tests will be necessary to 
assess the true immunogenicity of PEGylated VLPs. 
 
3. A9L specifically targeted VLP-PEG24-A9L to PSMA+ve LNCaP cells, but 
not PSMA-ve PC-3 cells, for binding and uptake. TR-BCL2 delivery by VLP-
PEG24-A9L produced significant responses in LNCaP cells, including ~50% 
BCL2 knockdown and a ~53% decrease in cell viability, at just 10 nM siRNA 
concentration. Further addition of free A9L significantly reduced the uptake of 
siRNA delivered by VLP-PEG24-A9L, as well as its cellular effects. As for VLP-
PEG24-Tf, the uptake of VLP-PEG24-A9L did not produce any off-target toxicity 
in cells. PC-3 cells were responsive to TR-BCL2 when delivered by a 
commercially available liposome. 
 
 
 
 
 
 
 
Chapter 5 
Aptamer-targeted cellular delivery of doxorubicin 
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5.1 Introduction 
5.1.1 Anthracyclines in chemotherapy  
Since the first report of their isolation from Streptomyces peucetius in the 1960s 
(Dimarco et al., 1964), the anthracyclines have proven to be one of the most 
effective anti-cancer therapeutics and have significantly improved cancer 
survival statistics. The anti-tumour activity of anthracyclines has been attributed 
to several mechanisms (Binaschi et al., 2001), including: 
 Inhibition of nucleic acid synthesis by intercalating between base pairs of 
DNA/RNA strands (Pratt and Ruddon, 1979), 
 Generation of free oxygen radicals resulting in DNA damage or lipid 
peroxidation (Vasquez-Vivar et al., 1997), 
 Inhibition of topoisomerase II triggering DNA damage and apoptosis 
(Jensen et al., 1993), and  
 Eviction of key histones implicated in DNA repair from the chromatin 
(Pang et al., 2013).  
 
Doxorubicin (Dox) and daunorubicin were among the first identified 
anthracyclines, both of which still remain prevalently used in the treatment of a 
range of haematological and solid cancers (Weiss, 1992). They are similar in 
structure, with an aglyconic group resembling a tetracyclic ring, attached to a 
daunosamine sugar, with the distinction being that the side chain terminates 
with either a primary alcohol or a methyl group for Dox and daunorubicin, 
respectively (Figure 5.1). Though subtle, this distinction seems to have a 
notable impact on their anti-tumour activities: Dox shows a broad spectrum of 
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activity against various solid tumours, whereas daunorubicin is more effective 
against acute leukemias (Martindale, 1996). 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Chemical structures of anthracyclines. Shown are the four most commonly used 
anthracyclines in the clinic. Epirubicin was structurally derived from Dox, resulting from an axial-
to-equatorial epimerisation of the hydroxyl on the daunosamine sugar. Idarubicin was 
structurally derived from daunorubicin, via removal of a 4-methoxy group.  
 
Whilst the anthracyclines have undoubtedly played a significant part in the 
treatment of cancers, they have some notable drawbacks. Firstly, non-specific 
uptake of Dox or daunorubicin can induce toxicity in healthy cells and lead to 
adverse effects. One major side effect is cumulative dose-dependent 
cardiotoxicity, which can lead to severe cases of chronic cardiomyopathy and 
congestive heart failure in patients (Volkova and Russell, 2011). Another 
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problem is the development of multiple drug resistance, with as many as ~70% 
of patients experiencing a relapse despite having complete remission after initial 
anthracycline treatment (Ma and Mumper, 2013). The mode of resistance 
typically involves overexpression of drug efflux proteins, such as P-glycoprotein 
and breast cancer resistance protein (Chien and Moasser, 2008). 
These problems have prompted the development of second generation 
anthracyclines, derived from modifying the structures of Dox and daunorubicin 
(Weiss, 1992). Two commonly used anthracycline derivatives in the clinic 
include epirubicin and idarubicin. Epirubicin is derived via an axial-to-equatorial 
epimerisation of the hydroxyl group on the daunosamine sugar of Dox (Figure 
5.1). This epimerisation opens an unique glucuronidation metabolic pathway 
that is not available to Dox, which enhances the plasma clearance of epirubicin, 
and has been shown to reduce cardiotoxic effects compared to Dox (Robert, 
1993). Idarubicin is derived via removal of a 4-methoxy group from one of the 
tetracyclic rings on daunorubicin (Figure 5.1). This modification has been 
demonstrated to significantly enhance the lipophilicity of the drug, resulting in 
faster cellular uptake, higher DNA-binding capacity and improved cytotoxicity 
compared to daunoribicin (Binaschi et al., 2001, Minotti et al., 2004). 
Additionally, idarubicin is more effective in some multidrug resistant tumour cell 
lines compared to daunorubicin (Jonsson-Videsater et al., 2003, Toffoli et al., 
1994), and has a wider spectrum of activity in cancers such as non-Hodgkin’s 
lymphoma, multiple myeloma and breast cancer (Borchmann et al., 1997). 
Many other anthracycline derivatives have also been developed, though only a 
few have been clinically approved for treating cancers (Minotti et al., 2004), with 
only modest improvements with respect to drug resistance and cardiotoxicity. 
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5.1.2 Dox delivery  
Aside screening for anthracycline derivatives, another approach to improve the 
pharmacological properties of anthracyclines has been to utilise drug delivery 
systems (Table 5.1). One of the earliest examples of an anthracycline delivery 
system is Doxil, which received FDA approval in 1995 for treating AIDS-related 
Kaposi’s sarcoma, and later for treating multiple myeloma, and advanced breast 
and ovarian cancers (Barenholz, 2012). Doxil is a PEGylated liposomal 
formulation of Dox, composed of PEG-coupled distearoyl 
phosphatidylethanolamine, hydrogenated soy phosphatidylcholine and 
cholesterol. With an average diameter of ~90 nm, Doxil nanoparticles benefit 
fully from EPR (Matsumura and Maeda, 1986). In addition, surface coating with 
PEG minimises the detection of liposomes by the mononuclear phagocytic 
system (Vail et al., 2004). As a result, Doxil displays significantly longer plasma 
retention, a lower volume of distribution, as well as reduced cardiotoxicity 
compared to free Dox (Batist, 2007).  
Polymer conjugates have also been utilised to deliver Dox to cancer cells. The 
first polymer-drug conjugate to enter clinical trials was AD-70, a ~70 kDa 
dextran polymer coupled to Dox via the formation of a Schiff base (Figure 5.2). 
In a phase I clinical trial, AD-70 resulted in significantly higher off-target 
toxicities compared to free Dox, which was attributed to dextran uptake by the 
mononuclear phagocytic system (Danhauser-Riedl et al., 1993), and therefore 
did not advance further.  
 
                                                                                                    ___   _ _                      Page 198 
 
 
 
 
Figure 5.2. Preparation of dextran-drug conjugates via Schiff base formation. Periodate 
(IO4
-
) oxidation of dextran yields aldehyde groups, which react with amine-containing drugs (R) 
to form a Schiff base. The Schiff base can then be reduced with sodium borohydride (NaBH4) to 
produce a stable dextran-drug conjugate. 
 
A more successful polymer conjugate currently undergoing clinical evaluation is 
PK1, a synthetic polymer composed of HPMA conjugated to Dox (Figure 5.3). 
Similar to PEG, HPMA is a highly soluble, non-toxic, and non-immunogenic 
polymer, and is commonly used as a carrier for low molecular weight drugs 
such as Dox. HPMA is conjugated to Dox via a tetrapeptide (GFLG) linker, 
which is stable in blood but readily degraded by lysosomal enzymes to facilitate 
drug release upon endocytosis. PK1 demonstrated promising results in a phase 
I study, producing partial and minor responses in some patients with 
anthracycline-resistant breast cancer, NSCLC, and colorectal cancer (Vasey et 
al., 1999). Importantly, the maximum tolerated dose of PK1 was ~5 times that of 
free Dox, and no cardiotoxicity was observed. In a subsequent phase II trial, 
partial response was again observed in patients with breast cancer and NSCLC, 
but not colorectal cancer (Seymour et al., 2009). PK1 seemed to be well 
tolerated even at higher doses, without any signs of immunogenicity or HPMA-
associated toxicity. A similar polymer, PK2 (Figure 5.3), has also shown 
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promise in clinical trials. The difference between PK2 and PK1 is the addition of 
a galactosamine, which targets the liver-specific asialoglycoprotein receptor. In 
a phase I study, PK2 demonstrated notable anti-tumour activity in hepatocellular 
carcinoma patients (Seymour et al., 2002). Importantly, ~17% of the 
administered drug localised to the liver after 24 h (Seymour et al., 2002), which 
is 12-50 times higher than free Dox (Duncan et al., 2005). PK1 and PK2 are 
currently undergoing phase III and phase II clinical trials, respectively. 
 
 
Figure 5.3. Compositions of the HPMA-Dox conjugates, PK1 and PK2. PK1 (left) is a 
synthetic polymer containing of N-(2-hydroxypropyl)methacrylamide (HPMA), conjugated to Dox 
via a Gly-Phe-Leu-Gly (GFLG) tetrapeptide linker. PK2 (right) has additional side chains that 
terminate with an N-acylated galactosamine. Synthesis of PK1/2 involves the copolymerisation 
of HPMA with N-methacryloylated GFLG tetrapeptides, which contain p-nitrophenyl esters. 
Subsequent addition of amine-containing moieties, such as Dox and galactosamine, results in 
their stable conjugation, with nitrophenol as the leaving group. Adapted from Kopecek and 
Kopeckova (2010). (Kopecek and Kopeckova, 2010). 
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Many other types of delivery systems have also been tested for delivering Dox, 
including micelles, carbon nanotubes, cyclodextrin polymers, as well as gold, 
silica and magnetic nanoparticles (Matyszewska, 2014). These have 
demonstrated improved pharmacological profiles compared to free Dox. For 
instance, some are able to circumvent multidrug resistance in cancers (Ma and 
Mumper, 2013), whilst some display improved pharmacokinetics or reduced 
cardiotoxicity (Zhang et al., 2013, Matsumura et al., 2004).  
 
 
 
Name 
 
 
Description 
 
Indication 
 
Development 
 
Ref 
 
Doxil 
 
PEGylated liposome 
 
Ovarian and 
breast cancers, 
MM, ARKS 
 
Approved 
 
(James et 
al., 1994) 
 
Livatag 
 
PIHCA nanoparticles 
 
Advanced HCC 
 
Phase III 
 
(Merle et 
al., 2006) 
 
NK911 
 
PEGylated micelle 
 
Metastatic 
pancreatic cancer 
 
Phase III 
 
(Matsumur
a et al., 
2004) 
 
PK1 
 
HPMA conjugate 
 
Breast cancer, 
NSCLC 
 
Phase III 
 
(Seymour 
et al., 2009) 
 
PK2 
 
HPMA conjugate + 
galactosamine 
 
HCC 
 
Phase II 
 
(Seymour 
et al., 2002) 
 
SP1049
C 
 
 
PEGylated micelle 
 
Upper GI cancer 
 
Phase II 
 
(Valle et al., 
2011) 
 
Table 5.1. Selected examples of Dox delivery systems in clinical use or under 
development. MM = multiple myeloma; ARKS = AIDS-related Kaposi’s sarcoma; PIHCA = 
polyisohexylcyanoaerylate; HCC = hepatocellular carcinoma; NSCLC = non-small cell lung 
carcinoma; HPMA = N-(2-Hydroxypropyl)methacrylamide; GI = gastrointestinal. 
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5.1.3 Targeted Dox delivery by MS2 VLPs 
Of the large number of Dox delivery systems already approved or in clinical 
trials, the majority depend on passive targeting to reach tumour tissues, but lack 
an active tumour-targeting mechanism. The aforementioned HPMA-Dox 
conjugate, PK2, is one of the only examples of tumour-targeted Dox delivery 
undergoing clinical evaluation. PK2 utilises galactosamine to target the liver-
specific asialoglycoprotein receptor, and aims to treat patients with 
hepatocellular carcinoma (HCC). However, these receptors are abundantly 
expressed on healthy hepatocytes, and there is evidence to suggest HCC cells 
have a significantly lower surface expression of the receptor (Hyodo et al., 
1993). Thus it is unsurprising that only a small fraction (<20%) of the 
administered PK2 which localised to the liver accumulated in cancer cells 
(Seymour et al., 2002).  
It might be beneficial to target tumour markers which are overexpressed on the 
surface of cancer cells, to facilitate preferential binding and uptake by them. 
VLP-PEG24-A9L has already demonstrated tumour-targeted siRNA delivery to 
prostate cancer cells, and can be tested for Dox delivery using the same cell 
lines. If successful, Dox will be added to the growing repertoire of cargos that 
can be delivered by MS2 VLPs (Brown et al., 2002, Wu et al., 2005, Ashley et 
al., 2011, Pan et al., 2012a, Pan et al., 2012b, Galaway and Stockley, 2013, Li 
et al., 2013), which would underline their versatility as a drug delivery system. 
Further, Dox has numerous advantages as a model drug cargo, including (i) it is 
a well-characterised, established cancer therapeutic, (ii) it is relatively cheap 
and commercially available, (iii) the presence of an amine group on its 
daunosamine sugar supports NHS chemistry if modifications are required, and 
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(iv) its affinity for nucleic acids might provide a simple method for packaging 
inside RNA encapsidated VLPs.  
 
5.1.4 Aims 
The aims of the work described in this chapter were to: 
1. Stably package Dox inside VLP-PEG24-A9L. 
2. Assess the capacity of VLP-PEG24-A9L to deliver Dox to LNCaP and PC-
3 cells, and also the cytotoxic effects of Dox delivery. 
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5.2 Results and discussion 
5.2.1 Preparation of Dox encapsidated VLP-PEG24-A9L 
In Chapters 3 and 4, cargo packaging was achieved by mixing TR-siRNA with 
dissociated CP2 at near neutral pH, resulting in VLP assembly with the siRNA 
encapsidated inside. In addition to siRNAs, which can be synthesised as an 
extension of TR, other non-nucleic acid based cargos have also been packaged 
this way, including ricin A chain (Wu et al., 1995), cisplatin and PEGylated 
quantum dots (Ashley et al., 2011). These cargos contain amine groups, and 
were covalently conjugated to thiol-modified TR using amine-to-thiol 
crosslinkers, before mixing with CP2 for VLP assembly and packaging. The 
presence of an amine on the daunosamine sugar of Dox makes it compatible 
with this packaging strategy. However, one concern was that the covalent 
attachment of TR to Dox might disrupt its capacity to intercalate with DNA and, 
consequently, reduce its cytotoxic effects in cancer cells. 
An alternative method for packaging Dox is to soak it into assembled, RNA-
encapsidated VLPs. MS2 VLPs contain pores, ~1.7 nm in diameter (Karin 
Valegård, 1990), which permit access for small molecules to the VLP interior 
(Wu et al., 2005). Once inside, the high affinity interaction between Dox and the 
encapsidated RNA should keep them stably retained (Subramanian et al., 
2012). This soaking method has been used to package a variety of therapeutic 
and imaging agents, which have an affinity to nucleic acids, inside CPMV VLPs 
(Yildiz et al., 2013). 
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A construction scheme of Dox encapsidated VLP-PEG24-A9L is shown in Figure 
5.4. TR-Cy5 is firstly mixed with dissociated CP2 at neutral pH to trigger in vitro 
assembly, resulting in VLP(TR-Cy5). VLP(TR-Cy5) is then mixed with Dox, 
which should permeate through the pores into the VLP interior, where it will be 
retained due to its high affinity interaction with encapsidated RNA. VLP(TR-
Cy5/Dox) is then surface decorated with SM(PEG)24 and A9L, as described 
previously, prior to cellular delivery experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Strategy for synthesising Dox encapsidated VLP-PEG24-A9L. TR-Cy5 is mixed 
with MS2 CP2 at neutral pH to trigger VLP assembly, as described previously. VLP(TR-Cy5) is 
incubated with Dox, which can enter the VLP interior via pores on the VLP surface, and should 
become stably encapsidated. VLP(TR-Cy5/Dox) can then be surface decorated with SM(PEG)24 
and A9L. The figure is not drawn to scale. 
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Free Dox was firstly analysed by UV-visible spectroscopy (Figure 5.5A). The 
wavelength of maximum absorption was determined to be 486 nm. Next, a 
calibration graph was constructed by measuring the A486nm of different 
concentrations of Dox. From this, a molar extinction coefficient of 9080 M-1.cm-1 
was obtained (Figure 5.5B), which is similar to values quoted in previous 
literature (Samra et al., 2013), and was used in subsequent experiments for the 
quantification of Dox.  
 
 
 
 
 
 
 
Figure 5.5. Spectroscopic analysis of free Dox. (A) UV-visible absorption profile of Dox. (B) 
Calibration graph showing the absorbance (at λmax) of varying concentrations of Dox. The 
equation for the line of best fit is shown. The gradient of the slope was used as the molar 
extinction coefficient of Dox (9080 M
-1
.cm
-1
). 
 
Trial Dox packaging experiments were set up to identify optimal conditions. A 
fixed concentration of VLP(TR-Cy5) was mixed with various concentrations of 
Dox in 10 µL pH 8.3 HEPES at room temperature for 1 h. The starting Dox:VLP 
molar ratio ranged from 54:1 to 3456:1. In addition, two controls were set up, 
containing either Dox only or VLP(TR-Cy5) only. The mixtures were centrifuged 
in 100 kDa MWCO spin concentrators three times to remove free Dox. The 
retentates were analysed by UV-visible spectroscopy: the A649nm was used to 
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estimate the concentration of VLP(TR-Cy5) present, and the A486nm was used to 
estimate the concentration of Dox present. Any Dox present in the retentate 
was assumed to be packaged within VLP(TR-Cy5).   
The Dox packaging efficiencies are shown in Figure 5.6. The average number 
of Dox packaged per VLP increased with the starting Dox:VLP molar ratio, 
saturating at 111.0±10.5 with a starting molar ratio of 1728:1. Further increasing 
the starting Dox:VLP molar ratio to 3456:1 produced a negligible change in the 
number of Dox packaged (113.7±18.7). No absorbance at 486 nm was detected 
for the Dox only and VLP(TR-Cy5) only controls, indicating that free Dox was 
fully removed by the 100 kDa MWCO filter, and that VLP(TR-Cy5) does not 
contribute to A486nm. From these results, a starting Dox:VLP molar ratio of 
1728:1 appeared to be optimal for maximum Dox loading.  
 
 
 
 
 
 
 
 
 
Figure 5.6. Dox packaging inside VLP(TR-Cy5). Scatter plot displaying the average number 
of Dox molecules packaged per VLP with different starting Dox:VLP molar ratios. 
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The Dox packaging experiment was scaled up, in which Dox was mixed with 
VLP(TR-Cy5) at a molar ratio of 1728:1 in 100 µL pH 8.3 HEPES. The resulting 
VLP(TR-Cy5/Dox) was eluted through a NAP-5 column, and concentrated into 
pH 8.3 HEPES using a 100 kDa MWCO spin concentrator. VLP(TR-Cy5/Dox) 
was then surface decorated with SM(PEG)24 to make VLP(TR-Cy5/Dox)-PEG24, 
or SM(PEG)24 and A9L to make VLP(TR-Cy5/Dox)-PEG24-A9L (as described in 
Chapter 4). The resulting particles were analysed (Figure 5.7). Native 2% (w/v) 
agarose gel electrophoresis showed the expected shifts in electrophoretic 
mobility when VLP(TR-Cy5/Dox) was decorated with SM(PEG)24, or SM(PEG)24 
and A9L (Figure 5.7A), as observed previously (Figure 4.6). TEM analysis 
confirmed the intact nature of the particles (Figure 5.7B). They were also 
analysed by UV-visible spectroscopy to determine the A486nm and A649nm, using 
which Dox:VLP molar ratios of 110.0±4.6 (for VLP(TR-Cy5/Dox)-PEG24) and 
105.3±6.2 (VLP(TR-Cy5/Dox)-PEG24-A9L) were estimated. This indicates that 
there was negligible loss, or ‘leakage’ of Dox, during VLP surface modification.  
Finally, a month-old stock of VLP(TR-Cy5/Dox)-PEG24-A9L – stored in DPBS at 
4oC – was concentrated three times through a 100 kDa MWCO spin 
concentrator. The A486nm and A649nm of the retentate were measured, using 
which a Dox:VLP molar ratio of 96.8 was estimated. This signifies >90% 
retention of Dox, and indicates that Dox can remain stably encapsidated inside 
VLP(TR-Cy5/Dox)-PEG24-A9L for at least one month when stored at 4
oC.   
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Figure 5.7. Analysis of VLP(TR-Cy5/Dox)-PEG24-A9L. VLP(TR-Cy5/Dox) was prepared as 
described above. Following elution through a NAP-5 column and concentration using a 100 kDa 
MWCO spin concentrator, the surface of VLP(TR-Cy5/Dox) was decorated with SM(PEG)24 to 
make VLP(TR-Cy5/Dox)-PEG24, or SM(PEG)24 and A9L to make VLP(TR-Cy5/Dox)-PEG24-A9L. 
The resulting particles were analysed. (A) Native 2% (w/v) agarose gel electrophoresis. 1: 
HyperLadder I; 2: VLP(TR-Cy5); 3: VLP(TR-Cy5/Dox); 4: VLP(TR-Cy5/Dox)-PEG24; 5: VLP(TR-
Cy5/Dox)-PEG24-A9L. The gel was visualised by ethidium bromide scanning or Cy5 
fluorescence scanning. (B) TEM analysis of VLP(TR-Cy5/Dox)-PEG24 and VLP(TR-Cy5/Dox)-
PEG24-A9L. Scale bar = 50 nm. 
 
5.2.2 Cellular effects of Dox delivery 
The emission spectra of all fluorescent dyes previously used in the cell assays, 
including Cy5 (TR-Cy5), FITC (annexin V-FITC) and PI, are shown in Figure 
5.8. These show that the dyes have minimal spectral overlap, and thus are 
compatible with one another. However, Dox has an emission spectrum which 
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ranges from 565 nm to 630 nm, peaking at ~580 nm (Dai et al., 2008) – this 
significantly overlaps with the emission spectrum of PI, therefore an alternative 
viability dye was required. One potential candidate, DAPI, utilises the same 
mechanism as PI – whilst impermeable to the membranes of healthy cells, it is 
readily taken up by cells undergoing late apoptosis or necrosis due to 
compromised membrane integrity (Hornicek et al., 1986). Importantly, the 
emission spectrum of DAPI lies closer to the UV region (Figure 5.8), and 
exhibits little overlap with that of Dox, therefore DAPI should be a suitable 
substitution for PI.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. Emission spectra of fluorescent dyes used. Displayed are the emission spectra 
of DAPI, FITC, PI and Cy5 when excited with 355 nm, 488 nm or 633 nm lasers. Highlighted in 
boxes are the range of filters used to detect specific fluorescent signals, which include 450/40 
for DAPI, 525/10 for FITC, 630 for PI and 660/20 for Cy5. The spectra were made using the BD 
Fluorescence Spectrum Viewer. 
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Free Dox can enter cells via passive diffusion (Skovsgaard and Nissen, 1982), 
and induce cytotoxicity via the multiple mechanisms previously discussed. Initial 
experiments were set up to assess these cytotoxic effects, and also to test the 
use of DAPI as a viability dye. LNCaP cells were incubated with 0 nM, 200 nM 
or 2000 nM Dox for 24 h on 24 well plates, and were either stained with annexin 
V-FITC and DAPI or left unstained, before they were analysed by flow 
cytometry for cytotoxicity (Figure 5.9).  
  
 
 
 
 
 
 
 
 
Figure 5.9. Control cytotoxicity assay using Dox treated LNCaP cells. LNCaP cells were 
incubated with different concentrations of free Dox for 24 h, and were either (A) unstained or (B) 
stained with annexin V-FITC and DAPI, prior to flow cytometry analysis. The histograms were 
divided into quadrants, based on the DAPI and FITC fluorescence emission of cells, to 
distinguish between cells that were live (green), early apoptotic (blue), late apoptotic (red) and 
necrotic (black).  
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For the unstained cells, increasing Dox concentrations did not affect the DAPI 
fluorescence, however, a small increase in FITC fluorescence was observed 
(Figure 5.9A), consistent with minor spectral overlap between Dox and FITC. 
For the stained cells, increasing Dox concentrations resulted in a significant 
increase in both the cell binding of annexin V-FITC and uptake of DAPI, 
suggesting that free Dox induced cytotoxicity in LNCaP cells in a concentration-
dependent manner (Figure 5.9B). As before, the flow cytometry histograms 
were divided into quadrants, and cells were designated as live (green), early 
apoptotic (blue), late apoptotic (red) or necrotic (black) based on their FITC and 
DAPI fluorescence emission. These results indicate that DAPI is a suitable dye 
for identifying cells that are late apoptotic or necrotic, and that LNCaP cells are 
responsive to Dox. 
LNCaP and PC-3 cells were incubated with various concentrations (0 nM to 
10000 nM) of free Dox for 24 h, and assayed for cytotoxicity (Figures 5.10, 
5.11). For LNCaP cells, a background level of toxicity was observed, with 
80±7% of untreated cells remaining live (Figure 5.10B). Increasing Dox 
concentrations correlated positively with cytotoxicity, as the percentage cell 
viability decreased to as low as 7±3% and 8±3%, at 5000 nM and 10000 nM 
Dox, respectively (Figure 5.10B). To estimate the LC50, the percentage viability 
of Dox treated cells were normalised to the live population of untreated cells, 
assuming that to represent 100% viability (Figure 5.10C, primary axis). From 
this, the LC50 of free Dox in LNCaP cells was estimated to be ~780 nM. 
Furthermore, the Dox fluorescence emission of LNCaP cells also increased in a 
Dox concentration-dependent manner (Figure 5.10C, secondary axis), which is 
indicative of increased cellular uptake of Dox. 
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Figure 5.10. Cytotoxicity in Dox-treated LNCaP cells. LNCaP cells were incubated with 
different concentrations of free Dox for 24 h, and assayed for cytotoxicity. (A) Representative 
flow cytometry histograms at selected Dox concentrations. Quadrants were drawn to distinguish 
between cell populations, as described. (B) Stacked bar chart showing the percentage of cells 
that were live (green), early apoptotic (blue), late apoptotic (red) or necrotic (black) after 
treatment. Numbers in green indicate mean percentage cell viability ± SD. (C) Scatter plot 
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showing the normalised percentage viability of Dox treated cells with respect to Dox 
concentration (primary axis, green). These were calculated on the basis that the live population 
of untreated cells represent 100% cell viability. The Dox fluorescence emission of cells is also 
shown (secondary axis, white). Data in (B) and (C) represent the averaged result of three 
repeats. 
 
In contrast, the Dox gradient did not produce a significant cytotoxic response in 
PC-3 cells (Figure 5.11B). The percentage cell viability remained relatively 
unchanged from the 0 nM control (80±1%) up to 2500 nM (78±6%), although 
low levels of toxicity was observed at the highest Dox concentrations used. 
Several mechanisms by which cancer cells develop anthracycline resistance 
have been reported, including (i) drug efflux through the overexpression of 
transporters such as P-glycoprotein (Chien and Moasser, 2008), (ii) loss of 
function of the DNA mismatch repair pathway (Fedier et al., 2001), (iii) 
alterations in the intracellular distribution of the drug (Coley et al., 1993), and 
(iv) downregulation or mutation of topoisomerase II (Deffie et al., 1992). The 
exact mechanism of Dox resistance in the PC-3 cells is unknown, although it 
appears to be unrelated to drug efflux, as the Dox fluorescence emission 
increased with higher Dox concentrations, indicating intracellular accumulation 
(Figure 5.11C). It was concluded that PC-3 was unsuitable for use as the 
negative control cell line, and another cell line, which is sensitive to Dox and 
does not express PSMA, was needed to confirm the effects of specific targeting 
by VLP(TR-Cy5/Dox)-PEG24-A9L.  
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Figure 5.11. Cytotoxicity in Dox-treated PC-3 cells. PC-3 cells were incubated with different 
concentrations of free Dox for 24 h, and assayed for cytotoxicity. (A) Representative flow 
cytometry histograms at selected Dox concentrations. (B) Stacked bar chart showing the 
percentage of cells that were live (green), early apoptotic (blue), late apoptotic (red) or necrotic 
(black) after treatment. Numbers in green indicate mean percentage cell viability ± SD. (C) 
Scatter plot showing the normalised percentage viability of Dox treated cells with respect to Dox 
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concentration (primary axis, green). The Dox fluorescence emission of cells is also shown 
(secondary axis, white). Data in (B) and (C) represent the averaged result of three repeats. 
 
HeLa cells do not express PSMA and might be suitable as the PSMA-ve control. 
To test this, HeLa cells were incubated with up to 10000 nM Dox for 24 h, 
before they were analysed for cytotoxicity (Figure 5.12). Higher levels of toxicity 
(Figure 5.12B) and Dox fluorescence emission (Figure 5.12C, secondary axis) 
were observed with increasing Dox concentrations. Again, the percentage 
viability was normalised to the live population of untreated HeLa cells (Figure 
5.12C, primary axis), from which an LC50 of ~2900 nM was obtained. This is ~4-
fold higher than the LC50 of Dox in LNCaP cells, and might reflect some level of 
Dox resistance in HeLa cells.  
Another possible reason for the discrepancy in the LC50 of Dox in LNCaP and 
HeLa cells is their different rates of division, as LNCaP cells have a doubling 
time of ~60 h compared to the ~24 h of HeLa cells. The faster rate of division of 
HeLa cells might result in an increased dilution of intracellular Dox, thereby 
increasing the concentration of Dox required to produce the same level of 
toxicity as in LNCaP cells. However, this seems unlikely as the Dox 
fluorescence emission was considerably higher in HeLa cells (Figure 5.12C) 
than in LNCaP cells (Figure 5.10C) at most Dox concentrations, which is the 
opposite as would be expected if there was an increased dilution effect in HeLa 
cells. Overall, HeLa cells were responsive to the cytotoxic effects of Dox, and 
were thus deemed suitable as the PSMA-ve control for testing Dox delivery by 
VLP(TR-Cy5/Dox)-PEG24-A9L. 
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Figure 5.12. Cytotoxicity in Dox-treated HeLa cells. HeLa cells were incubated with different 
concentrations of free Dox for 24 h, and assayed for cytotoxicity. (A) Representative flow 
cytometry histograms at selected Dox concentrations. (B) Stacked bar chart showing the 
percentage of cells that were live (green), early apoptotic (blue), late apoptotic (red) or necrotic 
(black) after treatment. Additional Dox concentrations tested are indicated by an asterisk. 
Numbers in green indicate mean percentage cell viability ± SD. (C) Scatter plot showing the 
normalised percentage viability of Dox treated cells with respect to Dox concentration (primary 
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axis, green). The Dox fluorescence emission of cells is also shown (secondary axis, white). 
Data in (B) and (C) represent the averaged result of three repeats. 
Next, the cytotoxic effect of Dox delivery by VLP(TR-Cy5/Dox)-PEG24-A9L was 
investigated. LNCaP and HeLa cells were incubated with a concentration of Dox 
equal to their respective LC50’s (780 nM for LNCaP, 2900 nM for HeLa), either 
as free drug or after packaging into various VLP formulations for 24 h, before 
they were analysed for cytotoxicity (Figures 5.13, 5.14). For LNCaP cells, 
incubation with 780 nM free Dox resulted in a normalised percentage viability of 
60±13% (Figure 5.13B), which is close to the expected 50%. Dox delivery by 
VLP(TR-Cy5/Dox)-PEG24 and VLP(TR-Cy5/Dox)-PEG24-A9L resulted in 
percentage viabilities of 90±13% and 57±6%, respectively, whilst further 
addition of 100 nM free A9L increased the percentage viability back to 89±4%. 
Dox delivery by VLP(TR-Cy5/Dox)-PEG24-A9L resulted in a moderate increase 
in Dox fluorescence emission (451±83 AU) compared to free Dox (384±72 AU), 
indicating higher Dox uptake by LNCaP cells (Figure 5.13C). Furthermore, there 
is a strong correlation between the percentage viability (Figure 5.13B) and Dox 
fluorescence emission (Figure 5.13C), suggesting that greater Dox uptake leads 
to higher levels of cytotoxicity.  
For HeLa cells, incubation with 2900 nM free Dox resulted in a normalised 
percentage cell viability of 48±12% (Figure 5.14B), which is expected of the 
LC50. In contrast, incubation with 2900 nM Dox packaged inside VLP(TR-
Cy5/Dox)-PEG24-A9L did not produce a significant change in percentage 
viability (87±9%) relative to untreated cells. Again, the level of cytotoxicity 
correlated positively with the Dox fluorescence emission (Figure 5.14C).  
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Figure 5.13. Comparative cytotoxic effects of Dox delivery in LNCaP cells. LNCaP cells 
were (from left) either untreated, or incubated with 780 nM Dox, or 780 nM Dox packaged inside 
VLP-PEG24 (VP), VLP-PEG24-A9L (VPA) or VLP-PEG24-A9L in the presence of 100 nM free A9L 
(+A9L) for 24 h, and assayed for cytotoxicity. All data shown represent the averaged result from 
three repeats. (A) Stacked bar chart showing the percentage of cells that were live (green), 
early apoptotic (blue), late apoptotic (red) or necrotic (black) after treatment. (B) Bar chart 
showing the normalised percentage viability of cells after various treatments. These were 
calculated on the basis that the live population of untreated cells represent 100% cell viability. 
(C) Bar chart showing the Dox fluorescence emission of cells after various treatments. 
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Figure 5.14. Comparative cytotoxic effects of Dox delivery in HeLa cells. HeLa cells were 
(from left) either untreated, or incubated with 2900 nM Dox, or 2900 nM Dox packaged inside 
VLP-PEG24-A9L (VPA) for 24 h, and assayed for cytotoxicity. All data shown represent the 
averaged result from three repeats. (A) Stacked bar chart showing the percentage of cells that 
were live (green), early apoptotic (blue), late apoptotic (red) or necrotic (black) after treatment. 
(B) Bar chart showing the normalised percentage viability of cells after various treatments. 
These were calculated on the basis that the live population of untreated cells represent 100% 
cell viability. (C) Bar chart showing the Dox fluorescence emission of cells after various 
treatments. 
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Overall, these results indicate that delivery by VLP(TR-Cy5/Dox)-PEG24-A9L did 
not significantly improve the degree of uptake or level of cytotoxicity of Dox 
compared to free Dox. Their comparable cytotoxicity in LNCaP cells indicates 
that intercalation of Dox into TR-Cy5 was no barrier to their release inside the 
cell. The uptake of VLP(TR-Cy5/Dox)-PEG24-A9L was specific to LNCaP cells, 
and could be largely inhibited by the addition of free A9L, suggesting A9L-
mediated targeting of PSMA on the surface of LNCaP cells. Importantly, only 
low levels of uptake of VLP(TR-Cy5/Dox)-PEG24-A9L and cytotoxicity were 
observed in HeLa cells, compared to free Dox. The ability to promote uptake by 
targeted cells whilst reducing uptake by non-targeted cells can significantly 
improve the efficacy of anti-cancer drugs, as well as reduce their side effects in 
vivo.  
Two further experiments were carried out to augment the data described above, 
but these were unsuccessful. The first involved the testing of two additional cell 
lines, PSMA+ve 22RV1 (Regino et al., 2009) and PSMA-ve PNT1A (Lang et al., 
2002), for Dox delivery by VLP(TR-Cy5/Dox)-PEG24-A9L. However, neither cell 
line responded to free Dox over a large concentration gradient up to 10000 nM 
(Figure 5.15A). As for PC-3 cells, internalisation of Dox was evident for both 
22RV1 and PNT1A cells (Figure 5.15B), thus their mechanism of resistance to 
Dox could not be attributed to drug efflux. Due to their insensitivity to Dox, it was 
decided that 22RV1 and PNT1A were unsuitable for further assays.  
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Figure 5.15. Cytotoxicity in Dox-treated 22RV1 and PNT1A cells. 22RV1 (left) and PNT1A 
(right) cells were incubated with different concentrations of free Dox for 24 h, and assayed for 
cytotoxicity. All data shown represent the averaged result from three repeats. (A) Stacked bar 
chart showing the percentage of cells that were live (green), early apoptotic (blue), late 
apoptotic (red) or necrotic (black) after treatment. (B) Scatter plot showing the Dox fluorescence 
emission of cells with respect to Dox concentration. 
 
The second experiment was inspired by a recent paper (Ashley et al., 2011), 
describing the specific delivery of a diverse range of imaging and therapeutic 
cargoes by MS2 VLPs. One of the cargoes used was a chemotherapeutic 
cocktail of Dox, cisplatin, and 5-fluorouracil, which induced significant 
cytotoxicity in Dox-resistant Hep3B cells. If Dox resistance could be built up in 
LNCaP and HeLa cells, the hypothesis that delivery by VLP(TR-Cy5/Dox)-
PEG24-A9L can overcome resistance could be tested. The same protocol for 
building cellular resistance to Dox was used, which entailed incubating LNCaP 
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and HeLa cells with increasing concentrations (25 to 250 nM) of free Dox at 24 
h intervals, interspersed with 48 h recovery periods, over a period of 3 weeks 
(Ashley et al., 2011). The resulting cells were incubated with different 
concentrations (0-10000 nM) of Dox for 24 h, before analysis by flow cytometry 
(Figures 5.16, 5.17). As before, the percentage viability was normalised to the 
live population of untreated cells (Figures 5.16B and 5.17B, primary axes), from 
which an LC50 of ~680 nM was estimated for LNCaP cells, and ~2500 nM for 
HeLa cells. These are comparable to the previous values of ~780 nM (LNCaP) 
and ~2900 nM (HeLa), suggesting that the experiment failed to increase Dox 
resistance in these cells. Furthermore, the Dox fluorescence emission of 
LNCaP and HeLa cells after incubation were comparable to previous results 
(Figures 5.16B and 5.17B, secondary axes), suggesting that the level of Dox 
uptake also remained unchanged. 
Modifications to the protocol were also made, including extending the Dox 
gradient from 25 to 250 nM to up to 25 nM to the LC50 (780 nM for LNCaP, 2900 
nM for HeLa). However, for both cell lines, the majority of cells (~95%) did not 
survive after incubation with higher Dox concentrations, whilst the remaining cell 
population ceased further growth and cell division during the subsequent 
recovery phase. This might reflect a cumulative dose-dependent or time-
dependent effect of Dox, which was not observed in the previous 24 h 
cytotoxicity assays. It is unclear why Dox resistance could not be built up this 
way in LNCaP and HeLa cells, as previously shown for Hep3B cells (Ashley et 
al., 2011). Further modifications to the protocol might be needed, for example 
changes in the duration of Dox incubation and recovery periods, and 
adjustments to the Dox gradients used.  
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Figure 5.16. Cytotoxicity of free Dox in ‘Dox-resistant’ LNCaP cells. To build Dox 
resistance, LNCaP cells were incubated with an increasing concentration (25 to 250 nM) of Dox 
at 24 h intervals, interspersed by 48 h recovery periods, over 3 weeks (as previously described 
(Ashley et al., 2011)). The resulting cells were then incubated with up to 10000 nM Dox for 24 h, 
before they were analysed by flow cytometry. All data shown represent the averaged result from 
three repeats. (A) Stacked bar chart showing the percentage of cells that were live (green), 
early apoptotic (blue), late apoptotic (red) or necrotic (black) after treatment. The percentages 
shown represent the average of three repeats. (B) Scatter plot showing the normalised 
percentage viability of Dox treated cells with respect to Dox concentration (primary axis, green). 
The Dox fluorescence emission of cells is also shown (secondary axis, white). 
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Figure 5.17. Cytotoxicity of free Dox in ‘Dox-resistant’ HeLa cells. To build Dox resistance, 
HeLa cells were incubated with an increasing concentration (25 to 250 nM) of Dox at 24 h 
intervals, interspersed by 48 h recovery periods, over 3 weeks (as previously described (Ashley 
et al., 2011)). The resulting cells were then incubated with up to 10000 nM Dox for 24 h, before 
they were analysed by flow cytometry. All data shown represent the averaged result from three 
repeats. (A) Stacked bar chart showing the percentage of cells that were live (green), early 
apoptotic (blue), late apoptotic (red) or necrotic (black) after treatment. The percentages shown 
represent the average of three repeats. (B) Scatter plot showing the normalised percentage 
viability of Dox treated cells with respect to Dox concentration (primary axis, green). The Dox 
fluorescence emission of cells is also shown (secondary axis, white). 
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5.3 Summary of Chapter 5 
1. Dox was soaked into pre-assembled VLP(TR-Cy5) via pores present on the 
capsid surface, and became encapsidated inside via interactions with TR-
Cy5. The resulting VLP(TR-Cy5/Dox) particles contained on average ~111 
molecules of Dox each, and were surface decorated with SM(PEG)24 and 
A9L (as described in Chapter 4), to produce VLP(TR-Cy5/Dox)-PEG24-A9L. 
There appeared to be minimal Dox escape from VLPs during the surface 
modification and subsequent purification process. 
 
2. Whilst toxicity was observed in LNCaP cells after incubation with free Dox, no 
effect was observed in PC-3 cells – even at extremely high Dox 
concentrations. This prompted the use of HeLa as the PSMA-ve control cell 
line.  
VLP(TR-Cy5/Dox)-PEG24-A9L delivered Dox specifically to LNCaP cells via 
A9L targeting, and induced comparable cytotoxicity to free Dox at LC50. 
Further addition of free A9L strongly inhibited the uptake and cytotoxic effects 
of VLP(TR-Cy5/Dox)-PEG24-A9L. Negligible uptake and cytotoxicity were 
observed in HeLa cells.  
 
3. Two additional prostate cancer cell lines, (PSMA+ve) 22RV1 and (PSMA-ve) 
PNT1A, were also tested. However, neither cell lines responded to high 
concentrations of free Dox, and thus could not be used. Furthermore, 
attempts at building Dox resistance in LNCaP and HeLa cells were made 
using protocols described in (Ashley et al., 2011), but were unsuccessful.  
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Conclusions and future perspectives 
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6.1 Conclusions 
The general aim of this project was to further develop the MS2 VLP-based drug 
delivery system first pioneered in the Stockley laboratory in 1995 (Wu et al., 
1995). Specific goals were to: (i) mitigate non-specific cellular uptake of VLPs, 
(ii) test a relatively novel class of targeting ligands, nucleic acid aptamers, to 
facilitate tumour-specific uptake, and (iii) incorporate various drug cargos inside 
VLPs for delivery.  
Chapter 3 addressed the issue of non-specific cellular uptake of VLPs that was 
previously observed (Wu et al., 1995, Brown et al., 2002, Wu et al., 2005, 
Galaway, 2011). Using established protocols (Galaway, 2011), TR-conjugated 
cargos were packaged inside VLPs during in vitro assembly, using a TR:CP2 
molar ratio of 10:1. On average ~10 molecules of TR-X were packaged inside 
each VLP. VLP-PEG24 and VLP-PEG24-Tf were then synthesised using the 
hetero-bifunctional crosslinker, SM(PEG)24, which contains an NHS terminus 
that conjugates to VLP surface amines, and a maleimide terminus that 
conjugates to thiol-modified Tf. Significant PEGylation of the VLP surface was 
achieved (~97% of CPs), and each VLP-PEG24-Tf particle displayed on average 
~7 molecules of Tf. PEGylation (VLP-PEG24) led to a ~4-fold decrease in the 
uptake of VLPs by HeLa cells at 2 h; further addition of Tf (VLP-PEG24-Tf) 
increased uptake ~9-fold, likely due to Tf receptor-mediated endocytosis. Next, 
VLPs were used to deliver an established siRNA (Galaway, 2011, Dassie et al., 
2009) targeted against mRNA of the anti-apoptotic factor, BCL2, to HeLa cells. 
TR-BCL2 delivery by VLP-PEG24-Tf resulted in ~50% BCL2 protein knockdown 
and a ~45% decrease in cell viability. Negligible cellular effects were observed 
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when TR-BCL2 was delivered by VLP-PEG24, or when a control siRNA was 
delivered by VLP-PEG24-Tf, indicating the absence of off-target toxicity. 
Chapter 4 explored the use of RNA aptamers as the tumour-targeting ligand. 
The model aptamer was A9L, which specifically targets the prostate cancer 
marker, PSMA, and enables uptake by PSMA expressing cell lines (Rockey et 
al., 2011). Thiol-modified A9L aptamers were conjugated to VLPs via 
SM(PEG)24, using the same chemistry as that used for Tf in Chapter 3. An 
average ligand density of ~16 per VLP was estimated using a shorter, 
fluorescently labelled RNA oligo, U6-FAM. After prolonged incubation in cell 
media, VLP-PEG24-A9L particles remained intact and their displayed A9L 
remained stable. However, there was evidence of A9L degradation after VLP-
PEG24-A9L was incubated in human serum, signifying the importance of using 
more stable, chemically modified RNA (Wang et al., 2011), or DNA aptamers for 
future in vivo studies. PEGylation significantly reduced VLP binding by 
antibodies, likely by masking viral epitopes. However, the true immunogenicity 
of PEGylated VLPs can only be accurately assessed in vivo. To date, there are 
only a few reports on the in vivo testing of MS2 VLPs (Li et al., 2013, Pan et al., 
2012a, Pan et al., 2012b), originating from the Wang laboratory. No significant 
immune response or off-target toxicity was observed in mice after systemic 
administration of non-PEGylated MS2 VLPs decorated with cell-penetrating Tat 
peptides, which is highly encouraging. VLP-PEG24-A9L delivered TR-BCL2 
specifically to PSMA+ve LNCaP cells via A9L targeting, triggering significant 
BCL2 knockdown and cytotoxicity at low nM siRNA concentrations. Negligible 
effects were observed in PSMA-ve PC-3 cells, suggesting the effects of A9L 
targeting were specific.  
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Finally, Chapter 5 assessed the use of the anthracycline, Dox, as an alternative 
drug cargo for the MS2 VLP delivery system. Dox was soaked into pre-
assembled VLP(TR-Cy5) via pores present on the capsid surface, and became 
stably encapsidated inside via interactions with TR-Cy5. The resulting VLP(TR-
Cy5/Dox) particles contained on average ~111 molecules of Dox each, and 
were surface decorated with SM(PEG)24 and A9L (as described in Chapter 4), 
to produce VLP(TR-Cy5/Dox)-PEG24-A9L. Free Dox induced toxicity in LNCaP 
cells, but not in PC-3 cells – even at extremely high concentrations. The 
mechanism of resistance was not associated with drug efflux. This prompted 
the use of HeLa as the PSMA-ve control cell line. VLP(TR-Cy5/Dox)-PEG24-A9L 
delivered Dox specifically to LNCaP cells via A9L targeting, and induced 
comparable cytotoxicity to free Dox at LC50. Negligible uptake and cytotoxicity 
were observed in HeLa cells. Two additional prostate cancer cell lines, 
(PSMA+ve) 22RV1 and (PSMA-ve) PNT1A, were tested, but neither responded to 
free Dox, and thus could not be used. Furthermore, attempts at building Dox 
resistance in LNCaP and HeLa cells were made using protocols described in 
(33), but were unsuccessful. 
 
6.2 Future perspectives 
One advantage of MS2 VLPs over some other drug delivery systems, such as 
liposomes and cyclodextrin polymers, is the consistency of capsids with fixed 
physical properties. However, after surface decoration with ligands, some level 
of heterogeneity was present in the resulting particles, as evidenced by agarose 
gels and TEM images (Figure 3.10). This can be attributed to the nature of the 
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ligand and the conjugation chemistry used. Tf displays numerous surface 
amines (Galaway, 2011), which were derivitised with SATA or SMCC to install 
appropriate chemical groups for conjugation to VLPs or VLP-PEG24. As a result, 
there was little control over the position and orientation of Tf displayed. One 
strategy to improve this is to target specific sites on Tf for modification, for 
example, at the terminal sialic acids, which are situated in a distal position from 
the Tf receptor-binding site (Banerjee et al., 2010). The resulting VLP-PEG24-Tf 
should then display Tf in a defined orientation that is optimal for Tf receptor 
binding. It is notable that this did not affect VLP-PEG24-A9L, because A9L was 
synthesised with a thiol modification at a single defined location (at the 3' end). 
Furthermore, there are now potentially better crosslinking chemistries available, 
such as the highly efficient copper-catalysed azide-alkyne cycloaddition click 
reaction (Kolb et al., 2001). They should be tested to compare the conjugation 
efficiency with currently used NHS-amine/maleimide-thiol chemistries. A more 
efficient crosslinking strategy can potentially reduce heterogeneity in ligand-
modified VLPs, and also allow more control over the number of the ligands 
displayed. 
Whilst the size and zeta potential of unmodified VLPs are established in 
literature (Pang et al., 2009, Strauss and Sinsheimer, 1963), those of modified 
VLPs have not been well defined. Subtle changes in these properties can 
significantly affect the pharmacokinetics and biodistribution of the drug delivery 
system, hence one focus for future work should be to characterise the physical 
properties of modified VLPs. Also needed is better characterisation of the 
mechanism of cell entry of VLPs. The receptor-mediated endocytosis of Tf- and 
A9L-targeted VLPs is presumed from previous studies of the targeting ligands 
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(Rockey et al., 2011, Daniels et al., 2006a). To confirm this, fluorescence 
colocalisation microscopy can be carried out, using Cy5-labelled cargo and a 
fluorescently-labelled endocytosis marker (such as Tf, early endosome antigen 
1, Rab6 or lysosomal-associated membrane protein 1). Time-lapse 
fluorescence microscopy might also reveal any limiting steps in the endocytosis 
pathway, for example, one common limiting step is the endosomal escape of 
drugs (Varkouhi et al., 2011). If this is the case for MS2 VLPs, proton sponges 
can be incorporated to facilitate endosomal escape and improve drug efficacy 
(Behr, 1997, Ashley et al., 2011, Varkouhi et al., 2011). Another possible 
limiting step is the release of drugs from VLPs. Although VLPs should 
disassemble in the acidified environment of the endosome (Anobom et al., 
2003), PEGylation of the surface might make VLPs more stable, thus reducing 
drug release and efficacy. For this reason, a less stable MS2 capsid mutant 
(Caldeira and Peabody, 2011) might be better suited for PEGylation and drug 
delivery, and could be tested.  
MS2 VLPs have proven to be a highly modular, flexible drug delivery system, 
capable of displaying numerous ligands on its surface, as well as packaging a 
diverse range of cargos for delivery (Galaway and Stockley, 2013, Li et al., 
2013, Pan et al., 2012a, Pan et al., 2012b, Ashley et al., 2011, Wu et al., 2005, 
Brown et al., 2002, Wu et al., 1995, Stephanopoulos et al., 2010). Many more 
ligands and drugs remain to be tested. Effective high-throughput screening 
systems (Galaway, 2011) will be needed to identify the best combinations of 
cargos and ligands, which can subsequently be tested in vivo for efficacy and 
safety. It is important to note that whilst adding extra components to a drug 
delivery system might impart additional functionalities, it also means extra 
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synthetic steps and concomitant cost of production, as well as more convoluted 
behavior in vivo (Cheng et al., 2012). It will therefore be important to critically 
assess and weigh the cost and clinical benefits of adding them. 
MS2 VLPs can incorporate multiple drug cargos to deliver them simultaneously 
to cancer cells. So far, various anti-cyclin siRNAs, and a chemotherapeutic 
cocktail containing Dox, cisplatin and 5-fluorouracil, have been delivered in 
vitro, achieving cytotoxicity at sub pM drug concentrations (Ashley et al., 2011). 
Various other combinations of drugs can be tested. Some of these, despite 
showing good synergy, are limited in vivo by having inherently different 
pharmacokinetics and biodistribution, and thus could benefit from simultaneous 
delivery (Kummar et al., 2010, Peters et al., 2000). Hence, it is likely that drug 
delivery systems such as MS2 VLPs will play an important future role in 
deterring the development of cancer drug resistance. 
Finally, in this project, the effects of MS2 VLP-mediated drug delivery were 
investigated in vitro using monolayer cell lines, which are often considered to be 
an oversimplified representation of cancer (Maitland et al., 2010). Therefore, 
one focus for future work should be to investigate its efficacy in more 
sophisticated cancer models, such as 2D bilayers (Swift et al., 2013) and 3D 
multicellular spheroids (Kurioka, 2011, Hirschhaeuser et al., 2010), which can 
better recapitulate various aspects of cancer in vivo, such as tissue structure as 
well as complex cell-cell and cell-matrix interactions found in 3D 
microenvironments. Once the ideal model disease, drug cargo and targeting 
ligand are established from these in vitro models, MS2 VLPs can then be tested 
in vivo using mice models, primate models and, ultimately, in human patients. 
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6.3 Closing remarks 
MS2 VLPs continue to show great potential as an effective, robust drug delivery 
system. This project highlighted the versatility of VLPs for displaying useful 
ligands for immunomasking and tumour-targeting, as well as packaging various 
drug cargos, and demonstrated their ability to specifically deliver cytotoxic drugs 
to targeted cancer cells. It seems likely that flexible drug delivery systems like 
MS2 VLPs – alongside our accumulating knowledge on the molecular 
mechanisms of cancer (Weber, 2007), with increasingly sophisticated 
sequencing and disease screening technologies (Shendure and Ji, 2008), 
coupled to the emergence of a plethora of novel tumour-targeting ligands 
(Zhong et al., 2014) – will help to pave the way to making personalised 
medicine a practical reality.  
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